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Chapter 1   General introduction and outline of the thesis
INTRODUCTION 
Colorectal cancer (CRC) is the second most common cause of cancer death in the Western 
World, and the life time risk of developing sporadic CRC is 5-6%.1 Approximately half of 
the CRC patients develop metastatic disease, either at diagnosis or during follow-up.2 for 
patients with unresectable metastatic CRC there are no curative options, but significant 
benefit in survival can be achieved with systemic treatment. In recent years, the systemic 
treatment options for patients with metastatic CRC have changed considerably. for many 
decades 5-fluorouracil plus leucovorin (5-fu/LV) was the only available treatment regimen 
with median overall survival (OS) times of approximately 12 months.3 Oral fluoropyrimidines 
(capecitabine, uracil/tegafur) have shown to be as effective and better tolerated in comparison 
to intravenous 5-fu/LV.4,5 therefore, capecitabine is a good alternative for 5-fu/LV, both 
when given as monotherapy and in combination schedules. The availability of oxaliplatin and 
irinotecan have further improved the median OS to 14-19 months. Prospective randomized 
clinical trials have shown that there is no preference for combined administration of these 
cytotoxic agents instead of their sequential use, at least in patients that are not eligible for 
secondary resections of metastases after downsizing and/or patients with good performance 
status allowing multiple lines of treatment.6,7 It is probably more important that patients are 
exposed to all three cytotoxic drugs (fluoropyrimidines, oxaliplatin, irinotecan) during the 
course of their disease, than that patients receive these drugs concurrently in first-line which 
also implies that (some of) these drugs have to be administered below their maximal tolerated 
dose. More recently, targeted agents have been approved for clinical use in metastatic CRC 
and these have added further benefit in OS. Bevacizumab, a humanized monoclonal antibody 
No treatment 
5 FU/LV 
5 FU/LV, oxaliplatin,  
irinotecan 
5 FU/LV, oxaliplatin,  
irinotecan, bevacizumab,  
cetuximab, panitumumab 
8 months 
10-12 months 
14-19 months 
>20 months 
Figure 1. Median OS in metastatic CRC patients with the current available chemotherapy and 
targeted agents.
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against vascular endothelial growth factor (VEGf), combined with 5-fu based chemotherapy 
is nowadays the standard first-line treatment for metastatic CRC.8-11 In patients with KRAS 
wild type tumors, two antibodies against the epidermal growth factor receptor (EGfR), 
cetuximab and panitumumab, have shown their greatest absolute benefits as monotherapy 
in chemo-refractory patients12,13 and have also shown survival benefits in first-line or second-
line treatment in combination with chemotherapy.14-17 The integration of targeted drugs in the 
standard treatment of patients with metastatic CRC has increased the median OS to approxi-
mately 2 years (figure 1).
PROGNOSTIC FACTORS IN METASTATIC COLORECTAL CANCER
Clinical trials in metastatic CRC, although using similar patient selection criteria, often 
display a surprising heterogeneity in survival rates. This heterogeneity is usually explained 
by differences in patient and tumor-related factors, irrespective of treatment. Identification 
of prognostic factors in metastatic CRC is important because the estimation of individual 
prognosis based on patient and tumor characteristics may allow a more personalized treatment 
approach. In addition, appropriate stratification based on established prognostic factors will 
allow a more reliable interpretation of study results by prevention of heterogeneity in baseline 
patient characteristics.
Clinical prognostic factors
Patient characteristics influence clinical outcome in metastatic CRC. A variety of clinical 
parameters such as performance status18, 19, serum lactate dehydrogenase (LDH)6, 20, the number 
of metastatic sites involved21, 22 and localization of the primary tumor23, 24 have been identified 
as prognostic factors. The prognostic value of other factors, such as the onset of metastases 
(synchronous vs. metachronous), carcinoembryonic antigen (CEA), age, gender, and obesity, 
is less clear. There is no real consensus and general acceptance of prognostic factors, which 
is probably due to a high level of heterogeneity in clinical trials reporting prognostic factors. 
However, risk group assessment based on baseline clinical parameters in a large patient 
cohort has been performed, identifying performance status, white blood cell count, alkaline 
phosphatase, and number of metastatic sites as the most important prognostic factors.24 Surpri-
singly, white blood cell count and serum alkaline phosphatase levels are not commonly used 
as stratification parameters in clinical trials. therefore, re-establishing clinical prognostic 
factors in metastatic CRC is necessary and could reduce the heterogeneity in survival rates in 
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randomized clinical trials. the development of a clinical nomogram in which these prognostic 
factors are included would greatly assist individual patient management. 
Histopathological prognostic factors
tumor extent (t stage), lymph node status (N stage), histological subtype, differentiation grade, 
and the assessment of lymphatic and venous invasion are still the most important morpho-
logical prognostic factors in CRC25, even in case of metastatic disease. Of these morphological 
features, lymph node status is the strongest prognostic factor and the main indicator for the 
application of adjuvant therapy. Throughout the years several guidelines have been issued 
suggesting a minimum number of lymph nodes to be evaluated to confirm node-negativity.26, 27 
In CRC patients the retrieval of lymph nodes depends on biological characteristics, choice of 
treatment, and pathologic assessment of the specimen. Due to the prognostic value of lymph 
Cell survival 
Cell proliferation 
Inhibition of apoptosis 
 
RAF 
MEK 
MAPK 
PI3K 
AKT 
RAS 
Cell survival 
Cell proliferation 
Inhibition of apoptosis 
 
Figure 2. the RAS/RAf/MAPK signaling pathway resulting in the simulation of cell proliferation  
and inhibition of apoptosis.
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node retrieval, it is clinically relevant to optimize lymph node assessment in CRC patients. 
This issue is more problematic in patients with rectal cancer who have received neoadjuvant 
treatment, due to the treatment effects on lymph node status.  
PREDICTIVE FACTORS IN METASTATIC COLORECTAL CANCER
Predictive markers indicate the likelihood of benefit from treatment, and are important to 
optimize the selection of metastatic CRC patients eligible for specific treatment regimes. 
Because treatment with chemotherapy and targeted agents is associated with potential (and 
sometimes severe) toxicity and high costs, it is important to establish markers that are predictive 
for efficacy. In this respect, the identification of KRAS mutation as a negative predictive marker 
for the response to anti-EGfR therapy has been one of the most recent important achievements 
in metastatic CRC. An oncogenic mutation in KRAS leads to constitutive activation of the 
RAS/RAf signalling pathway independent from EGfR activation by binding of the ligand28, 
ultimately resulting in the stimulation of cell proliferation and the inhibition of apoptosis 
(figure 2).29 Metastatic CRC patients with tumors harboring a KRAS mutation are resistant to 
treatment with anti-EGfR antibodies (panitumumab and cetuximab), showing lower response 
rates, decreased progression free survival and OS compared to patients with KRAS wild type 
tumors.13, 14, 30 therefore, the European Medicines Agency and the food and Drug Adminis-
tration have restricted the use of anti-EGfR antibodies in metastatic CRC to patients with 
KRAS wild type tumors. Nevertheless, since only a subset of patients with a KRAS wild type 
tumor respond to treatment with anti-EGfR antibodies, additional predictive markers are 
needed. The heterogeneity of both KRAS wild type and KRAS mutated tumors in terms of 
treatment response has been demonstrated. Within the group of KRAS wild type tumors, BRAF 
mutations  were shown to have a negative predictive value for anti-EGfR therapy.31 However, 
our group showed that BRAF mutations predominantly have a strong negative prognostic 
value.32 Recently, the negative predictive value of KRAS mutations appeared to be limited to 
patients with KRAS codon 12 mutations, while patients with codon 13 mutations were shown 
to derive comparable benefits from anti-EGfR treatment compared to patients with KRAS 
wild type tumors.33 these findings warrant further clinical validation. Other KRAS mutations 
(codon 61)34, PIK3CA mutations35, PTEN expression36, ligands to the EGfR37, 38, and germline 
single nucleotide polymorphisms39, 40 have shown promising results but need further testing 
before they can be implemented in routine clinical decision making. In absence of other 
molecular markers, the predictive strength of the KRAS mutation status stresses the importance 
of RAS-GtPase activity for the response to anti-EGfR therapy. therefore, other regulatory 
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mechanisms of RAS-GtPase activity, such as copy number alterations (CNA) of the KRAS gene 
or posttranslational factors (microRNAs) are obvious novel candidate markers (figure 3). 
An additional possible explanation for the failure rate to anti-EGfR antibodies in patients 
with KRAS wild type tumors may be a discordance of KRAS mutation status between primary 
colorectal tumors and their corresponding metastases. KRAS mutation status is almost 
invariably being tested in the primary tumor, since this tissue is usually available as opposed 
to tissue from metastases. Discordance in KRAS mutation status could possibly be explained 
by heterogeneity of the primary tumor with subsequent progression of one specific subset of 
tumor cells as a result of clonal selection. Also, late acquirement or loss of KRAS mutation 
during disease progression and the development of metastases could result in a discordance 
in KRAS mutation status. Current data on the concordance in KRAS mutation status between 
primary colorectal tumors and metastases are conflicting.41-43 Therefore, it is still uncertain 
whether the evaluation of KRAS mutation status in the most commonly available primary 
tumor correctly reflects the KRAS mutation status of corresponding metastases. This is highly 
relevant given the large number of CRC patients that are eligible for anti-EGfR treatment as 
well as the potential toxicity and costs of this therapy.
promotor KRAS gene 
Transcription factor 
Epigenetic factors SNP, mutation
Genomicaberrations: 
deletion, amplification, 
translocation  
Figure 3. Regulatory mechanisms of RAS-GTPase activity, including transcription factors, genomic 
aberrations, epigenetic changes, SNPs and mutations. Abbreviation: SNP: single-nucleotide 
polymorphisms.
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THE MOLECULAR PATHWAYS OF COLORECTAL CANCER METASTASES 
the formation of metastases is a highly inefficient and complex multistep process, in which 
malignant cells disseminate from the primary tumor to colonize distant organs. Invasion, 
which initiates the metastatic process, consists of changes in tumor cell adherence to cells and 
the extracellular matrix (ECM), proteolytic degradation of surrounding tissue and motility to 
navigate a tumor cell through tissue. After entering the bloodstream, tumor cells must survive 
in the circulatory system. These cells extravasate by inducing endothelial retraction, leading 
to the attachment of tumor cells to the subendothelial ECM and reformation of the capillary. 
Subsequent steps including proliferation, induction of angiogenesis, and evading apoptotic 
death are crucial for colonization at the secondary site.44 tumor cells need to be proficient in 
all these processes in order to produce metastatic outgrowth. Therefore, each step in metastatic 
outgrowth requires specific genetic and epigenetic changes. One of the challenges in effective 
detection and treatment lies in the elucidation of these (epi)genetic alterations underlying CRC 
metastases, which may provide novel targets for future diagnostic tests and treatments. 
Genetic instability and colorectal cancer metastases
Chromosomal instability (CIN) is the most common type of genetic instability in CRC, and 
occurs in approximately 85% of the colorectal carcinomas. CRC carcinogenesis is accom-
panied by a progressive accumulation of CIN45, and these DNA copy number alterations can 
lead to deregulation of gene expression.46 Several chromosomal regions in CRC frequently 
show gain combined with overexpression (7p, 8q, 13q and 20q) or decreased expression of 
genes at loci with losses (1p, 4, 5q, 14q, 15q and 18).47 
In comparison to the many molecular alterations involved in the CRC adenoma-carcinoma 
sequence, less information is available on the mechanisms responsible for metastases. To 
gain a better insight in molecular aberrations involved in CRC metastases, one approach is to 
compare DNA copy number profiles in primary tumors and metastatic tissues. Many studies 
on this topic have been performed, however in most of these an unmatched-pair approach was 
used. This type of unmatched comparison is unreliable due to the heterogeneity in endogenous 
copy number aberrations between primary colorectal carcinomas. In order to overcome this 
problem, comparison of matched metastatic and primary tumor tissue is essential. Studies 
including matched-pair data, show a high level of similarity between metastases and their 
corresponding primary tumors.48-49 Given this close resemblance between primaries and 
metastases, it was suggested that the capacity to metastasize is largely determined by the 
mutant alleles that are acquired relatively early during tumorigenesis. A second approach 
is to compare DNA copy number profiles in primary tumors of patients with and without 
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metastatic disease, to identify molecular aberrations in primary tumors that are more likely 
to metastasize. So far, a number of chromosomal aberrations in primary tumors have been 
associated with the ability to metastasize. Across all studies, gain of chromosome 20q is more 
frequently observed in primary tumors with liver metastases compared to primary tumors 
without metastases.50 However, a specific comparative genomic hybridization (CGH) profile 
to predict CRC metastases has not been established.
Microarray analysis is a useful approach for identifying candidate genetic alterations involved 
in metastases. The relative ease of which pathological specimens can be obtained has 
facilitated the application of technologies to allow the genome-wide analysis both at the RNA 
(gene expression) and DNA (aneuploidy) levels. In 1992, Kallioniemi developed chromosome-
based CGH, which is a technique used to analyze DNA copy number alterations on a genome-
wide scale.51 Due to its limited resolution, the (micro)array-based CGH was introduced in 
1997, which resulted in increased sensitivity.52 Briefly, tumor and normal DNA are labelled 
with green and red fluorochromes, respectively, and hybridized to genomic DNA attached to 
a slide. Images of the fluorescent signals are captured and the green to red ratios are digitally 
quantified for each target (figure 4). these ratios are called into amplifications, gains, losses 
and no copy number aberrations.53 Array CGH is a powerful molecular cytogenetic method 
to screen the entire genome for chromosomal imbalances. However, tumor heterogeneity, 
limited cohort sizes, and methodological differences among experimental and bioinformatic 
approaches still poses obstacles towards the optimal utilization and integration of genomic 
profiles.
Cy3 - genomic 
tumor DNA 
Cy5 - genomic 
normal DNA 
Hybridize 
Wash Cy3 / Cy5 
fluorescence 
intensity ratio 
Figure 4. Schematic overview of the microarray CGH technique. tumor and reference DNA are 
labeled with Cy3 and Cy5 respectively, and hybridized on a microarray slide containing DNA 
fragments of the genomes.
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Epigenetic alterations and colorectal cancer metastases
In addition to genetic alterations, epigenetic changes such as methylation, histone modifi-
cation, and post-transcriptional gene regulation by microRNA (miRNAs) also contribute to 
CRC metastases. Recently, miRNAs have been discovered and are of major interest due to their 
unique role in cancer development.54 MiRNAs are a family of small non-coding RNAs that act 
as endogenous suppressors of gene expression through imperfect binding the 3’-untranslated 
region (3’-utR) of target mRNAs, inducing either translational repression or mRNA degra-
dation (figure 5). to date, more than 1000 human miRNAs have been identified (miRBase 
Sequence Database – Release 16) and each individual miRNA may control hundreds of target 
genes. MiRNAs have important regulatory functions in basic biological processes that form the 
hallmarks of cancer, such as cellular differentiation, proliferation, migration, and apoptosis. An 
association between the dysregulation of miRNA expression and specific steps in the metastatic 
pathway is therefore highly likely. Specific miRNA signatures (miR-21, MiR-17-92, MiR-200 
family, miR-196 and MiR-34) have been associated with clinical and biological phenotypes 
of tumors, and are often dysregulated in CRC.55, 56 Alterations in miRNA expression can be 
caused by various mechanisms, including deletions, amplifications or mutations involving 
miRNA loci, epigenetic silencing or the dysregulation of transcription factors that target 
Pri-miRNA 
Pre-miRNA  
Drosha  
Pre-miRNA  
Exportin 
Mature miRNA 
RISC  
Complete similarity Partial similarity
Translation repression mRNA degradation
miRNA-miRNA duplex 
Dicer 
Figure 5. Biogenesis and function of miRNAs.
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specific miRNAs. When specific miRNAs involved in metastases are identified, novel thera-
peutic strategies can be developed.
ORGAN-SPECIFIC METASTASES IN COLORECTAL CANCER
Similar like other types of cancer, CRC metastases show organ preference. The liver is the 
predominant site in approximately 80% of CRC patients. In 40 to 50% of these patients, extra-
hepatic organs are also involved in metastatic colonization. Metastatic cells prefer to grow in 
certain organs in a way that cannot be explained by circulatory patterns alone. Mechanical 
entrapment combined with receptor-specific seed- and soil adhesions are currently discussed 
as determining factors for cancer cell arrest in target organs. Organ specificity has mainly 
been investigated in mouse models and in vitro assays using CRC cell lines. In these studies 
it appears that organ-specific formation of CRC metastases is mainly mediated by specific 
interactions between circulating tumor cells and the vessel wall of potential target organs. The 
molecular mechanisms underlying these specific adhesive interactions in metastatic target 
organs remain poorly understood. 
the (epi)genomic programmes that determine organ specificity in regard to metastases are 
probably present at the time when the primary tumor arises. Evidence for this hypothesis 
comes from the similarity between DNA copy number profiles and mRNA expression profiles 
between primary tumors and metastases.57 Secondly, genomic profiling studies in primary 
tumors has identified ‘metastases signatures’ that can predict the metastatic phenotype in breast 
cancer patients.58 Identifying genomic regions and genes involved in organ-specific metastases 
should learn us more about the underlying mechanisms of organ specificity in regard to CRC 
metastases. This will also help to identify clinically applicable diagnostic markers, preventive 
approaches, and to find molecules that might be useful targets for therapy. 
OUTLINE OF THE THESIS
Metastatic CRC is a common malignancy in the Western World and recent therapeutic 
advances have prolonged survival of these patients. Nevertheless, the survival rates are very 
heterogeneous due to the presence of various patient, pathological, and treatment-related 
prognostic factors. The presence of lymph node metastases is the most powerful prognostic 
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factor for recurrence and OS in CRC. In chapter 2 we correlate the amount of lymph nodes 
retrieved with clinical outcome in rectal cancer patients treated with short-term radiotherapy 
followed by tME surgery. furthermore, we evaluated which clinical, primary tumor, and 
treatment related factors influence lymph node retrieval. the study in chapter 3 aims to identify 
the prognostic value of primary tumor histology in metastatic CRC patients treated with the 
currently used systemic therapy, including targeted agents. In chapter 4 we present data on 
a potential prognostic marker in metastatic CRC by comparing clinical outcome between 
patients with synchronous versus metachronous metastases. 
Next to establishing prognostic markers, it is highly relevant to find predictive markers in order 
to optimize the selection of metastatic CRC patients for specific treatment regimes. the identi-
fication of a KRAS mutation as predictive marker for the response to anti-EGfR therapy has 
been one of the most important achievements in the last years. Since only a minority of KRAS 
wild type patients respond to anti-EGfR therapy, it is necessary to find additional predictive 
markers. We investigated the KRAS mutation status and other regulatory mechanisms of 
KRAS in more detail. One possible explanation for the suboptimal response in KRAS wild 
type patients is described in chapter 5, where we investigate the level of concordance in 
KRAS mutations status between primary tumors and their corresponding liver metastases. In 
chapter 6 we present the correlation of other regulatory mechanisms beyond the KRAS point 
mutation, such as KRAS copy number alterations and miRNAs targeting KRAS, with response 
of metastatic CRC patients treated with chemotherapy, bevacizumab and cetuximab.
to develop new therapeutic targets in metastatic CRC, a better insight is required in the (epi)
genetic alterations that are responsible for metastases. Recently, miRNAs have been discovered 
which play a relevant role in cancer progression. In chapter 7 we review the role of miRNAs 
in CRC metastases, including escape of apoptosis, epithelial-mesenchymal transition (EMt), 
angiogenesis, invasion, migration, and proliferation. The presence of additional chromosomal 
aberrations in CRC metastases compared to matched primary tumors are investigated in a 
paired approach using array CGH, of which the results are presented in chapter 8. In addition 
to metastases-associated genes in general, an individual primary tumor probably deploys 
distinct (epi)genetic programs in order to colonize different metastatic sites. finally, in chapter 
9 we address the issue of metastatic tropism by describing the differences in clinicopatho-
logical features and array CGH profiles between primary tumors of CRC patients with hepatic 
versus extrahepatic metastases. 
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ABSTRACT
Lymph node status is the strongest prognostic factor for survival in colorectal cancer. There are 
several guidelines concerning the minimum numbers of lymph nodes that need to be examined 
to make reliable staging possible, but there is no consensus in the available literature. In this 
study, we determine in patients with rectal cancer factors that relate to the number of lymph 
nodes found and the presence of lymph node metastasis. In addition, the number of examined 
lymph nodes was correlated with prognosis. 
A total of 1227 patients were selected from a multicenter prospective randomized trial inves-
tigating the value of neoadjuvant radiotherapy. The median number of examined lymph nodes 
in all patients was 7.0. The number of retrieved lymph nodes in patients with node metastasis 
was significantly higher than in node negative patients. After neoadjuvant radiotherapy fewer 
lymph nodes were retrieved (6.9 vs. 8.5; P<0.0001). Variations in lymph node yield between 
pathology laboratories and individual pathologists were striking. The following patient and 
tumor characteristics are associated with a significant lower lymph node retrieval: age over 60 
years, overweight, small size, low invasion depth of the tumor, poor differentiation grade, and 
absence of a lymphoid reaction. Node negative patients in whom seven or less lymph nodes 
were examined had a lower recurrence free interval than patients in whom at least 8 lymph 
nodes were examined (17.0% vs. 10.7%, P=0.016).
We conclude that in pathology laboratories a median of at least 8 lymph nodes need to be 
examined in rectal cancer specimens, but that higher numbers are desirable and achievable in 
most cases, even after preoperative radiotherapy. 
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INTRODUCTION
the presence of metastases in lymph nodes (LN) is the most powerful negative prognostic 
factor in colorectal cancer and the main indicator for the application of adjuvant therapy. 
Throughout the years several guidelines have been issued suggesting minimum numbers of LN 
to be evaluated before patients can be declared node negative, varying from 6 to 17 nodes.1-5 
In this tumor node metastases (tNM) guidelines, a minimum examination of 12 LN is advised6, 
on the basis of single center studies and data from cancer registries. However, in the era of 
evidence-based medicine, evidence is preferably gathered using data from well-documented 
multicenter clinical trials. Data concerning numbers of analyzed LN in clinical trials are scarce, 
and in general lower than those reported in single center studies. Absence of real evidence 
in the literature is the reason why the current Dutch guideline advises a minimum exami-
nation of 10 LN.7 We have shown previously, using the data from a large nation-wide trial for 
rectal carcinoma, that 12 of more LN are found in only 18% of the cases.8 The application 
of neoadjuvant therapy (short-term radiotherapy (Rt) or radio-chemotherapy), now standard 
care for rectal carcinoma in many European countries, results in even less examined LN.9 An 
adequate nodal staging is difficult because many factors influence the number of LN retrieved. 
the number of LN found in resection specimens of rectal tumors are significant less than those 
in resection specimen of colon tumors.10 Other factors are related to the patient (sex, weight), 
the surgeon (specimen size, type of surgical procedure) and to the tumor (size, differentiation, 
and invasion depth). Pathologic procedures, such as time and type of fixation, have also been 
shown to be of influence. 
the aim of this study was therefore to analyze the influence of several patient, tumor, 
and treatment related factors on the number of both LN retrieved and the presence of LN 
metastasis in optimal treated rectal cancer specimens. furthermore, we correlated the number 
of examined LN with prognosis. for this analysis data were taken from a large prospective 
multicenter trial comparing no preoperative treatment with 5 x 5 Gy RT shortly before surgery.
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
26
Chapter 2   Lymph node retrieval in rectal cancer
MATERIALS AND METHODS
Study population
Patients were selected from the Rt + total mesorectal excision (tME) trial, a large multicenter 
trial, in which 1530 Dutch patients were included from January 1996 to December 1999.11 
this prospectively randomized trial evaluated tME surgery with or without preoperative Rt 
(5 x 5 Gy) for patients with clinical resectable adenocarcinoma of the rectum. Radiotherapeutic, 
surgical and pathological procedures were described in detail elsewhere.8, 12 
Patient selection
for this study we analyzed the data of the eligible Dutch patients in the trial. the following 
patients were excluded from the analysis: no resection (n=27), resection locally not complete 
(n=98), distant metastases at operation (n=81), no tumor at operation (n=20). from the Rt 
group those patients who did not receive RT according to protocol: total dose not 25 Gy 
(n=23), overall treatment time >10 days (n=82), leaving 1227 patients for the analysis. the 
median follow-up was 68 months.
Pathological procedures 
Standardized pathology examination was performed in the pathology laboratories of the 
referring hospitals using the protocol of Quirke et al.13, 14 The specimens were examined for LN, 
and all found LN were processed for microscopic examination. LN retrieval was performed 
in a routine matter; no fat clearance methods were applied. The use of the protocol of Quirke 
et al.13, 14 implies a 48-hour formalin fixation and careful slicing of the mesorectal fat, which 
can contribute to high yields of LN. In a subset of cases the size of the LN was measured on 
its largest diameter using a grid.
Pathological parameters
Histopathologic classification of tumors was performed using the World Health Organization 
guidelines.15 A tumor was considered to be of the mucinous type when at least 50% of the 
tumor was mucinous. The tumors were graded according to the histological differentiation into 
well, moderately, poorly, and undifferentiated adenocarcinomas on the basis of the part of 
poorest differentiation in the tumor. Growth pattern and the presence of inflammatory reaction 
were assessed according to Jass.16 The maximum diameter was noted with an invasion depth 
described in terms of the t classification (tNM).17
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Data collection and statistics
All case record forms were sent to the central data office at the surgery department of the Leiden 
University Medical Center in Leiden, the Netherlands. The data were checked and entered in a 
database and analyzed with the SPSS package (SPSS 14.0 for Windows, SPSS Inc, Chicago, IL). 
Relations between various parameters were analyzed by using χ2 test, Mann-Whitney u test, 
and Kruskal-Wallis nonparametric testing procedures. Multivariate analysis was performed 
using the enter method in logistic regression model. Univariate survival analyses of time to 
overall recurrence free survival were performed using the Kaplan-Meier method, with the time 
of surgery as the entry date. Differences in observed survival between groups were tested for 
statistical significance using log-ranks tests. A P value of ≤0.05 was considered statistically 
significant.
RESULTS
Patient population
One thousand two hundred twenty seven patients (782 male, 63.9%) with a median age of 
64.1 years at randomization (range: 23 to 92 years) were analyzed in this study. All patients 
underwent a potentially curative operation and 46.1% (n=564) received short-term preope-
rative RT. 
Pathologic examination showed that most tumors were t3 (57.8%). the majority of tumors 
were adenocarcinomas (89.6%), within 67.2% a moderate differentiation, and in 26.9% a 
poor differentiation. 
A total number of 10748 LN was examined, varying from 0 to 52 LN per patient (median 7.0, 
quartile range: 4.0 to 12.0). Of all patients, 38.8% (n=474) presented with LN metastases (N+), 
the remaining 61.2% (n=749) presented without LN metastases (N0).
Factors influencing lymph node retrieval
In N0 patients the mean number of LN examined was 7.7 compared with 10.5 in N+ patients 
(P<0.001). Because of this finding, the different factors, which influence lymph node retrieval 
were separately analyzed in patients with positive and negative LN, to avoid bias because of 
the effects of lymph node status.
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Treatment-related factors
Radiotherapy
In the RT group of N0 patients the mean number of examined nodes was 6.9 versus 8.5 in the 
surgery only group (P<0.0001). this signifi cant difference was also present in node positive 
patients (table 1).
In series of 258 LN (28 patients) from 1 of the participating hospitals, we evaluated the effects 
of Rt on the size of the examined LN. LN were somewhat smaller after Rt (mean size 12.6 
mm2 in TME vs. 10.8 mm2 in Rt), however, this difference was only present in the LN with 
metastases. the size of the uninvolved LN was 9.9 mm2 in both groups (figure 1).
Surgical procedures
The type of resection, being directly related to the location of the tumor, was strongly correlated 
with the number of LN in N0 patients. Lymph node retrieval after low anterior resection was 
8.7, versus 6.0 after abdominoperineal resection. This difference was not observed in N+ 
patients (table 1).
However, contrary to expectations, when longer parts of bowel were removed, the number 
of examined LN did not increase. Especially in the N0 group, there seemed to be almost an 
inverse relation between length of specimen and number of LN, that is, 7.8 in specimen ≤20 
cm vs. 5.8 in specimen >40 cm (P=0.06) (table 1).
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Figure 1. the mean LN size (mm2) in relation to the randomization arm. the fi rst column shows the 
overall mean LN size. In the second and third column the mean LN sizes are shown for N0 and N+ 
patients, respectively. the fourth and fi fth column show the mean sizes of LN that, respectively, do 
not and do contain metastases.
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Pathological procedures
Substantial variance was found between the 49 participating pathology laboratories (Kruskal-
Wallis P<0.001), with median (quartile range, number of specimens) yields varying between 
1.5 (0.75-4.3, n=6) and 13.5 (4.5-24.8, n=4) (figure 2). the number of specimens per laboratory 
varied between 2 and 120, but this was not associated with the median LN yield. In figure 2 
individual scores per pathologist are shown for 3 selected laboratories. Only data from nonir-
radiated patients were used as it is likely to fi nd more LN in this subset, as described above. 
from this fi gure can be deduced that large differences exist between various pathologists and 
between laboratories, median yields vary from 3.5 (laboratory B) to 17 (laboratory C).
	  
	  
A 
B 
C 
Figure 2. Number of examined lymph nodes in node-negative patients in 3 different pathology 
laboratories. the fi rst one (A) is a large laboratory with a median number of 7.0 (quartile range 5.5 
to 11.0) LN per specimen. the second laboratory (B) with 2 pathologists reached a median number 
of 4.0 (quartile range 1.75 to 6.0) LN per specimen. the third laboratory (C) recovered the highest 
median number of lymph nodes in the Netherlands (median 13.0, quartile range 9.0 to 17.0). On 
the x-axis the number of specimen per pathologist is given. Numbers of lymph nodes are given as 
median ± quartile range.
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Table 1. factors influencing mean lymph node retrieval in node positive and negative  
patients (univariate analysis) 
 Node negative Node positive
Mean LN N P value Mean LN N P value
Treatment characteristics
Randomization TME 8.5 392 0.000* 11.6 269 0.000*
TME + RT 6.9 360 9.1 204
OK type LAR 8.7 462 0.001* 10.5 309 0.693*
APR 6.0 234 10.5 135
Quality of 
mesorectum
Good/moderate 8.5 364 0.060* 10.4 245 0.294*
Poor 6.7 166 9.8 96
CRM ≤ 2 mm 8.3 110 0.529† 10.7 135 0.836†
2 - 5 mm 7.5 160 10.3 104
> 5 mm 7.7 481 10.5 234
Distal margin ≤ 2 mm 8.0 285 0.026† 10.6 131 0.713†
2 - 5 mm 7.2 303 10.6 212
> 5 mm 8.6 118 10.6 71
Length of 
specimen
≤ 20 cm 7.8 151 0.060† 9.9 95 0.683†
20 - 30 cm 7.8 344 10.2 219
31 - 40 cm 7.5 139 10.5 92
> 40 cm 5.8 41 12.2 20
Patient characteristics
Sex Male 7.8 489 0.156* 10.5 296 0.873*
female 7.5 263 10.5 177
Age < 60 years 9.0 247 0.001* 10.9 182 0.342*
> 60 years 7.1 505 10.2 291
BMI ≤ 20 10.4 25 0.021† 9.6 20 0.155†
20 - 25 8.3 238 10.7 171
> 25 7.4 322 9.3 178
Weight loss Yes 8.2 218 0.075* 10.7 146 0.260*
No 7.5 498 10.3 310
Tumor characteristics
Histological 
type
Adenocarcinoma 7.8 689 0.298* 10.3 407 0.196*
Mucinous carcinoma 6.9 60 11.3 62
Invasion depth T1 5.3 63 0.001† 8.5 2 0.563†
T2 7.1 322 10.5 92
T3 8.6 352 10.3 356
T4 9.7 15 13.7 23
Size ≤ 2 cm 4.4 62 0.000† 7.4 21 0.000†
2 - 5 cm 7.3 502 9.8 329
> 5 cm 10.0 181 13.1 114
Differentiation Well/moderate 8.0 584 0.004* 10.5 303 0.933*
Poor/undifferentiated 6.6 167 10.4 169
Lymphoid 
reaction
None/few 7.5 631 0.014* 10.5 430 0.831*
Extensive 8.8 117 10.4 43
Abbreviations: BMI = body mass index; LN = lymph node; RT = radiotherapy;  
APR = abdominoperineal resection; LAR =  low anterior resection;  
TME = total mesorectal excision; CRM = circumferential resection marge 
* Mann Whitney U test † Kruskal-Wallis test
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Patient-related factors
the number of examined LN was significantly smaller in N0 patients of 60 years and older 
(9.0 vs. 7.1, P<0.001). there was no effect of sex. In overweighed N0 patients (BMI >25) less 
LN were examined compared with patients with normal weight or underweight (7.4 vs. 8.3 
and 10.4, respectively, P=0.021). None of the patient related factors had a significant effect on 
lymph node retrieval in N+ patients (table 1).
Tumor-related factors
In specimens with larger tumors more LN were found, 10.0 in tumors over 5 cm in diameter, 
compared with 4.4 in tumors less than 2 cm in size in N0 patients (P<0.0001). this significant 
difference was also present in N+ patients. this was also reflected in the relation of the number 
of LN with invasion depth. Well-differentiated tumors showed more LN in N0 patients (8.0 vs. 
6.6, P=0.004). In N0 patients the retrieval of LN was increased in tumors with an extensive 
lymphoid reaction (8.8 vs. 7.5, P=0.014). Histological type did not influence the numbers of 
LN (table 1).
Table 2. Multivariate analysis in node negative patients for at least 12 examined lymph nodes
Tumor, treatment, and patient characteristics OR 95% CI P value
Randomization TME + RT 0.8 0.5 - 1.2 0.22
TME 1.0
OK type LAR 2.1 1.4 - 4.0 0.017
APR 1.0
Age < 60 years 1.7 1.2 – 2.6 0.007
> 60 years 1.0
Invasion depth T1 0.3 0.1 – 0.5 0.13
T2 0.5 0.1 – 1.9 0.31
T3 0.7 0.2 – 2.7 0.65
T4 1.0
Size ≤ 2 cm 0.3 0.1 – 0.9 0.027
2 - 5 cm 0.6 0.4 – 0.9 0.022
> 5 cm 1.0
Differentiation Well/moderate 2.1 1.0 – 2.8 0.061
Poor/undifferentiated 1.0
Factors are included in the multivariate analysis if their p-value was < 0.05 in the univariate analysis.
Abbreviations: APR = abdominoperineal resection; CI = confidence interval; LAR =  low anterior 
resection; RT = radiotherapy; TME  = total mesorectal excision
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Multivariate analysis in node negative patients
In the multivariate analysis we included all factors showing a significant correlation with the 
number of LN in the univariate analyses in node negative patients. The cut-off value of 12 LN 
was chosen on the basis of current TNM guidelines.23 In these analyses only the age of the 
patient, the size of the tumor, and the surgical procedure showed a significant relation with 
the number of LN (table 2).
Factors associated with the presence of lymph node metastases
Younger patients (<60 years) are more often diagnosed with N+ status compared with older 
patients, however, this difference was not significant (P=0.051). None of the other patient 
related factors were associated with lymph node status. Short-term neoadjuvant RT did not 
affect nodal status (P=0.10). Of all the surgical related factors only distal and circumferential 
margin involvement were associated with N+ status (P=0.007 and P<0.0001, respectively), 
furthermore the tumor was located closer to the circumferential margin in N+ patients 
(P<0.0001). 
Almost all morphology-assessed features were associated with LN status. N+ status was 
positively associated with larger tumor diameter (P=0.038), higher t-stage (P<0.0001), 
mucinous carcinoma (P=0.002), poor differentiation (P<0.0001) and absence of/or little 
lymphoid reaction (P=0.001) (data not shown).	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Figure 3. Overall recurrence free interval on the basis of median LN yields per pathology laboratory. 
A, N0 patients. B, N+ patients.
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Lymph node status and retrieval in correlation with survival
To evaluate the impact of a low number of LN examined on patients survival we divided the 
participating pathology laboratories into 2 groups, the ones with a high median number of 
examined LN (>8, 48 laboratories, 513 patients) and those with a low median number of 
examined LN (<7, 48 laboratories, 711 patients). these cut-off value was determined using 
the median lymph node numbers in the RT arm of our trial and by various studies in the 
literature.3,25 When evaluating prognosis, we found that N0 patients from low LN laboratories 
have a significantly lower recurrence free interval (17.0% vs. 10.7%, P=0.016, figure 3A). 
there was no difference in prognosis for N+ patients (50.6% vs. 46.7%; P=0.38, figure 3B). 
This suggests that the LN status is more reliable if it is determined in a laboratory with high 
LN yields.
DISCUSSION
The presence of LN metastases is the most powerful prognostic factor for recurrence and overall 
survival in colorectal cancer. In this study, we evaluated factors involved in the amount of both 
examined LN and lymph node status in rectal cancer patients. furthermore, we demonstrated 
that the amount of LN retrieved is correlated with clinical outcome. 
the number of patients in our study with 12 or more LN was low, only 19% of patients who 
received preoperative Rt and 31% of patients that underwent surgery only. these percentages 
are similar to those found by Baxter et al.18 in a large retrospective study on the impact of 
preoperative RT on LN retrieval in rectal cancer. Tepper et al.5 conducted a study in 1664 rectal 
cancer patients that underwent tME surgery and subsequently Rt and 5-fu-based chemo-
therapy. The quartile ranges of the number of LN examined in this study were similar to our 
TME only group. 
The number of 12 LN is not based upon large-scale support, so continuously data is being 
generated and calculations are being made, attempting to find clinically relevant cut-off points. 
This has resulted in diverging recommendations, from 6 to 16 LN per colorectal resection 
specimen.1-4, 10, 19, 20 
We identified several treatment, patient and tumor related factors that influence the number 
of retrieved LN. Because LN status is an important factor involved in the amount of examined 
LN, we analyzed all factors in these 2 groups separately. Compared with surgery alone, the 
application of neoadjuvant RT seriously interferes with the detection of LN and results in lower 
LN yields. In LN with metastases the mean size of the node is smaller because the lymphoid 
cells disappear by radiation. This phenomenon is not seen in negative LN, most likely because 
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the shrinking negative LN become so small that they are under the level of detection after 
neoadjuvant therapy. 
Not only neoadjuvant therapy is affecting the number of LN retrieved. Indeed, surgical 
procedures play a part too. One can imagine that when tME surgery has been carried out 
adequately, more fatty tissue will be removed and as a consequence more LN can potentially 
be found. Indeed, in cases where the surgical quality of the resection specimen was good 
(i.e. resection margin on the mesorectal fascia), more LN were found. One would expect that 
more LN could be found, if a longer segment of bowel is removed. In contrast, the longer the 
resection specimen, the less LN (per 10 cm) were found, although this did not reach the signi-
ficance. these results partly can be explained by anatomy, as LN are not equally distributed 
along the bowel.21-24 The majority of mesorectal LN were located within the upper two-thirds 
of the posterior mesorectum.22 Complete removal of nodes in this area may, in part, explain 
higher yield of LN in a smaller resection specimen.
Pathology laboratories showed large differences of the median amount of examined LN. The 
International Union against Cancer guidelines advise to examine at least 12 LN per specimen 
for accurate N-staging. This number is arbitrary, however, and in this study we found that this 
number is only met in the upper quartile of the study population. In the lowest quartile, no 
more than 4 LN were examined per specimen, a result obtained even after special training of 
pathologists. In this Rt+tME trial the pathologic examination of the specimen was standardized 
and pathologists were trained according to the protocol of Quirke et al.13 Nevertheless, for the 
examination of most specimens the criteria of the International Union against Cancer minimum 
LN yield were not met. It is speculative to precisely indicate the underlying explanations for 
these variations, but it is plausible that in spite of training, working standards still did not meet 
the minimal demands in some laboratories. In contrast to most studies, derived from single 
institutions, we believe that our findings reflect routine practice better, as was confirmed by 
the data from the Surveillance, Epidemiology and End Results program database.25 This is an 
important issue, as we found that prognosis is more adequately predicted for N0 patients in 
laboratories where at least 8 LN were retrieved. In laboratories where routinely 7 or less LN 
was examined, N0 patients have a lower recurrence free interval. this confirms that low LN 
yields leads to the understaging as positive LN are not retrieved, thereby excluding patients 
from adjuvant therapy, probably resulting in a poor prognosis.26
Understaging because of low LN yields is not only attributable to the pathologist, patient 
and tumor related factors are of significant importance too. Biologic difference in immune 
response may lead to more prominent LN, which makes them easier to identify. The amount 
of inflammatory response is dependent on the age of the patient, size, and invasion depth of 
the tumor.27 
Most of the studies concerning lymph node counts were performed in a mixture of colorectal 
cancer patients, like the studies of Caplin et al.28 (at least 7 LN should be analyzed) and Wong 
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et al.10 (at least 14 LN should be analyzed). these numbers cannot simply be extrapolated for 
rectum carcinomas, as several previous studies report that the mean LN in rectum is lower 
compared with other colon segments.21-24 
In a large single center study of 2427 pT3 colorectal adenocarcinomas, Goldstein et al.26 
showed that, increasing numbers of recovered LN were associated with a greater number of 
LN metastases and specimen without LN metastases had lower mean LN yields. During the 
45 years of this study, the standard dissection of LN did not change much, but before 1992 LN 
dissections were performed by pathologists and residents, and after 1992 this was performed 
by trained pathology assistants. This switch led to a striking increase of yearly means of 
recovered LN, suggesting a crucial role for the person that is performing the dissection. Thorn 
et al.29 confirmed this in their search for factors that affect LN yield in surgery for rectal cancer. 
they found that besides tumor size and number of positive LN, the examining pathologist was 
of independent significance in multivariate analysis. Our data confirm this finding. 
Conventional manual node dissection is accurate and efficient but time-consuming. We were 
able to show that in a number of pathology laboratories the median of 12 LN per patient is 
achieved with conventional methods, the number suggested as minimum by the TNM-system 
for both colon and rectal cancer, thereby demonstrating its feasibility, however, this was 
achieved in only a minority of all specimens. 
Several studies have reported about additional techniques to improve the N-staging by 
increasing the number of detected LN, using techniques like sentinel node procedures, fat 
clearing methods, and ex vivo methylene blue injection.30 However, studies are small, clinical 
relevance is unclear and reliability is a major issue. Therefore, as long as the clinical conse-
quences of these procedures have not been confirmed indisputably, there is a limited need for 
additional methods and standard evaluation of LN should be sufficient. 
In conclusion, we showed that the number of retrieved LN after TME surgery is partially 
dependent on biologic characteristics, and is partially influenced by the choice of treatment 
and pathologic assessment of the specimen. Standard evaluation of LN should be sufficient 
if standard pathologic procedures are carried out thoroughly and accurately. The potential 
additional benefit of immunohistochemical or sentinel procedures can only thereafter be 
assessed. The International Union against Cancer guidelines advise to examine at least 12 LN 
per specimen for accurate N-staging, both for colon and rectal cancer. This number is arbitrary, 
however, and in this study we found that this number is only met in the upper quartile of the 
study population. In the lowest quartile, no more than 4 LN were examined per specimen. 
Our data indicate that a median of 8 or more LN indicate that adequate staging is performed 
in patients with rectal cancer.
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ABSTRACT
PURPOSE: Mucinous histology of metastatic colorectal cancer (CRC) has been associated with 
poor prognosis, however this has never been assessed in large well-defined study populations 
treated with the current used systemic agents. We investigated the prognostic value of mucinous 
histology in two large phase III studies in metastatic CRC.
PATIENTS AND METHODS: The study population included 1010 metastatic CRC patients who 
were treated with chemotherapy and targeted therapies in two phase III studies. Patients were 
classified according to the histology of the primary tumor in mucinous adenocarcinomas (MC) 
and non-mucinous adenocarcinomas (AC). 
RESULTS: Patients with MC (n=99) were older, had more often a normal serum lactate dehydro-
genase (LDH), extrahepatic localization of metastases, larger primary tumor diameter and a 
higher t classification compared to patients with AC (n=911). A deficient mismatch repair 
system and BRAF mutations were observed in 17% and 22% of patients with MC, compared 
to 3% and 7% in patients with AC, respectively. Clinical outcome was investigated in both 
studies separately, showing a worse overall survival (OS), progression free survival, and overall 
response rate in patients with MC compared to patients with AC. Patients with MC received 
less cycles of treatment compared to AC, but did not suffer from a higher incidence of grade 
3/4 toxicity. In multivariate analysis, mucinous histology was as an independent negative 
prognostic factor for OS, resulting in a combined hazard ratio of 1.78 (95%CI 1.35-2.35).
CONCLUSIONS: Patients with metastatic mucinous CRC have distinct clinicopathological 
features and poor response to chemotherapy and targeted agents. The strong negative 
prognostic value of MC warrants the use of this pathological feature as a stratification factor 
for clinical trials in metastatic CRC.  
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INTRODUCTION
Mucinous adenocarcinomas (MC) are a histological subtype of colorectal cancer (CRC), in 
which the tumor cells secrete abundant extracellular mucin involving more than 50% of the 
tumor volume. they account for 5-15% of all primary colorectal carcinomas1, and MC are 
clinically, morphologically, and molecularly different from adenocarcinomas (AC). MC are 
more often correlated with an advanced stage at presentation2, 3, a larger diameter4, localization 
in the proximal colon2, 4, and peritoneal dissemination.5-7 furthermore, MC affect younger 
patients and are associated with the Lynch syndrome.8, 9 Mucinous tumors exhibit a distinct 
molecular profile compared to AC, involving a higher incidence of KRAS and BRAF mutations10, 11, 
diploidy12,  deficient mismatch repair system (dMMR)13, and CpG island hypermethylation.14 
Approximately 50% of CRC patients develop metastatic disease and in case of irresectable 
metastases there is no curative treatment available. However, survival can be improved by 
using cytotoxic regimens (fluoropyrimidines, oxaliplatin, irinotecan) in combination with 
targeted therapy (VEGf- and EGfR antibodies). two studies investigated the response to 
chemotherapy in advanced CRC patients with MC versus AC. Mucinous tumors appeared to 
be less responsive to  fluoropyrimidines6, irinotecan and oxaliplatin-based chemotherapy.7 The 
response of tumors with  mucinous histology to chemotherapy plus targeted agents has not 
been reported. 
The prognostic value of mucinous histology remains controversial. Several studies report that 
MC are associated with poor prognosis6, 7, 15, which however is not confirmed by others.2, 16 This 
may be attributed to the small number of patients with MC in these studies. It should be noted 
that several known prognostic factors, like tNM classification and BRAF mutation status17, 
were not included in most of these studies.
Therefore, the aim of this retrospective analysis was to assess the prognostic value of MC in 
metastatic CRC in more detail. 
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PATIENTS AND METHODS
Study population
All patients included in our analysis participated in two phase III randomized clinical trials 
from the Dutch Colorectal Cancer Group (DCCG). In the CAIRO study18 (CKtO 2002-07, 
Clinicaltrials.gov; NCt00312000) 820 metastatic CRC patients were randomized between 
first-line sequential or combination treatment with capecitabine, irinotecan, and oxaliplatin. 
the primary endpoint was overall survival (OS), and secondary endpoints included progression 
free survival (PfS) and response rate. Median OS was 16.3 months (95% CI 14.3-18.1) for 
the sequential treatment group and 17.4 months (95% CI 15.2-19.2) for the combination 
group (p=0.33). As expected, combination therapy was associated with a prolonged first-line 
PfS compared with sequential therapy (7.8 vs 5.8 months; p=0.0002). the CAIRO2 study19 
(CKtO 2005-02, Clintrials.gov; NCt00208546) included 755 metastatic CRC patients, who 
were randomly assigned to receive first-line treatment with capecitabine, oxaliplatin, and 
bevacizumab, or the same schedule with the addition of cetuximab. the primary endpoint 
of this study was PfS, and secondary endpoints were OS and response rate. the addition of 
cetuximab significantly decreased the median PfS (9.6 months (95% CI 8.4-10.5) versus 10.7 
months (95% CI 9.7-12.3); p=0.01). the median OS was 20.3 months (95% CI 17.8-24.7) in 
the patients treated without cetuximab and 19.4 months (95% CI 17.5-21.4) in the patients 
treated with cetuximab (p=0.16). In both studies, treatment cycles were given every 3 weeks. 
Assessment of the tumor response was performed every 3 cycles (9 weeks) using Ct imaging 
and evaluated according to the Response Evaluation Criteria for Solid tumors (RECISt).20 The 
written informed consent required for all patients before study entry also included translational 
research on tumor tissue.
In our analysis, we included eligible patients with a resection of the primary tumor of which 
formalin-fixed paraffin-embedded (ffPE) tissue was available. the patients were classified 
based on the histology of the primary tumor according to the guidelines of the World Health 
Organization (WHO).21 tumors were considered MC if more than 50% of their volume 
consisted of mucin. AC were defined as tumors without extracellular mucin. Other histological 
subtypes were excluded from our analysis. 
Clinicopathological features
The following clinical parameters were collected for each patient: age, gender, Eastern 
Cooperative Oncology Group (ECOG) performance status, serum lactate dehydrogenase 
(LDH), site of the primary tumor, prior adjuvant therapy, number and sites of metastatic 
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disease, metachronous (>6 months after initial diagnosis) or synchronous (≤6 months of initial 
diagnosis) presentation of metastases, and regimen used as first-line treatment.
Histopathological review was performed on haematoxylin and eosin-stained coupes by two 
independent observers, including an experienced pathologist (IDN). the tNM classification of 
malignant tumors was used to describe the extent of cancer spread in terms of invasion depth 
and lymph node stage.22 The maximum diameter, median number of detected and involved 
lymph nodes were recorded.
Microsatellite instability
Immunohistochemistry (IHC) was performed on tissue microarrays (tMA’s) of ffPE material of 
the primary tumor. to determine the expression of the four mismatch repair (MMR) proteins 
(MLH1, MSH2, MSH6 and PMS2) the slides were stained with antibodies against these proteins, 
as described before.23 Tumors were considered positive for MMR expression if nuclear staining 
was present in at least one tumor cell and negative if there was complete absence of nuclear 
staining. 
Analysis of microsatellite instability (MSI) was performed in all tumors of which at least one 
staining for the MMR proteins was negative or the IHC staining was not interpretable, using a 
validated protocol.23 two microsatellite markers (BAt 25 en BAt 26) were used, and if only one 
of these markers showed instability, the analysis was extended with four other markers (BAt 
40, D2S123, D5S346, D17S250). A tumor was defined MSI if at least two of the six markers 
showed instability. 
Hypermethylation of MLH1 promoter
the DNA methylation status of the MLH1 promoter regions was determined after bisulphite 
treatment of the DNA using the EZ DNA methylation KIt, ZYMO Research (Orange, CA, 
united States of America (uSA)) as described before.24
KRAS and BRAF mutation analysis
Genomic DNA was isolated from 4-8 microdissected 50µm sections of ffPE primary tumor 
tissue as previously described.25 The KRAS and BRAF mutation status25, 26 were assessed in 
duplicate by sequencing analysis in patients of the CAIRO2 study. 
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Statistical analysis
The comparison in baseline clinicopathological features between MC and AC was done 
regardless of study treatment, using the χ2-test, fisher’s Exact test or Wilcoxon rank sum 
test where appropriate. Clinical outcome of patients with MC and AC was investigated in 
both studies separate, due to an improvement of clinical outcome caused by the addition 
of bevacizumab to first-line chemotherapy in the CAIRO2 study. OS was calculated as the 
interval from the date of randomization until death from any cause or until the date of last 
follow-up. PfS for first-line treatment was calculated from the date of randomization to the 
first observation of disease progression, death from any cause or last follow-up date. OS and 
PfS curves were estimated using the Kaplan-Meier method and compared with the log-rank 
test. Overall response was defined as partial response or complete response. Disease control 
was defined by stable disease with a duration of more than four months or partial response 
or complete response. Differences in response and disease control rates were tested with a 
χ2-test. Multivariate analysis of OS was performed by means of a Cox proportional hazard 
model to determine if mucinous histology was an independent prognostic factor for survival 
after correction for; age, gender, localization of metastases, performance status, serum LDH, 
site of primary tumor, prior adjuvant therapy, metastatic sites involved, onset of metastases, 
treatment arm, invasion depth, and lymph node status. In the CAIRO2 study, KRAS and BRAF 
mutation status were also included in the multivariate analysis. the adjusted hazard ratios of 
mucinous histology in the CAIRO and CAIRO2 study were checked for heterogeneity. If no 
heterogeneity was present, the hazard ratios were combined on a log scale, using a DerSi-
monian-Laird random effects meta-analysis with inverse variance weighting. P values below 
0.05 were considered as statistically significant. the analyses were performed using SAS 8.2 
software. 
RESULTS
Study population
A total of 1099 eligible patients, 552 from the CAIRO and 547 from the CAIRO2 study were 
available for our analysis. In the CAIRO study, 50 patients (9%) were classified with MC, 435 
patients (79%) with AC, and 67 patients (12%) with other histological subtypes, including 
adenocarcinomas with a mucinous component of less than 50%. In the CAIRO2 study, 49 
patients (9%) were diagnosed with MC, 476 patients (87%) with AC, and 22 patients (4%) with 
other histological subtypes of CRC. Patients with other histological subtypes were excluded 
from our analysis. 
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Table 1. Baseline characteristics of patients with MC and AC treated in the CAIRO  
and CAIRO2 study
MC 
n = 99
AC
n = 911
p-Value
Age Median (range) 67 (36-84) 63 (28-81) 0.005
Gender Male 58 (59%) 548 (60%) 0.83
female 41 (41%) 363 (40%)
Localization 
metastases
Hepatic 19 (20%) 303 (34%) 0.02
Extrahepatic 40 (41%) 281 (31%)
Hepatic+extrahepatic 38 (39%) 312 (34%)
Locally advanced 0 7 (1%)
Unknown 2 8
WHO 
performance 
status 
0 66 (67%) 594 (65%) 0.61
1 30 (30%) 301 (33%)
2 3 (3%) 16 (2%)
Serum LDH Normal 80 (82%) 557 (62%) <0.0001
>uLN 18 (18%) 347 (38%)
Unknown 1 7
Site of primary 
tumor
Colon 52 (53%) 418 (46%) 0.08
Rectosigmoid 30 (30%) 240 (26%)
Rectum 17 (17%) 252 (28%)
Unknown 0 1
Prior adjuvant 
therapy
No 84 (85%) 758 (83%) 0.69
Yes 15 (15%) 152 (17%)
Unknown 0 1
Metastatic sites 
involved
1 41 (42%) 420 (47%) 0.47
2 34 (35%) 316 (35%)
>2 22 (23%) 160 (18%)
Unknown 2 15
Metastases 
onset
Metachronous 46 (46%) 411 (45%) 1.00
Synchronous 53 (54%) 500 (55%)
Treatment arm 
CAIRO study
Sequential 26 (52%) 212 (49%) 0.77
Combination 24 (48%) 223 (51%)
Treatment arm 
CAIRO2 study
CAPOX + Bev 32 (65%) 231 (49%) 0.03
CAPOX + Bev + Cet 17 (35%) 245 (51%)
Abbreviations: ULN = upper limit of normal; CAPOX = capecitabine and oxaliplatin;  
Bev = bevacizumab; Cet = cetuximab; MC = mucinous adenocarcinoma; AC = adenocarcinoma
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Patient characteristics
the median age of patients with MC (n=99) was 67 years compared to 63 years for patients 
with AC (n=911)(p=0.005). Patients with MC more often had a normal serum LDH (p<0.0001), 
and extrahepatic localization of metastases (p=0.02) compared to patients with AC. A trend 
was observed for a decreased incidence of MC versus AC in rectum carcinomas (p=0.08). 
In the CAIRO2 study, a lower percentage of patients with MC was treated with cetuximab 
(p=0.03) (table 1).
Table 2. Primary tumor characteristics of patients with MC and AC treated in the CAIRO  
and CAIRO2 study
MC 
n = 99
AC
n = 911
p-Value
Diameter (mm) Median (range) 50 (20-140) 40 (3-135) <0.0001
Invasion depth T 1-2 3 (3%) 71 (8%) 0.03
T 3 64 (67%) 632 (72%)
T 4 28 (30%) 172 (20%)
Unknown 4 36
Lymph node status N 0 24 (26%) 246 (29%) 0.20
N 1 27 (30%) 307 (36%)
N 2 40 (44%) 294 (35%)
Unknown 8 64
Number lymph nodes Median (range) 9 (1-55) 8 (0-44) 0.23
Number positive 
lymph nodes 
Median (range) 3 (0-54) 2 (0-41) 0.06
MMR status pMMR 82 (83%) 884 (97%) <0.0001
dMMR 17 (17%) 27 (3%)
KRAS mutation status 
(CAIRO2 study)
Wild-type 27 (59%) 275 (61%) 0.75
Mutation 19 (41%) 176 (39%)
Unknown 3 25
BRAF mutation status 
(CAIRO2 study)
Wild-type 35 (78%) 421 (93%) 0.002
Mutation 10 (22%) 30 (7%)
Unknown 4 25
Abbreviations: MMR = mismatch repair genes; pMMR = proficient MMR;  
dMMR = deficient MMR; MC = mucinous adenocarcinoma; AC = adenocarcinoma
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Primary tumor characteristics
the primary tumor diameter of patients with MC (n=99) was significantly higher compared 
to primary tumors of AC patients (n=911)(p<0.0001). tumors with mucinous histology had a 
higher t classification in comparison with AC (p=0.03). furthermore, a trend was observed 
towards a higher median number of positive lymph nodes in patients with MC compared to AC 
(p=0.06). dMMR was observed in 17% of the mucinous primary tumors compared to 3% in AC 
(p<0.0001). Hypermethylation of the MLH1 promoter was the cause of dMMR in 83% of the 
tumors with mucinous histology. In the CAIRO2 study, BRAF mutations were demonstrated in 
22% of the MC patients compared to 7% in AC patients (p=0.002) (table 2). 
Outcome of treatment with chemotherapy (CAIRO study)
Patients in the CAIRO study were treated with first-line sequential or combination chemo-
therapy containing capecitabine, irinotecan and oxaliplatin. In univariate analysis, the median 
OS for patients with MC was 13.2 (95%CI 10.2-17.9) compared to 19.2 months (95%CI 
17.9-20.6) in the group with AC (p=0.03). A trend of decreased PfS was observed in patients 
with MC versus AC (p=0.09). these differences in OS and PfS were observed in both treatment 
arms. the overall response rate in the 437 patients who were evaluated was 12% in the MC 
group and 37% in the group patients with AC (p=0.0006). Disease control was observed in 
79% of the patients in the MC group and 87% of those in the AC group (p=0.17). the median 
number of the overall treatment cycles was significantly different between patients with MC 
versus AC (6 versus 12 respectively, p=0.004). the reasons for treatment discontinuation were 
not significantly different between both patients groups. the incidence of any grade 3 or 4 
adverse event was 72% in the patients with mucinous histology and 66% in the AC patients 
(p=0.43) (table 3). 
Outcome of treatment with chemotherapy plus targeted agents  
(CAIRO2 study)
In the CAIRO2 study patients received first-line capecitabine, oxaliplatin and bevacizumab 
with or without cetuximab. the median OS was significantly lower for patients with MC 
compared to patients with AC (median 13.1 (95%CI 9.9-20.2) versus 21.5 months (95%CI 
19.8-22.9); p=0.009). furthermore, the median PfS in the MC group was 7.2 months (95%CI 
5.7-8.6) compared to 10.6 months (95%CI 10.1-11.4) in patients with AC (p<0.0001). these 
differences in OS and PfS were observed in both treatment arms. the overall response rate for 
the patients with MC was 10%, and 54% for the group with AC (p<0.0001). In 85% of the MC 
patients disease control was observed compared to 94% of the patients with AC (p=0.003). 
Patients with MC received less cycles of treatment compared to patients with AC (6 versus 9 
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cycles, p=0.006). No significant differences were observed in the causes for discontinuation of 
treatment between the group with MC and the group with AC. The incidence of any grade 3 or 
4 adverse event was 71% versus 79% in the MC and AC patients (p=0.27) (table 4). 
The independent prognostic role of mucinous histology
In multivariate Cox regression analysis, mucinous histology was a strong predictor of OS in the 
CAIRO study (HR 1.80; 95%CI 1.24-2.62; p=0.003). Other independent negative predictors for 
OS in metastatic CRC patients were male gender (HR 1.32; 95%CI 1.05-1.64; p=0.01), primary 
tumor localization in the colon (HR 1.55; 95%CI 1.19-2.01; p=0.01), WHO performance status 
2 (HR 1.92; 95%CI 1.16-3.23; p=0.01), abnormal serum LDH (HR 1.85; 95%CI 1.48-2.31; 
Table 3. Efficacy of the CAIRO study treatment (capecitabine, oxaliplatin and irinotecan)  
in patients with MC and AC
MC 
n = 50
AC
n = 435
p-Value
Median OS Months (95% CI) 13.2 (10.2-17.9) 19.2 (17.9-20.6) 0.03
Median PFS1 Months (95% CI) 5.3 (3.9-6.6) 7.2 (6.6-8.1) 0.09
Overall response rate 1 CR+PR 5/43 (12%) 144/394 (37%) 0.0006
Disease control rate 1 CR+PR+SD 34/4 (79%) 341/394 (87%) 0.17
Median cycle number Median (range) 6 (1-42) 12 (0-55) 0.004
Overall toxicity Grade >3 36 (72%) 287 (66%) 0.43
Abbreviations: OS = overall survival; PFS = progression free survival;  
CR = complete response; PR = partial response; SD = stable disease;  
MC = mucinous adenocarcinoma; AC = adenocarcinoma
Table 4. Efficacy of the CAIRO2 study treatment (capecitabine, oxaliplatin,  
bevacizumab with or without cetuximab) in patients with MC and AC
MC 
n = 49
AC
n = 476
p-Value
Median OS Months (95% CI) 13.1 (9.9-20.2) 21.5 (19.8-22.9) 0.009
Median PFS Months (95% CI) 7.2 (5.7-8.6) 10.6 (10.1-11.4) <0.0001
Overall response rate CR+PR 4/41 (10%) 222/411 (54%) <0.0001
Disease control rate CR+PR+SD 35/41 (85%) 387/411 (94%) 0.03
Median cycle number Median (range) 6 (1-36) 9 (0-48) 0.006
Overall toxicity Grade >3 35 (71%) 376 (79%) 0.27
Abbreviations: OS = overall survival; PFS = progression free survival;  
CR = complete response; PR = partial response; SD = stable disease;  
MC = mucinous adenocarcinoma; AC = adenocarcinoma
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p<0.0001), more than 2 metastatic sites involved (HR 2.53; 95%CI 1.89-3.38; p<0.0001), t4 
classification (HR 1.59; 95%CI 0.99-2.56; p=0.04), and a poor differentiation grade (HR 1.53; 
95%CI 0.89-2.64; p=0.006).
In the CAIRO2 study, mucinous histology remained also strongly associated with OS in multi-
variate analysis (HR 1.76; 95%CI 1.16-2.67; p=0.008). Other clinicopathological features 
associated with worse survival in this multivariate model were; WHO performance status 
1 (HR 1.36; 95%CI 1.06-1.75; p=0.02), abnormal serum LDH (HR 1.65; 95%CI 1.28-2.12; 
p=0.0001), N2 classification (HR 1.45; 95%CI 1.05-2.01; p=0.05), and BRAF mutations (HR 
2.61; 95%CI 1.57-4.32; p=0.0002).
the test for heterogeneity (p=0.93) showed that the adjusted hazard ratios for MC versus 
AC were similar in the CAIRO (1.80; 95%CI 1.24-2.62) and CAIRO2 study (1.76; 95%CI 
1.16-2.67). therefore these hazard ratios were combined in a meta-analysis which resulted in 
an overall hazard ratio of 1.78 (95%CI 1.35-2.35) for mucinous histology in advanced CRC 
patients treated with systemic therapy (figure 1). 
 
 
DISCUSSION
This is the largest retrospective analysis in mucinous metastatic CRC patients treated with 
the current standard systemic treatments. We demonstrated that MC are less responsive to 
fluoropyrimidine-based chemotherapy and targeted agents compared to AC. furthermore, in a 
multivariate analysis mucinous histology was shown to be a strong negative prognostic factor 
for survival. 
It is recognized that MC are a different entity in patients with CRC. Specific clinical and patho-
logical features are associated with mucinous histology, of which a larger diameter, higher 
t classification, and extrahepatic localization of metastases were confirmed in our analysis. 
Patients with MC treated in the CAIRO studies were older compared to the patients with AC, 
which has not been previously described. In stage II and III CRC, patients with MC were 
Figure 1. Meta-analysis of both studies estimating the prognostic value of mucinous histology in 
metastatic CRC treated with systemic therapy.
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
50
Chapter 3   Mucinous adenocarcinomas
significantly younger. Mucinous histology is associated with Lynch syndrome27, however, the 
incidence of MSI in metastatic CRC is low.23 Therefore, it is likely that the association between 
mucinous histology and age depends on the presence and cause of a dMMR system.
Our data confirm previous results on differences in molecular signatures between MC and AC 
in respect to MMR10, 28, 29 and BRAF mutation status14, 30, supporting the hypothesis that MC are 
a distinct biologic entity. In previous studies, the incidence of KRAS mutations between MC 
and AC showed opposite results.30, 31 However, these data were derived from a small subset 
of patients and could not be confirmed in our larger patient cohort. further identification of 
specific genetic changes in the mucinous phenotype, i.e. using gene expression profiling, are 
necessary and useful to understand the molecular etiology of these tumors. 
fluoropyrimidines, irinotecan, and oxaliplatin are the effective chemotherapeutic agents 
used in metastatic CRC. Negri et al.6 first reported about the reduced response to 5-fu based 
chemotherapy of metastatic mucinous CRC. these results were confirmed in a similar subset 
of patients that received irinotecan and oxaliplatin in addition to fluoropyrimidines as first-line 
chemotherapy.7 Our analysis also showed a highly significant worse response to these chemo-
therapeutic agents for MC compared to AC. Bevacizumab, a humanized monoclonal antibody 
against vascular endothelial growth factor (VEGf), combined with 5-fu based chemotherapy 
is nowadays the standard first-line treatment for metastatic CRC. Our study is the first reporting 
the outcome of chemotherapy plus targeted agents in MC versus AC. Since the CAIRO2 study19 
had a negative outcome, possibly due to a negative interaction between the study drugs32, the 
responsiveness of metastatic mucinous CRC to cetuximab cannot be assessed in our series.
The mechanisms for the difference in treatment sensitivity of MC compared to AC remains 
unclear, but there are several possible explanations. first, differences in molecular features 
may partly explain the unresponsiveness of tumors with mucinous histology. dMMR is more 
frequently observed in MC compared to AC, and associated with a reduced response to 
adjuvant 5-fu treatment in stage II and III CRC patients.33, 34 However, the predictive value of 
dMMR in response to systemic therapy in metastatic CRC is difficult to assess due to its low 
incidence in metastatic CRC patients.23 Other molecular markers, such as thymidylate synthase 
(TYMS) and GSTP1, are also overexpressed in mucinous CRC35 and possibly correlated with 
resistance to chemotherapy. We did not investigate these or other chemotherapy pathway 
markers in our analysis, because they have not been validated for clinical use in metastatic 
CRC.36 No predictive markers for response to bevacizumab have yet been identified. 
Secondly, the mucins themselves may play a role in the ability of tumor cells to escape the effect 
of systemic therapy. It has been established that mucins play a role in the processes of tumor 
progression, invasion, survival, and protection against the host immune response.37 MUC2 is 
a colonic mucin that is overexpressed in the mucinous subtype of CRC38 and correlated with 
resistance to 5-fu in vitro.39 The mucin lakes may also be a physical barrier for the delivery of 
targeted therapy to the tumors cells, however this has not been investigated. 
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A third explanation could be that the evaluation of the response to treatment is inadequate in 
MC patients. In the CAIRO studies we used Ct scanning and evaluated response according to 
RECIST criteria. If neoplastic cells in MC respond to systemic therapy, the total tumor volume is 
probably more affected by the unresponsive mucin lakes, which could result in false negative 
conclusions. Our observation that the difference in disease control rate between MC and AC 
was less compared to the difference in objective response rate supports this hypothesis. If 
confirmed, the RECISt criteria may not be the optimal instrument to evaluate the objective 
response rate to treatment in the mucinous subtype of CRC.  
The prognostic value of MC is highly controversial, which may be attributed to a large amount 
of heterogeneous studies with small subsets of patients. Most studies suggested that MC are 
associated with poor prognosis6, 7, 15, while others found no correlation between histological 
subtype and clinical outcome.2, 16 Our study differs from the published literature in one 
important aspect, in that only patients with a previous resection of the primary tumor were 
included, for the obvious reason of tissue availability. Our group has shown that patients with 
a resection of the primary tumor may have a better prognosis compared to patients without 
resection.40 Since the prognostic value of resection of the primary tumor in metastatic CRC 
patients has not been clearly established, the possible influence of this parameter cannot 
be assessed. Therefore we assessed the prognostic value of mucinous histology in metastatic 
patients with a resection of the primary tumor, and we observed a significant shorter OS in 
patients with MC compared to AC. As mentioned before, MC present with distinct clinico-
pathological features, and most of these features are correlated with a worse prognosis. for 
example, BRAF mutations were more frequently observed in MC compared to AC, which is a 
strong negative prognostic marker in metastatic CRC.17 However, even with BRAF mutations 
included in a multivariate analysis, mucinous histology remained a strong independent 
negative prognostic factor. the hazard ratio for mucinous histology is equal or even higher 
compared to well known stratification factors, such as serum LDH, WHO performance status 
and number of metastatic sites involved. Appropriate stratification facilitates the interpretation 
of study results and prevent heterogeneity in response and survival rates. Our findings suggest 
that mucinous histology should be one of the stratification factors in metastatic CRC trials. 
Due to the considerable inconsistency in reporting clinicopathological features and use of 
stratification factors, we believe there is an urgent need for re-establishing the most important 
prognostic factors in metastatic CRC. 
In conclusion, MC are a distinct entity of CRC with specific clinicopathological and genetic 
features. Mucinous histology is an independent negative prognostic factor for OS in 1010 
metastatic CRC patients treated with chemotherapy and targeted agents, which may be 
explained by resistance to this systemic treatment. We recommend including mucinous 
histology as a prognostic factor for patients with metastatic CRC.
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ABSTRACT
BACKGROUND: Synchronous metastases of colorectal cancer (CRC) are considered to be of 
worse prognostic value compared with metachronous metastases, but only few and conflicting 
data have been reported on this issue.
METHODS: We retrospectively investigated patient demographics, primary tumor charac-
teristics, and overall survival (OS) in 550 advanced CRC patients with metachronous vs 
synchronous metastases, who participated in the phase III CAIRO study. for this purpose only 
patients with a prior resection of the primary tumor were considered.
RESULTS: The clinical and pathological characteristics associated with poor prognosis that we 
observed more often in patients with synchronous metastases (n=280) concerned an abnormal 
serum lactate dehydrogenase (LDH) concentration (P=0.01), a worse WHO performance status 
(P=0.02), primary tumor localization in the colon (P=0.002), and a higher t stage (P=0.0006). 
No significant difference in median OS was observed between patients with synchronous 
metastases and metachronous metastases (17.6 vs 18.5 months, respectively, P=0.24).
CONCLUSION: Despite unfavorable clinicopathological features in patients with synchronous 
metastases with a resected primary tumor compared to patients with metachronous metastases, 
no difference in the median OS was observed. Possible explanations include a (partial) chemo-
resistance in patients with metachronous disease because of previous adjuvant treatment, 
whereas differences between the two groups in screening procedures resulting in a lead time 
bias to diagnosis or in prognostic molecular markers remain speculative.
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INTRODUCTION
Approximately 20% of colorectal cancer (CRC) patients present with synchronous distant 
metastases at the initial diagnosis, and about 50% of the patients without metastases at presen-
tation develop distant metastases within 3 years of diagnosis.1 for patients with unresectable 
metastatic CRC there are no curative options, but a significant benefit in median overall survival 
can be achieved with palliative systemic treatment.2 This treatment consists of cytotoxic 
chemotherapy (fluoropyrimidines, oxaliplatin, irinotecan) and targeted therapy (VEGf- and 
EGfR antibodies).
Only few data have been reported on the prognostic role of synchronous and metachronous 
metastases in patients with advanced CRC treated with chemotherapy, and the results are 
conflicting. Moreover, there is no consensus about the definition of synchronous and 
metachronous disease.  Synchronous metastases were defined as metastases detected by 
pre-operative screening or during resection of the primary tumor3-5, and occurring within 
three6, six7, 8 or twelve months9, 10 of the initial diagnosis of CRC. It is not clear whether patients 
with synchronous vs metachronous metastases may represent two different categories of CRC. 
Only in some surgical intervention trials the clinicopathological features have been compared 
between patients with metachronous and synchronous metastases.6, 7, 10 However, these studies 
involved small numbers of patients, and only limited clinical and pathological features were 
evaluated.
In a review of 143 phase II and III studies with 21.214 metastatic CRC patients, metachronous 
vs synchronous metastases were reported as baseline characteristics in only 18 studies.11 
Consequently, few data are available on the prognostic value of this parameter with conflicting 
results.12-17
to our knowledge, this is the first large retrospective analysis on the clinical and pathological 
characteristics of advanced CRC patients with metachronous vs synchronous metastases, and 
their correlation with outcome. Data were obtained from the phase III CAIRO study of the 
Dutch Colorectal Cancer Group (DCCG).18
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MATERIALS AND METHODS
Patients 
Data were used from the phase III CAIRO study of the DCCG.18, 19 In this study patients were 
randomized between sequential and combination treatment with capecitabine, irinotecan, 
and oxaliplatin. Stratification parameters included WHO performance status, serum lactate 
dehydrogenase (LDH), prior adjuvant therapy, predominant localization of metastases, and 
participation institution. Assessment of tumor response was scheduled every three cycles (nine 
weeks) according to RECISt criteria.20 follow-up after completion of treatment was performed 
every 3 months until death. the primary endpoint was overall survival (OS). 
Patients were divided into synchronous and metachronous disease, with synchronous disease 
defined as distant metastases occurring within, and metachronous disease beyond 6 months 
of the primary diagnosis of CRC. for two reasons only patients in whom a resection of the 
primary tumor had been performed were included in the analysis. first, tissue of the primary 
tumor was required for histopathological review. Second, the arguments for non-resection may 
greatly vary, from patients with an asymptomatic primary and excellent performance status to 
patients with a symptomatic primary with extensive metastases and poor performance status in 
whom a delay in systemic treatment is not warranted. These arguments are often not  recorded 
in the patients’ files.
Pathologic procedures and parameters
Standardized pathology examination was performed in the pathology laboratories of the 
referring hospitals. The maximum diameter was noted with an invasion depth described in 
terms of the t classification and lymph node stage in terms of the N classification (tNM).21 
All reports of these examinations with haematoxylin and eosin stained coupes of the primary 
tumors were collected. Histopathologic review was carried out by two independent observers. 
If the scoring was not unambiguous, the two observers discussed until agreement was reached. 
Classification of the tumors was performed using the World Health Organization guidelines.22 
A tumor was considered to be of the mucinous type when at least 50% of the tumor was 
mucinous. The tumors were graded according to the grade of differentiation into well, 
moderately and poorly adenocarcinomas on the basis of the part of poorest differentiation in 
the tumor. Growth pattern, the presence of inflammatory reaction and fibroblastic reaction 
were assessed according to Jass.23 the mismatch repair system (MMR) status was determined 
by immunohistochemistry and microsatellite instability (MSI) analysis.24
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Statistical analysis
The comparison of patient and primary tumor characteristics between patients with synchronous 
and metachronous metastases was done using Wilcoxon’s rank sum test or χ2-test where 
appropriate. the progression free survival (PfS) for first line treatment was calculated from 
the date of randomization to the first observation of disease progression or death from any 
cause. OS and PfS curves were estimated using the Kaplan-Meier method and compared with 
Table 1. Baseline characteristics
Metachronous 
(n=270) 
Synchronous 
(n=280)
p-Value
Age at randomization Median (range) 66.0
(31.0-79.0)
62.5
(34.0-81.0)
<0.0001a
Gender Male 163 (60%) 179 (64%) 0.43b
female 107 (40%) 101 (36%)
Predominant locali-
zation metastases
Liver 131 (49%) 240 (86%) <0.0001b
Extrahepatic 135 (50%) 39 (14%)
Unknown 4 (1%)  1 (<1%)
WHO performance 
status at randomi-
zation
0 and 1 265 (98%) 262 (94%) 0.02b
2 5 (2%) 17 (6%)
Unknown 1 (<1%)
Serum LDH at rando-
mization
Normal 183 (68%) 161 (58%) 0.01b
> uLN 84 (31%) 117 (42%)
Unknown 3 (1%) 2 (<1%)
Site of primary tumor Colon 114 (42%) 149 (53%) 0.002b
Rectosigmoid 65 (24%) 73 (26%)
Rectum 91 (34%) 58 (21%)
Prior adjuvant 
therapy
No 189 (70%) 276 (99%) <0.0001b
Yes 81 (30%) 3 (1%)
Unknown 1 (<1%)
Metastatic sites 
involved
1 121 (45%) 141 (50%) 0.63b
2 96 (35%) 95 (34%)
>2 45 (17%) 44 (16%)
Unknown 8 (3%)
Treatment arm Sequential 130 (48%) 138 (49%) 0.80b
Combination 140 (52%) 142 (51%)
Abbreviations: ULN = upper limit of normal; WHO = World Health Organization
aWilcoxon’s rank sum test;  bχ2
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Table 2. Primary tumor characteristics
Metachronous
(n = 270)
Synchronous
(n = 280)
p-Value
Diameter Median (range) 40.0
(15.0-120.0)
62.5
(34.0-81.0)
0.007a
Invasion depth T 1-2 28 (10%) 7 (3%) 0. 0006b
T 3 187 (69%) 200 (71%)
T 4 45 (17%) 59 (21%)
Unknown 10 (4%) 14 (5%)
Lymph node status N 0 104 (39%) 50 (18%) <0.0001b
N 1 97 (36%) 97 (35%)
N2 56 (21%) 113 (40%)
Unknown 13 (5%) 20 (7%)
Classification Adenocarcinoma 216 (80%) 217 (78%) 0.53b
Adenocarcinoma 
with mucinous 
component
28 (10%) 33 (12%)
Mucinous 
carcinoma
24 (9%) 24 (8%)
Other 2 (1%) 6 (2%)
Differentiation grade Well 11 (4%) 11 (4%) 0.15b
Moderate 143 (53%) 125 (45%)
Poor 115 (43%) 141 (50%)
Unknown 1 (<1%) 3 (1%)
Infiltration pattern Circumscribed 69 (26%) 48 (17%) 0.02b
Diffuse 199 (74%) 226 (81%)
Unknown 2 (<1%) 6 (2%)
Fibroblastic reaction None/little 84 (31%) 76 (27%) 0.39b
Extensive 184 (68%) 196 (70%)
Unknown 2 (1%) 8 (3%)
Lymphoid reaction None/little 193 (71%) 218 (78%) 0.04b
Extensive 74 (27%) 55 (20%)
Unknown 3 (1%) 7 (2%)
MSI status pMMR 261 (97%) 271 (97%) 0.94b
dMMR 9 (3%) 9 (3%)
Abbreviations: MSI = microsatellite instability; pMMR = proficient mismatch repair system;  
dMMR = deficient mismatch repair system
aWilcoxon’s rank sum test;  bχ2
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the log-rank test. Multivariate analysis of survival was performed by means of a Cox propor-
tional hazard model. Patients were considered evaluable for response if they had completed at 
least 3 cycles of chemotherapy. Overall response was defined as partial response or complete 
response. Disease control was defined by stable disease with a duration of more than 4 months 
or partial response or complete response.20 Differences in response and disease control rates 
were analysed by a χ2 (univariate) model. All tests were two-sided and P-values of less than 
0.05 were considered statistically significant. the analyses were performed using SAS 8.2 
software.
RESULTS
Patient characteristics
In 550 of 803 eligible patients in the CAIRO study, a resection of the primary tumor was 
performed and material for histological review of the primary tumor was available, and these 
550 patients were included in this analysis. Compared to the metachronous group (n=270), 
patients with synchronous metastases (n=280) were younger (p<0.0001), had more often an 
abnormal serum LDH at randomization (p=0.01), and more often the liver as predominant 
site of metastases (p<0.0001). Primary tumor localization in the colon (p=0.002), a worse 
WHO performance status at randomization (p=0.02), and no previous adjuvant chemotherapy 
(p<0.0001) were more frequently observed in patients with synchronous metastases (table 1). 
Primary tumor characteristics
tumors of patients with synchronous metastases had larger diameters (p=0.007), a higher t 
(p=0.0006) and N stage (p<0.0001), absent or little lymphoid reaction (p=0.04) and more 
frequently a diffuse infiltration pattern (p=0.02) than patients with metachronous disease. 
there were no significant differences between the synchronous and metachronous group in 
terms of classification, differentiation grade, MSI status, and fibroblastic reaction surrounding 
the tumor (table 2).
Correlation of clinical and pathological characteristics with outcome
the effect of clinical and pathological characteristics on median OS was evaluated. In the 
overall population of 550 patients, the following parameters significantly correlated with the 
median OS: predominant liver localization of metastases yes vs no (17.9 vs 19.5 months, 
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respectively; p=0.02), WHO performance status 2 vs 0-1 (6.2 vs 18.5 months, respectively; 
p<0.0001), serum LDH concentration abnormal vs normal (12.8 vs 21.3 months, respectively; 
p<0.0001), and number of metastatic sites involved >2 vs 2 vs 1 (12.4 vs 18.0 vs 21.4 months, 
respectively; p<0.0001). In the effect on median OS a significant trend was observed for the 
following pathological characteristics of the primary tumor: t4 vs t3 vs t1-2 (14.3 vs 18.9 vs 
21.9 months, respectively; p=0.03), N2 vs N1 vs N0 (14.4 vs 18.9 vs 20.7 months, respec-
Table 3. Prognostic value of clinical and pathological characteristics for OS  
(multivariate analysis)
Multivariate analysis for OS Hazard ratio (95%CI) p-Value
Onset of metastasis Metachronous 1.05 (0.81-1.36) 0.74
Synchronous R
Gender female 0.78 (0.63-0.97) 0.03
Male R
Site of primary tumor Colon 1.29 (0.98-1.70) 0.0008
Rectosigmoid 0.78 (0.58-1.04)
Rectum R
WHO performance 
status at randomi-
zation
0 and 1 0.53 (0.32-0.88) 0.01
2 R
Serum LDH at rando-
mization
> uLN 1.79 (1.44-2.23) <0.0001
normal R
Number of metastatic 
sites involved
1 0.40 (0.30-0.53) <0.0001
2 0.55 (0.41-0.75)
>2 R
Invasion depth T 1-2 0.69 (0.42-1.12) 0.04
T 3 0.72 (0.55-0.93)
T4 R
Classification Adenocarcinoma 1.00 (0.44-2.25) 0.007
Adenocarcinoma with 
mucinous component
1.56 (0.66-3.68)
Mucinous carcinoma 1.71 (0.71-4.13)
Other R
Differentiation grade Well 0.69 (0.40-1.20) 0.01
Moderate 0.73 (0.59-0.91)
Poor R
Abbreviations: R = reference group; ULN = upper limit of normal;  
WHO = World Health Organization
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tively; p=0.003), mucinous adenocarcinoma vs adenocarcinoma with mucinous component 
vs adenocarcinoma (13.5 vs 13.7 vs 19.3 months, respectively; p=0.006), and differentiation 
grade poor vs moderate vs well (14.8 vs 20.4 vs 24.9 months, respectively; p=0.0001). By 
univariate analysis no effect on median OS was found for age, gender, site of the primary 
tumor, prior adjuvant therapy, treatment arm, infiltration pattern, fibroblastic reaction, 
lymphoid reaction, and MSI status. 
In a multivariate model all patient and primary tumor characteristics were included. 
Independent predictors for median OS in advanced CRC patients, were t stage (p=0.04), differ-
entiation grade (p=0.01), classification (p=0.007), serum LDH at randomization (p<0.0001), 
WHO performance status (p=0.01), site of the primary tumor (p=0.0008), gender (p=0.03), 
and metastatic sites involved (p<0.0001) (table 3). 
Outcome in patients with metachronous vs synchronous metastases
No significant difference in median OS was observed for patients with metachronous vs 
synchronous metastases in an univariate analysis (18.5 vs 17.6 months, respectively; p=0.24) 
(figure 1). In addition, to assess a possible effect of tumor burden, we compared the largest 
diameter of liver metastases between the two groups, and no difference was observed (p>0.05, 
data not shown). In a multivariate model, in which all patient and primary tumor character-
istics were included, the hazard ratio for metachronous vs synchronous metastases was 1.05 
(95% CI 0.81-1.36; p=0.74) (table 3). 
 
 
 
Figure 1. Kaplan-Meier curve for overall survival of advanced CRC patients with metachronous ( ---) 
and synchronous (- - -) metastases in whom a resection of the primary tumor was performed.
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the median PfS in first line treatment was not significantly different between patients with 
metachronous vs synchronous metastases (7.2 vs 6.6 months, respectively; p=0.23). Overall, 
494 patients were assessable for response in first line treatment: 235 in the metachronous 
group and 259 in the synchronous group. the overall response rate (complete plus partial 
tumor response) in first line treatment was significantly better in patients with synchronous 
metastases compared to patients with metachronous metastases (38% vs 28%, respectively; 
p=0.02). the disease control rate (complete plus partial tumor response plus stable disease) 
in first line treatment was not significantly different between patients with synchronous and 
metachronous metastases (81% vs 87%, respectively; p=0.11). 
Interaction of worse prognostic factors in patients with synchronous vs 
metachronous metastases
Patients with synchronous vs metachronous metastases in whom a resection of the primary 
tumor was performed showed significantly different clinical and pathological characteristics. 
Most of these clinicopathological features were correlated with outcome in the total study 
population. However, despite the presence of factors associated with poor prognosis, patients 
with synchronous metastases had no worse survival compared to patients with metachronous 
metastases. 
to find a possible explanation for this observation we analysed whether the median OS of 
patients with individual clinical and pathological characteristics was significantly different 
between the synchronous and metachronous group. However, this proved not to be the case 
(p>0.05 for all analyses). 
Next, we compared the number of worse prognostic factors per patient between the 
synchronous and metachronous group to detect whether there was a skewed distribution. 
Again, this analysis showed no significant difference in the distribution of these characteristics 
per patient between the synchronous and metachronous group (p>0.05 for all analyses). 
DISCUSSION
In this retrospective analysis of the phase III CAIRO trial, we observed that CRC patients with 
synchronous metastases, in whom the primary tumor was resected, significantly more often 
had clinical and pathological characteristics associated with poor prognosis compared to 
patients with metachronous metastases. 
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there is no consensus in the literature on the definition of synchronous vs metachronous 
metastases. We selected a cut-off value of 6 months after the initial diagnosis for two reasons. 
first, in some patients a staging procedure is performed only after full recovery from surgery 
of the primary tumor, which may take several months in some patients. A 6-month period will 
assure adequate classification of these patients. Second, metastases developing during the first 
6 months after surgery of the primary tumor probably reflect similar tumor biology compared 
with metastases detected at initial diagnosis. Therefore, we consider a 6-month cut-off value to 
be a clinically useful distinction between synchronous and metachronous disease.   
The unfavorable clinical characteristics that we observed more often in patients with 
synchronous disease concerned a worse performance status, an abnormal serum LDH, 
and the colon as the primary site of the tumor. Only the primary site of the tumor has been 
previously described as being different between synchronous and metachronous disease.6, 10 
We identified a higher t stage of the primary tumor as an independent worse prognostic 
factor for median OS, which we observed more in patients with synchronous metastases. this 
confirms previously reported results of smaller series.5, 7, 10 
Despite these poor baseline characteristics in patients with synchronous metastases, the 
median OS was not decreased compared to patients with metachronous metastases. tsai 
et al.10 found differences in diameter, number, and distribution of liver metastases between 
patients with synchronous and metachronous disease, and concluded that these character-
istics were of significant importance for survival. tumor burden, as determined by the largest 
diameter of measurable disease and the number of metastatic sites, were comparable between 
patients with synchronous and metachronous metastases, indicating that this parameter did 
not influence our results. However, several other factors may explain this unexpected finding. 
first, a significant percentage of patients with metachronous metastases were treated with 
prior adjuvant chemotherapy, whereas patients with synchronous metastases obviously were 
not. theoretically, this may have resulted in a (partial) resistance to chemotherapy in the 
former group. Indeed, we observed a higher overall response rate to first line chemotherapy 
in patients with synchronous metastases, suggesting that this may compensate the presence 
of worse prognostic factors in this group. Second, there may be heterogeneity between and 
also within the groups of patients with synchronous and metachronous disease with regard to 
symptomatic vs asymptomatic disease and, in the latter situation, a lead time bias caused by 
different time schedules for screening. third,  survival of CRC patients could be influenced by 
a difference in presence of prognostic molecular markers between patients with synchronous 
vs metachronous metastases.8
Comparing our results with the literature, only few chemotherapy trials performed propor-
tional hazard models to determine the influence of metachronous and synchronous disease 
on median OS. Several authors showed no prognostic role for these parameters13, 14, 17, 25, 26 
whereas others identified metachronous disease as a favorable prognostic parameter.12, 15, 16, 27 
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Our analysis differs from the published literature in one important aspect, in that only patients 
with a previous resection of the primary tumor were included in the synchronous group. If 
patients with both resected and non-resected primary tumors were included in the synchronous 
group, a significant median OS benefit was observed for patients with metachronous vs 
synchronous metastases.28 therefore, the conflicting results of previous studies on the 
prognostic role of synchronous disease may be caused by differences among these studies 
in the status of the resection of the primary tumor. Support for our data is provided by two 
recent prospective analyses in which no difference in OS was observed between patients 
with resected synchronous vs resected metachronous CRC liver and lung metastases, with a 
resection of the primary tumor having been performed in all patients.5, 6 
In conclusion, despite the presence of factors associated with poor prognosis in patients with 
synchronous metastases, the parameter of synchronous and metachronous metastases was 
not of prognostic value in advanced CRC patients in whom a resection of the primary tumor 
was performed. Possible explanations include a (partial) chemoresistance in patients with 
metachronous disease because of prior adjuvant treatment, whereas differences between the 
two groups in screening procedures resulting in a lead time bias to diagnosis or in prognostic 
molecular markers remain speculative.
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ABSTRACT 
BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-
epidermal growth factor receptor (EGfR) antibody in metastatic colorectal cancer (CRC). KRAS 
mutation analysis is usually performed on primary tumor tissue because metastatic tissue is 
often not available. However, controversial data are available on the concordance of test 
results between primary tumors and corresponding metastases. We assessed the concordance 
of KRAS mutation status in a study of 305 primary colorectal tumors and their corresponding 
liver metastases.
 
METHODS: Patients with histologically confirmed CRC who underwent surgical resection of 
the primary tumor and biopsy or surgical resection of the corresponding liver metastasis were 
included. KRAS mutation analysis was performed for codons 12 and 13.
RESULTS: KRAS mutation was detected in 108 out of 305 primary tumors (35.4%). In 11 cases 
(3.6%) we found a discordance between primary tumor and metastasis: 5 primary tumors had 
a KRAS mutation with a wild-type metastasis, 1 primary tumor was wild-type with a KRAS 
mutation in the metastasis, and in 5 cases the primary tumor and the metastasis had a different 
KRAS mutation. 
 
CONCLUSION: We observed a high concordance of KRAS mutation status of 96.4% (95% 
CI 93.6-98.2%) between primary colorectal tumors and their corresponding liver metastases. 
In only 6 patients (2.0%; 95% CI 0.7-4.2%) the discordance was clinically relevant. In this 
largest and most homogenous study to date, we conclude that both primary tumors and liver 
metastases can be used for KRAS mutation analysis. 
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INTRODUCTION
Recent advances in specific signalling pathways of cancer cells have introduced targeted 
therapy into treatment regimes for patients with metastatic colorectal cancer (CRC).1 Cetuximab 
and panitumumab are monoclonal antibodies that bind to the extracellular domain of the 
epidermal growth factor receptor (EGfR). they inhibit ligand-induced stimulation of several 
intracellular signalling pathways, such as RAS/RAf/MAPK and phosphoinositide-3 pathway, 
which results in decreased stimulation of cell cycle progression, proliferation, angiogenesis, 
and stimulation of apoptosis.2 The KRAS oncogene is currently the most relevant molecular 
biomarker that predicts the response to EGfR-targeted therapy in CRC. An oncogenic mutation 
in KRAS leads to constitutive activation of the RAS/RAf signalling pathway independent from 
EGfR activation by binding of the ligand.3 KRAS mutations occur in approximately 38% of 
colorectal tumors and involve codon 12 and 13 in more than 96% of cases.4 Metastatic CRC 
patients with tumors harboring a KRAS mutation are resistant to treatment with anti-EGfR 
antibodies, showing lower response rates, decreased progression free survival, and overall 
survival compared to patients with KRAS wild-type tumors.5-7 Therefore, the European 
Medicines Agency and the food and Drug Administration have restricted the use of anti-EGfR 
antibodies in metastatic CRC to patients with KRAS wild-type tumors. 
Cetuximab and panitumumab have shown efficacy both as monotherapy6, 8 and in combi-
nation with chemotherapy5, 7 in patients with KRAS wild-type metastatic CRC. Nevertheless, 
even among patients with KRAS wild-type tumors, the majority of patients does not respond 
to anti-EGfR therapy. Efficacy of anti-EGfR therapy was suggested to be further restricted to 
patients with BRAF wild-type tumors.9 An additional explanation for the suboptimal response 
rates to anti-EGfR antibodies in patients with KRAS wild-type tumors is discordance of KRAS 
mutation status between primary colorectal tumors and corresponding metastases. In the 
early dissemination model, tumor cells depart the primary lesion before the acquisition of 
a fully malignant phenotype to undergo new mutations and metastatic growth at a distant 
site.10 According to this model, a discordance in mutation status between primary tumors and 
metastases may occur, and as a consequence the mutation status of the primary tumor might 
not be adequate to predict the response of metastases to anti-EGfR treatment. 
Current data on the concordance in KRAS mutation status between primary colorectal tumors 
and metastases are conflicting. five studies showed a 100% concordance of KRAS mutation 
status in primary CRC and corresponding metastases.11-15 In contrast to these data, others have 
reported a discordance of KRAS mutation status in primary tumors and metastatic sites, with 
an overall discordance observed in 4-32% of the patients.16-28 These controversial results are 
probably due to the fact that these studies were underpowered with a small number of patients, 
and included a wide variety of metastatic sites. Therefore it is still uncertain whether the 
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evaluation of KRAS mutation status in the most commonly available primary tumor correctly 
reflects the KRAS mutation status of corresponding metastasis. This is highly relevant given the 
large number of CRC patients as well as the potential toxicity and costs of anti-EGfR therapy.
We assessed the concordance in KRAS mutation status in primary tumors and their corre-
sponding liver metastases in an adequately powered study of 305 CRC patients.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed CRC who underwent surgical resection of the primary 
tumor and biopsy or surgical resection of the corresponding liver metastasis were included in 
this analysis. Results were obtained from archived material of three large pathology labora-
tories and from material collected from the CAIRO2 study, a large multicentre trial of the 
Dutch Colorectal Cancer Group (DCCG).5 
In patients with a discordance of KRAS mutation status between the primary tumor and 
metastasis, additional blocks of the primary tumor were obtained to exclude heterogeneity 
within the tumor. Lymph node metastases present at the time of diagnosis were also acquired 
in these patients.
Tumor DNA preparation
formalin-fixed paraffin-embedded tissue blocks were cut at 4 µm thickness and stained with 
heamatoxylin and eosin (HE). the presence of tumor tissue was marked by a pathologist. 
Subsequently the blocks were cut at 20-40 µm thickness and micro dissected for DNA 
extraction. tumor tissue was dissolved in 200 µl lysis buffer (QIAamp DNA Micro Kit, Qiagen, 
the Netherlands) and incubated with proteinase K overnight at 56°C for two nights. DNA 
was extracted according to the manufacturer’s protocol (QIAamp DNA Micro Kit, Qiagen, 
the Netherlands), and DNA concentration was determined at 260 nm using the Nanodrop 26 
ND-1000 spectrophotometer (Nanodrop technologies Inc, Wilmington, uSA).
KRAS mutation analysis
for KRAS mutation analysis, exon 2 (codon 12 and 13) was amplified using a 50 µl reaction 
mixture containing 0.2 µM forward (tGtAAAACGACGGCCAGtAGGCCtGCtGAAAAtGACtG) 
and reverse (CAGGAAACAGCtAtGACCtGGAtCAtAttCGtCCACAAAA) primer (Invitrogen, 
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the Netherlands); dAtP, dCtP, dGtP and dttP (GE Healthcare, the Netherlands) at 0.2 mM 
each; 50 mM KCl; 10 mM tris-HCl (pH 8.3); 2.5 mM MgCl2; 1 U AmpliTaq Gold polymerase 
(Applied Biosystems, Nieuwkerk a/d IJsel, the Netherlands) and 50 ng of template DNA. the 
PCR conditions were as follows: 94°C for 10 min; 92°C for 1 min, 60°C for 1 min, 72°C for 1 
min (40 cycles); and 72°C for 10 minutes.
All PCR products were purified with the MultiScreen HtS 96 well filtration System (Millipore, 
Ireland). Subsequently, the purified products were sequenced using fluorescently labeled 
terminators (BigDye® terminators (v 1.1); Applied Biosystems, uSA) with both M13-forward 
and M13-reverse sequencing primers. the sequencing products were analyzed on an ABI 3730 
DNA Analyzer (Applied Biosystems) and the data analysis was performed using Sequencing 
Analysis Software Sequencing Analysis Software v5.3.1 with KBTM Basecaller. Sequence 
results were scored by visual inspection of the chromatograms.
Statistical analysis
We considered a discordance level of 5% or more to be clinically relevant, that is, leading to 
substantial change in routine clinical practice. To exclude such level of discordance under the 
assumption that the true discordance was 2.5% or less, we set the sample size at 304 paired 
samples. With this sample size, the precision in the estimated percentage of discordance was 
2.5% (i.e. standard error 1.25, half-width of the 95%-confidence interval equal to 2.5%). 
The comparison of patient and primary tumor characteristics between patients with KRAS 
wild-type and KRAS mutant primary tumors was done using Wilcoxon’s rank sum test or χ2 for 
numerical or categorical variables, respectively. Differences in KRAS mutation status between 
the primary tumor and corresponding metastasis were analyzed by calculating the percentage 
of concordance, and (clinically relevant) discordance, together with the corresponding 
Clopper-Pearson 95% confidence intervals. Differences were considered to be statistically 
significant when the P-value was below 0.05. All statistical tests were two-sided. 
RESULTS
Patient characteristics
We analyzed KRAS codon 12 and 13 mutations in 320 matched primary colorectal tumors and 
liver metastases. The tumor cell percentages in all primary tumors and metastases were above 
30%. We failed to obtain a KRAS mutation status in 15 patients, therefore our further analyses 
were performed in 305 paired samples. Patient characteristics are shown in Table 1. 
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Table 1. Distribution of tumor characteristics according to KRAS status of the primary tumor
Overall
n = 305
KRAS mutation
n=108
KRAS wild-type
n=197
p-Value
Age 0.20
Median (IQR) 64 (57-70) 65 (58-71) 64 (57-70)
Gender 0.37
Male 191 (62.6%) 64 (59.3%) 127 (64.5%)
female 114 (37.4%) 44 (40.7%) 70 (35.5%)
Metastases presentation 0.45
Synchronous 169 (55.4%) 63 (58.3%) 106 (53.8%)
Metachronous 136 (44.6%) 45 (41.7%) 91 (46.2%)
Tumor location 0.63
Colon 167 (54.8%) 59 (54.6%) 108 (54.8%)
Rectum 54 (17.7%) 16 (14.8%) 38 (19.3%)
Rectosigmoid 80 (26.2%) 32 (29.6%) 48 (24.4%)
Unknown 4 (1.3%) 1 (0.9%) 3 (1.5%)
Histopathological subtype 0.12
Adenocarcinoma 271 (88.9%) 90 (83.3%) 181 (91.9%)
Adenocarcinoma with 
mucinous component
21 (6.9%) 10 (9.3%) 11 (5.6%)
Mucinous adenocar-
cinoma
8 (2.6%) 5 (4.6%) 3 (1.5%)
Unknown 5 (1.6%) 3 (2.8%) 2 (1.0%)
Differentiation grade 0.21
Good 33 (10.8%) 13 (12.0%) 20 (10.2%)
Moderate 196 (64.3%) 65 (60.2%) 131 (66.5%)
Poor 52 (17.0%) 17 (15.7%) 35 (17.8%)
Unknown 24 (7.9%) 13 (12.0%) 11 (5.6%)
T stage 0.62
T1 4 (1.3%) 2 (1.9%) 2 (1.0%)
T2 20 (6.6%) 9 (8.3%) 11 (5.6%)
T3 231 (75.7%) 81 (75.0%) 150 (76.1%)
T4 36 (11.8%) 11 (10.2%) 25 (12.7%)
Unknown 14 (4.6%) 5 (4.6%) 9 (4.6%)
N stage 0.10
N0 114 (37.4%) 46 (42.6%) 68 (34.5%)
N1 87 (28.5%) 31 (28.7%) 56 (28.4%)
N2 86 (28.2%) 26 (24.1%) 60 (30.5%)
Unknown 18 (5.9%) 5 (4.6%) 13 (6.6%)
Number of lymph nodes examined 0.28
Median (IQR) 10 (6-15) 10 (6-13) 10 (6-16)
Number of lymph node metastases 0.15
Median (IQR) 1 (0-4) 1 (0-3) 1 (0-4)
Abbreviation: IQR = interquartile range
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Figure 1. Overall concordance of the KRAS mutation status between primary tumor and liver 
metastasis (A), discordance without clinical impact (B) and discordance with clinical impact (C).
Abbreviations: Wt = wild-type; Mt = mutation
KRAS mutation and histopathological parameters
A total of 108 patients (35.4%) had a KRAS mutation in the primary tumor; of which 37 patients 
had a Gly12Asp mutation, 28 patients a Gly12Val mutation, 14 patients a Gly13Asp mutation, 
10 patients a Gly12Cys mutation, 7 patients a Gly12Ser mutation, 7 patients a Gly12Ala 
mutation, 3 patients a Gly12Arg mutation, 1 patient a Gly12Asp and Gly12Ala mutation, 
and 1 patient a Gly12Phe mutation (table 2). Histopathological characteristics of the primary 
tumor were comparable between patients with and without a KRAS mutation (table 1).
Concordance of KRAS status in primary tumors and corresponding liver 
metastases
In 294 patients (96.4%; 95% CI 93.6-98.2%), the same KRAS mutation status was obtained 
from the primary tumor and the corresponding liver metastasis. In 11 patients (3.6%; 95% CI 
1.8-6.4%), of which 7 had synchronous metastases at diagnosis and 4 developed metachronous 
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metastases, we found a discordance between primary tumors and metastases. five patients had 
a KRAS mutation in the primary tumor and not in the liver metastasis. Only one patient had 
a wild-type status of the primary tumor, while the metastasis showed a KRAS mutation. In 5 
patients the primary tumors had different KRAS mutations compared with the metastases. One 
of these patients had two primary tumors. Both primary tumors had the same KRAS mutation 
(Gly13Asp), while the liver metastasis had a different KRAS mutation (Gly12Ser). In another 
patient the primary tumor had a double mutation (Gly12Asp/Gly12Val) and the metastasis 
had a Gly12Asp mutation (figure 1, table 3). taken together, the observed discordance was 
clinically relevant in only six patients (2.0%; 95% CI 0.7-4.2%). 
Subsequent analyses in patients with a discordance of KRAS status
Several tests were performed to exclude bias of the test results. first, the HE coupes of all 
patients with a discordant KRAS mutation status between the primary tumor and liver metastasis 
were revised. The primary tumors and liver metastases had a mean tumor cell percentage of 
65 and 60%, respectively. Subsequent independent reanalysis of the KRAS mutation status 
resulted in the same discordances. 
Second, several mutation analyses were performed on different areas of the tumor and from 
different tumor blocks in order to establish possible tumor heterogeneity. Two patients showed 
heterogeneity of KRAS status within the primary tumor. One of these patients demonstrated 
two areas with a Gly12Asp mutation and one area with wild-type status, of which the latter 
resembled the liver metastasis. The other patient showed two different KRAS mutations within 
the same tumor, of which one is concordant with the liver metastasis (table 3).
Third, six of the eleven patients with discordant results did have lymph node metastases at 
the time of diagnosis. KRAS mutation testing of all lymph nodes separately revealed overall 
Table 2. Distribution of KRAS mutation types
Codon 12 / 13 Patients with KRAS mutation 
(n, %)
Gly12Asp 37 (34%)
Gly12Val 28 (26%)
Gly13Asp 14 (13%)
Gly12Cys 10 (9%)
Gly12Ser 7 (6%)
Gly12Ala 7 (6%)
Gly12Arg 3 (3%)
Gly12Phe 1 (1%)
Gly12Asp + Gly12Ala 1 (1%)
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Table 3. Patients with a discordant KRAS status between primary tumor and metastasis
KRAS status 
primary tumor
KRAS status
2nd tumor
KRAS status
lymph node metastasis
KRAS status
liver metastasis
1 Gly12Ala - LN 1: Gly12Ala Wt
LN 2: Gly12Ala
LN 3: Gly12Ala
2 Gly12Asp - - Wt
Gly12Asp
Wt
3 Gly12Cys - - Wt
4 Gly12Asp - LN 1: Gly12Asp Wt
Gly12Asp LN 2: Gly12Asp
Gly12Asp LN 3: Gly12Asp
Gly12Asp LN 4: Gly12Asp
LN 5: Wt
5 Gly12Ser - - Wt
6 Wt - - Gly12Cys
7 Gly12Asp - LN 1: Wt Gly12Ala
LN 2: Wt
LN 3: Wt
8 Gly13Asp Gly13Asp LN 1: Gly13Asp Gly12Ser
9 Gly12Ser - - Gly12Ala
10 Gly12Cys - LN 1: Gly12Asp Gly12Asp
Gly12Asp LN 2: Gly12Asp
LN 3: Gly12Asp
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: Wt
11 Gly12Asp/
Gly12Val
- LN 1: Gly12Val Gly12Asp
LN 2: Gly12Val
LN 3: Gly12Val
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: Gly12Asp
LN 7: Gly12Asp
Multiple blocks of primary tumor tissue and lymph node metastases were tested when available 
Abbreviation: Wt = wild-type
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Table 4. Overview of studies providing data on KRAS status of primary tumor and related metastases
Author 
study
Year No. 
of 
pts
Analyzed 
metastatic 
site
Method KRAS 
mutation 
in PT (%)
KRAS 
mutation in 
PT, WT in M
KRAS WT in 
PT, mutation 
in M
Total 
percentage of 
discordance
Albanase 2004 30 liver SSCP analysis 14 (47%) 5/14 (36%) 4/16 (25%) 9/30 (30%)
Al-Mulla 1998 26 liver ASO/direct 
seq
10 (38%) 2/10 (20%) 3/16 (19%) 5/26 (19%)
31 lymph node ASO/direct 
seq
10 (32%) 1/10 (10%) 5/21 (24%) 6/31 (19%)
Artale 2008 48 diverse, 81% 
liver
direct seq 11 (23%) 1/11 (9%) 2/37 (5%) 3/48 (6%)
Baldus 2010 20 visceral 
metastasis 
direct seq   9 (45%) 1/9 (11%) 1/11 (9%) 2/20 (10%)
55 lymph node direct seq 29 (53%) 15/29 (52%) 2/26 (8%) 17/55 (31%)
Cejas 2010 93 liver direct seq 30 (32%) 1/30 (3%) 4/63 (6%) 5/93 (5%)
17 lung direct seq 10 (59%) 1/10 (10%) 1/7 (14%) 2/17 (12%)
Etienne-
Grimaldi
2008 48 liver biopsy PCR-RfLP 16 (33%) 0 (0%) 0 (0%) 0 (0%)
Italiano  2009 59 not specified seq 23 (39%) 1/23 (4%) 2/36 (6%) 3/59 (5%)
Losi 1992 19 local 
recurrence
multiplex-
ASPCR
12 (63%) 0 (0%) 0 (0%) 0 (0%)
16 metastasis, 
38% liver
multiplex-
ASPCR
13 (81%) 0 (0%) 0 (0%) 0 (0%)
Loupakis 2009 43 liver seq not 
mentioned
0 (0%) 2/* 2/43 (5%)
Molinari 2009 37 diverse, 74% 
liver
seq 16 (43%) 2/16 (13%) 1/21 (5%) 3/37 (8%)
15 lymph node seq 8 (53%) 0 (0%) 0 (0%) 0 (0%)
Oliveira 2006 28 lymph node not 
mentioned
18 (64%) 2/18 (11%) 7/10 (70%) 9/28 (32%)
Oudejans 1991 31 liver and lung hybridization 14 (45%) 1/14 (7%) 1/17 (6%) 2/31 (6%)
Perrone 2008 10 diverse, 
mainly liver
direct seq 2 (20%) 1/2 (50%) 1/8 (13%) 2/10 (20%)
Santini 2008 99 diverse, 80% 
liver
seq 38 (38%) 3/38 (8%) 1/61 (2%) 4/99 (4%)
Garm 
Spindler 
2009 31 not specified qPCR 11 (35%) 2/11 (18%) 0/20 (0%) 2/31 (6%)
Suchy 1992 58 autopsy 
material, not 
specified
dot-blot 
hybridization
15 (26%) 0 (0%) 0 (0%) 0 (0%)
Weber 2006 36 liver seq 14 (39%) 0 (0%) 0 (0%) 0 (0%)
Zauber 2003 42 diverse, 93% 
lymph node, 
5% liver
SCCP 
analysis + seq
22 (52%) 0 (0%) 0 (0%) 0 (0%)
Overall 892 All sites All methods 345/849
(41%)
39/345
(11%)
35/504
(7%)
76/892
(9%)
276 Liver All methods 84/233 
(36%)
8/84
(10%)
11/149
(7%)
21/276
(8%)
129 Lymph nodes All methods 65/129
(50%)
18/65
(28%)
14/64
(22%)
32/129
(25%)
Abbreviations: ASO = allele-specific oligonucleotides; ASPCR = allele-specific polymerase chain reaction; 
M = metastasis; pts = patients; PT = primary tumor; qPCR = quantitative PCR; RFLP = restriction fragment 
length polymorphism; SSCP = single strand conformational polymorphism; seq = sequencing
* Total number of cases not specified
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concordant KRAS status between lymph node metastases and the primary tumor in three 
patients. The KRAS status of the lymph nodes in the other three patients showed heterogeneity, 
of which at least one lymph node metastasis showed a different KRAS status compared with 
the primary tumor. However, this explains the discordance between the primary tumor and 
liver metastasis only in one patient (table 3). 
DISCUSSION
this is the first adequately powered study in CRC that compares KRAS mutation status between 
primary tumors and their corresponding liver metastases. We showed that tissue from the 
primary tumor can reliably be used for KRAS mutation testing in order to select patients for 
anti-EGfR therapy. 
We observed a concordant KRAS mutation status in 96.4% of 305 paired samples of colorectal 
tumors and liver metastases. However, the difference in KRAS status was not clinically relevant 
in 5 of the 11 patients with discordant results, because both primary tumor and metastasis 
had a different KRAS mutation. Given the high statistical power of our analysis, we were able 
to obtain a highly accurate estimate of the level of discordance that enabled us to conclude 
that the level of discordance was 2.0%. the high rate of concordance is in agreement with the 
notion that KRAS mutations are considered as early driving events in CRC progression, and 
associated with the growth of small adenoma to clinically significant size.29 Therefore, KRAS 
mutation status is expected to be equal in both primary tumors and metastases.10 
The previously reported lower concordance levels between primary tumors and metastases 
are most likely due to bias caused by false-negative results in underpowered studies. We 
calculated that 304 paired cases were needed to reliably exclude a rate of discordance of 
> 5%, while previous studies included only 10 to 110 patients (table 4). Moreover, in these 
studies metastases of different sites were compared with the primary tumor. As the molecular 
patterns may differ between metastatic sites10, more reliable results are obtained when KRAS 
mutation status is tested more rigorously for each metastatic site. The liver is the predominant 
site of metastases in the majority of metastatic CRC patients, therefore the results of our large 
series of 305 liver metastases provide a solid reference for clinical decision making as to 
anti-EGfR therapy. Another issue is the fact that KRAS testing is technically not as straight-
forward as is often assumed. Several quality assurance systems are now in place, and the first 
‘round robin’ test indicates that at least 30% of the experienced pathology laboratories fail 
to pass the threshold level of the quality assurance programs.30 Other important facts about 
KRAS testing are the correct evaluation of the amount of tumor tissue in the sample and the 
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
80
Chapter 5   KRAS mutation analysis
sensitivity of testing methods. In a previous study we demonstrated in > 500 samples that both 
sequencing and real-time PCR are reliable methods.31
A discordant KRAS status between the primary tumor and metastasis was observed in a small 
number of patients (3.6%). In these cases tumor cells may have departed the primary lesions 
prior to the acquisition of a fully malignant phenotype to undergo somatic mutations or 
deletions at a distant site.10 Another explanation for the discordant results may be hetero-
geneity of KRAS status within the primary tumor, although this was the case in only a small 
number of patients. Lastly, a discordance may in theory be explained by metastases from a 
non-detected second primary.  
Previously published data showed that a considerable fraction (25%, table 4) of colorectal 
lymph node metastases does not resemble the primary tumor in terms of KRAS mutation status. 
In 5 of the 25 lymph node metastases that we tested the KRAS status was not concordant with 
the primary tumor, which is consistent with the literature (table 4). therefore lymph node 
metastases do not seem suitable for determination of the KRAS mutation status of colorectal 
carcinomas. Discordance in KRAS mutation status might be due to clonal selection during the 
process of metastasis, however heterogeneity in lymph node metastases could explain this 
discordance in only one patient.
Eight different KRAS mutation types were observed in our study, of which Gly12Asp showed 
the highest frequency. five patients (1.6%) harbored different KRAS mutation types in the 
primary tumor compared with the metastases. this confirms the findings of Cejas et al.20 
and Albanese et al.16, who reported a small number of patients (4 and 7% respectively) with 
different mutation types between primary tumors and metastases. A different KRAS mutation 
type between primary lung adenocarcinomas and corresponding lymph node metastases 
was also observed in only 1% of the patients.32 Currently, all patients with a KRAS mutation 
are excluded from treatment with anti-EGfR antibodies, independently of the mutation 
type. However, a recent paper indicated that codon 13 mutated tumors may be sensitive to 
cetuximab treatment.33 As we observed a low frequency in KRAS mutation type discrepancies 
between primaries and metastases, this is not of clinical importance in selecting patients for 
anti-EGfR therapy.
In conclusion, we demonstrated a high level of concordance of 96.4% between primary tumors 
and liver metastases, which for clinical purposes to select CRC patients for anti-EGfR therapy 
was even higher with 98%. the implication of these results for general oncology practice is 
that both tissue of primary tumor or liver metastasis may be used for KRAS mutation testing. 
The results of our study are only valid for liver metastases and cannot be extrapolated to other 
metastatic locations. furthermore, we demonstrated that discordance of test results between 
primary tumor and metastases cannot account for the failure rate of anti-EGfR therapy in 
patients with KRAS wild-type tumors. Therefore novel predictive markers in addition to KRAS 
and BRAF mutation status are warranted. 
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Chapter 6   Beyond KRAS mutation status
ABSTRACT 
BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-
epidermal growth factor receptor (EGfR) antibodies in metastatic colorectal cancer (mCRC). 
Novel predictive markers are required to further improve the selection of patients for this 
treatment. We assessed the influence of modification of KRAS by gene copy number aberration 
(CNA) and microRNAs (miRNAs) in correlation to clinical outcome in mCRC patients treated 
with cetuximab in combination with chemotherapy and bevacizumab.
METHODS: formalin-fixed paraffin-embedded primary tumor tissue was used from 34 
mCRC patients in a phase III trial, who were selected based upon their good (n = 17) or poor 
(n = 17) progression-free survival (PfS) upon treatment with cetuximab in combination with 
capecitabine, oxaliplatin, and bevacizumab. Gene copy number at the KRAS locus was 
assessed using high resolution genome-wide array CGH and the expression levels of 17 
miRNAs targeting KRAS were determined by real-time PCR.
RESULTS: Copy number loss of the KRAS locus was observed in the tumor of 5 patients who 
were all good responders including patients with a KRAS mutation. Copy number gains in two 
wild-type KRAS tumors were associated with a poor PfS. In KRAS mutated tumors increased 
miR-200b and decreased miR-143 expression were associated with a good PfS. In wild-type 
KRAS patients, miRNA expression did not correlate with PfS in a multivariate model.
CONCLUSIONS: Our results indicate that the assessment of KRAS CNA and miRNAs 
targeting KRAS might further optimize the selection of mCRC eligible for anti-EGfR therapy.
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INTRODUCTION
Recent advances in our understanding of the specific signalling pathways of cancer cells have 
introduced targeted therapy into treatment regimes for patients with metastatic colorectal 
cancer (mCRC). Antibodies against the epidermal growth factor receptor (EGfR), cetuximab 
and panitumumab, have shown a survival benefit in mCRC patients with KRAS wild-type 
tumors both as monotherapy1,2 and when added to chemotherapy.3,4 Patients with a tumor 
harboring a KRAS codon 12 or 13 mutation are resistant to anti-EGfR therapy.1,5 Therefore 
the use of these antibodies is restricted to patients with KRAS wild-type tumors. However, 
within this subset not all patients respond to this treatment, and therefore additional predictive 
markers are needed. We have previously excluded a discordance in KRAS mutation status 
between the primary tumor and corresponding metastases as an explanation for the hetero-
geneous response rate in patients with KRAS wild-type tumors.6 In routine practice, KRAS 
mutations in codons 12 and 13 are tested, which comprise approximately 96 % of the observed 
KRAS mutations.7 Recent data suggest that a codon 13 KRAS mutation has a distinct clinical 
behavior and is not associated with cetuximab resistance.8 Whether other KRAS mutations 
(like codon 61) result in similar resistance to EGfR monoclonal antibodies remains specu-
lative.9 A mutation in the BRAF oncogene occurs in approximately 10% of mCRC patients 
and is restricted to KRAS wild-type tumors, and was first shown to have a negative predictive 
value for anti-EGfR therapy.10 Subsequently, we have shown that a BRAF mutation predomi-
nantly has a strong negative prognostic value.11 Other biomarkers in the PI3K and RAS/MAPK 
pathways12-16, ligands to the EGfR17,18, and germline single nucleotide polymorphisms19-21 have 
not yet shown a predictive value that can be used in clinical practice.
Point mutations in the KRAS oncogene lead to a significantly increased RAS-GtPase activity, 
ultimately resulting in the stimulation of cell proliferation and the inhibition of apoptosis via the 
RAS/MAPK pathway.22 However, in addition to oncogenic mutations, copy number changes of 
the KRAS gene or posttranslational factors may also be involved in the regulatory mechanism 
of RAS-GtPase activity. Copy number aberrations (CNA) occur throughout the tumor genome 
and are an important mechanism in colorectal cancer development.23 Genome-wide studies 
in mCRC patients have identified loci that are associated with a poor prognosis24 and with the 
prediction of response to chemotherapy.25 However, little is known about the prevalence and 
effect of CNA of the KRAS locus on chromosome 12p12.1. By using a TaqMan-based KRAS 
copy number assay, KRAS amplifications were observed in approximately 2% of the 106 inves-
tigated colorectal primary tumors.26 In CRC cell lines, gains of the KRAS locus were shown 
to be associated with an eleven-fold increase in RAS-GTPase activity, which is comparable 
with the twelve-fold increase caused by a codon 12 or 13 mutation.27 However, no data have 
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been reported on CNA affecting the KRAS locus and their possible association with response 
to cetuximab.
In recent years, a rapidly expanding interest has manifested on microRNAs (miRNAs). these 
single stranded RNAs of 19–23 nucleotides regulate gene expression by translational inhibition 
or mRNA degradation via imperfect base pairing to the 3’-untranslated region (3’utR) of their 
target mRNAs.28 MiRNAs are involved in the development of human cancer, and in case of 
dysregulation they can act either as oncogenes or tumor suppressors, depending on their target 
genes.29 Recently several miRNAs were identified that target KRAS, resulting in the suppression 
of cancer development.30-33 KRAS contains multiple let-7 complementary sites, allowing the 
let-7 family of miRNAs to act as a tumor suppressor by regulating the KRAS mRNA.30,31 Also 
mir-18a and miR-143 directly recognize KRAS, and downregulation of these miRNAs accel-
erates tumorigenesis by reversal of KRAS suppression.32 The targeting effect of miR-18a on 
KRAS has been demonstrated in colon cancer cell lines irrespective of KRAS mutation status.33 
MiRNAs interfering with the RAS-signaling pathway may have predictive value or may even 
serve as targets for treatment. Currently no data are available on the clinical relevance of 
miRNAs involved in KRAS activity in patients treated with cetuximab.
In this study we analyzed the KRAS copy number status and the expression of miRNAs targeting 
KRAS in relation to clinical outcome in mCRC patients treated with first-line cetuximab-
containing therapy.
MATERIAL AND METHODS
Patients
the patients included in this study participated in the CAIRO2 trial (CKtO 2005–02; Clintrials.
gov NCt00208546) of the Dutch Colorectal Cancer Group (DCCG).34 In this multicenter phase 
III trial, 755 mCRC patients were randomized between first-line treatment with capecitabine 
(1000mg/m2 bid.), oxaliplatin (130 mg/m2), and bevacizumab (7.5 mg/kg), or the same 
schedule with the addition of weekly cetuximab (250 mg/m2, after initial 400 mg/m2). transla-
tional research on tumor tissue was part of the informed consent procedure. The primary end 
point of the study was progression free survival (PfS), and secondary end points were overall 
survival, response rate, and toxicity. the median PfS in patients treated with cetuximab was 
9.4 months (95 % CI 8.4-10.5 months), which was significantly shorter than the PfS of patients 
treated in the group without cetuximab (median PfS 10.7 months, 95 % CI 9.7-12.3 months, 
p = 0.01). Patients in the cetuximab-group with a KRAS mutated tumor had a significantly 
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decreased median PfS compared to patients with a KRAS wild-type tumor (8.1 versus 10.5 
months, respectively, p = 0.04).
for the current analysis we selected patients who had been randomized to the cetuximab 
treatment arm, received at least three treatment cycles, did not discontinue treatment for other 
causes than disease progression, had a normal serum lactate dehydrogenase at randomization, 
and of whom formalin-fixed paraffin-embedded (ffPE) material of the primary tumor as well 
as normal tissue was available. Patients with a rectal carcinoma and patients who had received 
preoperative radiotherapy on the pelvis have been excluded for these analyses. from this 
group the 17 best and 17 worst responding patients were selected based on both extremes of 
the PfS time. throughout the article the terms good and poor responders are used, which does 
not apply to response according to RECIST, but to the patients with the longest and shortest 
PfS on cetuximab-based treatment. this outcome parameter was chosen for the current study 
because it is the best reflection of the clinical trial upon which this analysis is based. Next, 
especially with respect to targeted agents PfS appears to be superior of response rate in terms 
of clinical outcome.
DNA extraction and mutation analysis
Genomic DNA was extracted from 4–8 manually micro dissected 50 µm sections of ffPE 
tissue as previously described.35 DNA concentration was determined using the Nanodrop 
ND-1000 spectrophotometer (Nanodrop technologies Inc., Wilmington, uSA). DNA quality 
was assessed by performing a multiplex PCR using 4 primer sets, resulting in fragments of 100, 
200, 300 and 400 base pairs.36 The KRAS mutation status35 and BRAF mutation status11,12 were 
assessed by sequencing analysis as previously described.
Assessment of the KRAS gene copy number and data analysis
High-resolution genome-wide DNA copy number profiles were generated by array-based 
comparative genomic hybridization (array CGH) using 720 k Whole-Genome tiling CGH 
arrays (Roche NimbleGen Inc., Madison, uSA). Optimal signal-to-noise ratios were obtained 
by hybridizing test (tumor) and reference (normal colon) DNA of similar quality, which was 
determined by giving similar yield in a Bioscore Screening and Amplification kit (ENZO 
diagnostics Inc., farmingdale, uSA). for hybridization, 500 ng of amplified DNA from test 
and reference samples were labelled with Cy3 and Cy5, respectively, using random-primed 
labelling (Bioprime genomic DNA labelling kit, Invitrogen, Breda, the Netherlands), and 
hybridized for 48 hours at 42°C using a MAuI hybridization system (Biomicro Systems, Salt 
Lake City, uSA). After washing, arrays were scanned in an Axon Genepix 4200AL microarray 
scanner. the NimbleScan 2.4 software package (NimbleGen Systems Inc., Madison, uSA) 
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was used to calculate log2 ratios after performing spatial correction, normalization and a 25 
kb average smoothing window on the data. further data interpretation and CNA calling was 
done with Nexus Copy Number 5.0 software (Biodiscovery, El Segundo, uSA) using the Rank 
Segmentation Algorithm. In 26 patients, hybridizations were performed against normal DNA 
from the same patient to normalize for germline copy number changes. In the other 8 cases, 
germline copy number changes were excluded using both public (http://projects. tcag.ca/
variation/) and private CNA databases. the cut-off value for gene copy number gain and loss 
were manually set for each sample to adjust for differences in signal strength and incorrectly 
centered baselines.
Prevalence of KRAS locus gene copy number changes
In order to assess the clinical relevance in terms of prevalence of KRAS gene copy number 
changes in mCRC patients, we assessed the KRAS gene copy number status in ffPE primary 
tumor tissue of 225 unselected mCRC patients who participated to our previous phase III study 
which did not involve the use of targeted agents.37 In these patients a 250 k oligonucleotide 
array CGH was performed as previously described.25
Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA was performed according to the manufacturer’s instruction using the SALSA P145-A2 
kit (MRC Holland, Amsterdam, the Netherlands), containing 40 probes including the 12p12.1 
KRAS probe. Briefly, 200 ng DNA was denatured and allowed to hybridize for 16 h at 60°C 
in a thermocycler. then SALSA Ligase-65 enzyme was added and ligation was allowed at 
54°C. After heat inactivation of the ligase enzyme at 98°C, primers, dNtPs and polymerase 
were added and PCR amplification was performed for 35 cycles (60s at 95°C, 30s at 60°C, 
and 90s at 72°C). Reactions were performed on a PtC 200 thermal cycler (MJ Research Inc., 
Waltham, Massachusetts, uSA). One microliter of PCR product was analyzed by capillary 
electrophoresis on an ABI 3730 Analyzer (Applied Biosystems), and quantitative data were 
obtained by Genemapper analysis (Applied Biosystems).
MLPA data analysis
for each tumor sample, the peak area of the 12p12.1 and reference probes were determined in 
duplicate for further analysis. The reference peak area was obtained from blood samples from 
three different individuals, each of which were analyzed at least two times independently. In 
every sample, for every probe, a tumor to normal DNA copy number ratio was calculated by 
dividing the median area under the peak for the 12p12.1 probe by the value for the reference 
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DNA. Subsequently, all ratios were normalized by setting the median tumor to normal DNA 
copy number ratio of the reference genes in de probe mixture to 1.0. A ratio lower than 0.8 
was considered a loss and a ratio higher than 1.2 a gain.
MiRNA selection
Selection of miRNAs regulating KRAS was performed using Pictar (http://pictar.mdc-berlin.
de/), targetScan (http://www.targetscan.org/) and miRNA targets (http://cbio.mskcc.org/mirna-
viewer/). Venn diagram analysis was used to select 14 miRNAs who were identified by at least 
two algorithms (Additional file1). In addition to the prediction programs we also selected 
six extra miRNAs (Let-7, miR-18a, miR-21, miR-133a, miR-133b, miR-205) which have been 
shown to target KRAS in previous studies30,33,38, resulting in a total test series of 20 miRNAs. 
two taqman microRNA assay were not available (mir-18a, mir-200c), resulting in 18 miRNAs 
to analyze.
Total RNA extraction, miRNA reverse transcription and real-time PCR
total RNA was isolated from ffPE tissue of 34 primary tumors and matched normal tissue 
using the RecoverAllTM total Nucleic Acid Isolation Kit (Applied Biosystems, foster city, uSA). 
In brief, four tissue slices of 20 µm were micro dissected and incubated with 100% xylene 
at 50°C to remove paraffin excess, followed by ethanol washes. Proteins were degraded by 
protease at 50°C and 80°C. the RNA was extracted followed by nuclease digestion. total RNA 
Additional figure 1. Selection of MiRNAs that were identified by multiple algorithms.
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quantity and quality were determined using the Nanodrop 26 ND-1000 spectrophotometer 
(Nanodrop technologies Inc., Wilmington, uSA).
To determine the expression levels of miRNAs, Taqman miRNA assays directed to seventeen 
miRNAs and the endogenous reference gene (RNu 6B) were used following the manufacture’s 
protocol (Applied Biosystems, foster City, uSA). firstly, cDNA was synthesized in duplicate 
from total RNA using miRNA specific stem loop primers. Reverse transcriptase reactions were 
conducted using 10 ng total RNA, 1 mM dNTPs, 50 U MultiScribeTM Reverse Transcriptase, 
1 x Rt buffer, 3.8 u RNase inhibitor and 1 x taqman® MicroRNA Rt Primer (Applied 
Biosystems, foster city, uSA). the 15 µl reactions were incubated at 16°C for 30 minutes at 
42°C for 30 minutes and at 85°C for 5 minutes.
Secondly, the quantitative PCR was performed in which the total mixture of 20 µl included 
1.33 µl Rt product (1:5 diluted from Rt reaction), 1 x taqman® universal PCR Master Mix 
(No AmpErase® uNG, Applied Biosystems, foster City, uSA) and 1 x the dedicated primer and 
probe mix. the reactions were incubated in a 96-well optical plate at 95°C for 10 minutes, 
followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. All reactions were 
carried out in duplicate in a 7500 Real time PCR System (Applied Biosystems, foster City, uSA). 
the threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence 
passes the fixed threshold. Relative quantification of miRNA expression was calculated using 
the ΔΔCt method as described previously.39
Statistical analysis
PfS was defined as the interval from the date of randomization to the date of first documented 
disease progression or death, whichever occurred first. Statistical differences of clinical and 
pathological parameters between good and poor responders were evaluated using the Student’s 
t-test, Pearson’s χ2 test or fisher’s exact test where appropriate. the miRNA expression in 
colorectal tumors was described by the relative quantity (RQ) of the target miRNA, normalized 
in respect to RNU6B and relative to matched normal tissue. Box plots were used to appreciate 
the descriptive statistics of the data. Differences in expression of the target miRNA between 
good and poor responders were evaluated on the log scale (ΔΔCt scale) to obtain normally 
distributed data. The Student’s t-tests was used in exploratory analyses on the miRNA expression 
in relation to response and to KRAS mutation status. When focusing on the actually observed 
PfS, we investigated by Cox regression analysis the influence of each miRNA on PfS, using 
KRAS mutation status, the interaction term between miRNA and KRAS mutation, and differ-
entiation grade as covariates. Due to the limited number of patients and the ensuing risk for 
overfitting, it was not possible to assess the influence of all miRNAs together (i.e. correct the 
influence of miRNA for each other), nor to correct for other baseline characteristics.
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RESULTS 
Patients
Of the 34 patients selected for this analysis, the median PfS was 22.5 months (range 14.8-39.8 
months) in the 17 good responders, and 6.0 months (range 2.3-7.2 months) in the 17 poor 
responders. Clinical and pathological characteristics of the primary tumor were well balanced 
between the 17 good and 17 poor responders. Only poor differentiation grade of the primary 
tumor was more frequently observed in the poor responders.
Additional figure 2. Heat map representation and individual array CGH plots of patients with KRAS 
copy number aberrations A: Heat map representation of the 7 patients with CNA of the KRAS locus. 
Each row represents a patient with a CNA of the KRAS locus (loss, gain, amplification). Whole 
chromosome 12, containing the KRAS locus, is depicted on the horizontal axis. B: Amplification of 
a genomic region in 12p12.1 detected by array CGH in two patients, as confirmed by MLPA. the 
DNA log2 ratios and whole chromosome 12 are represented on the vertical and horizontal axis, 
respectively. C: Array CGH plot of chromosome 12 of a patient with a deletion of KRAS, which 
could not be validated using MLPA, but was detected by the Nexus copy number algorithm. Most 
of the genomic deletions detected by array CGH appeared to be present subclonal, below the 
detection threshold of MLPA. the DNA log2 ratios and whole chromosome 12 are represented on the 
vertical and horizontal axis, respectively. Abbreviation: ampl = amplification.
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Table 1. Clinical and histopathological characteristics of patients and their respective tumors
All eligible  
patients
n = 34
Good  
responders
n =17
Poor
Responders
n =17
P-value
Age Mean 58.6 58.0 59.2 0.07
Gender female 14 (41%) 5 (29%) 9 (53%) 0.30
Male 20 (59%) 12 (71%) 8 (47%)
Number of metastatic 
sites
1 17 (50%) 9 (53%) 8 (47%) 0.60
>1 17 (50%) 8 (47%) 9 (53%)
WHO PS 0 23 (68%) 11 (65%) 12 (71%) 0.71
1 11 (32%) 6 (35%) 5 (29%)
Site of primary tumor Colon 22 (65%) 11 (65%) 11 (65%) 0.90
Rectosigmoid 12 (35%) 6 (35%) 6 (35%)
T stage 1-2 4 (12%) 2 (12%) 2 (12%) 0.49
3 21 (62%) 12 (71%) 9 (53%)
4 9 (26%) 3 (18%) 6 (35%)
N stage 0 9 (26%) 4 (24%) 5 (29%) 0.61
1 8 (24%) 4 (24%) 4 (24%)
2 14 (41%) 9 (53%) 5 (29%)
Unknown 3 (9%) 0 3 (18%)
Differentiation grade Good 1 (3%) 1 (6%) 0 0.02
Moderate 23 (68%) 15 (88%) 8 (47%)
Poor 10 (29%) 1 (6%) 9 (53%)
BRAF mutation status Wild-type 30 (88%) 16 (94%) 14 (82%) 0.29
Mutant 4 (12%) 1 (6%) 3 (18%)
KRAS mutation status Wild-type 19 (56%) 11 (65%) 8 (47%) 0.30
Mutant 15 (44%) 6 (35%) 9 (53%)
KRAS mutation type Codon 12 14 (93%) 6 (100%) 8 (89%) 0.40
Codon 13 1 (7%) 0 1 (11%)
PFS (months) Median  
(range)
11.0
(2.3-39.8)
22.5
(14.8-39.8)
6.0
(2.3-7.2)
<0.0001
Abbreviations: WHO = World Health Organization; PS = Performance status;  
PFS = progression-free survival
A KRAS mutation was demonstrated in the primary tumor of 15 patients (6 good responders 
and 9 poor responders), and KRAS wild-type in the primary tumor of 19 patients (11 good 
responders and 8 poor responders). KRAS codon 12 mutation was observed in 14 patients, and 
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one poor responder had a codon 13 mutation. Of the KRAS wild-type patients, 4 had a BRAF 
mutated tumor (1 good responder and 3 poor responders) (table 1).
12p12.1 copy number changes in good and poor responders
By using high resolution array CGH, two copy number gains (of which one amplification) 
and 5 losses were detected at the 12p12.1 locus where KRAS is localized (Additional file2). 
Both copy number gains, which were confirmed by MLPA, were observed in poor responders 
with a KRAS wild-type tumor. Of these tumors one sample contained a gain of the complete 
p-arm of chromosome 12 and the other sample contained a high copy number gain of a region 
including the KRAS locus.
A 12p12.1 copy number loss, detected by array CGH, was observed in the tumor of 5 patients 
with a good response. One tumor contained a loss of the whole chromosome, three tumors 
included a loss of the short arm of the chromosome and one tumor contained a loss of a 27.5 
Mb region of the short arm of chromosome 12 including the KRAS locus (Additional file2). 
Of these 5 tumors with loss of the 12p12.1 locus, 2 tumors harbored a KRAS mutation, and 
one tumor had a BRAF mutation, suggesting that the mechanism of gene copy number loss is 
independent of the KRAS and BRAF mutation status (figure 1).
Figure 1. 12p12.1 copy number changes in good and poor responders according to the KRAS 
mutation status. Abbreviation: CNA = copy number aberration.
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12p12.1 gene copy number changes in a control group of mCRC patients
In an unselected group of 222 mCRC patients from our previous trial with comparable baseline 
characteristics37, the prevalence of 12p12.1 copy number changes was assessed. In this group 
three amplifications (1.4%), 32 copy number gains (14.4%), and 12 losses (5.4%) of the 
12p12.1 locus were observed. There was no effect of KRAS copy number gain or loss on 
prognosis in these patients treated with first-line chemotherapy without cetuximab (p = 0.97 
and p = 0.75, respectively, data not shown).
MiRNA expression in good and poor responders
To assess the role of miRNA expression in relation to clinical outcome, the expression levels 
of 18 miRNAs targeting KRAS were determined by real-time RT-PCR in 32 primary colorectal 
tumors relative to their matched normal tissue. two patients (1 good and 1 poor responder) 
were not accessible for miRNA expression due to an insufficient RNA amount in normal 
Table 2. MiRNA expression in good versus poor responders
Good responders Poor responders RQ good 
versus 
poor
P-value
Mean 
ddCt
SE RQ Mean 
ddCt
SE RQ
MiR-27b -0.98 0.77 1.98 -0.92 0.64 1.90 1.04 0.80
MiR-105 -1.04 2.80 2.05 0.57 3.15 0.68 3.01 0.21
MiR-155 -0.66 1.25 1.58 -0.19 0.89 1.14 1.39 0.24
MiR-346 0.32 1.52 0.80 0.57 1.14 0.67 1.19 0.60
MiR-181a -1.64 0.85 3.11 -1.27 0.75 2.42 1.29 0.21
MiR-19a -3.39 1.84 10.45 -2.82 1.55 7.04 1.48 0.35
MiR-200b -0.57 0.92 1.49 0.05 1.42 0.97 1.54 0.15
MiR-27a -2.10 0.98 4.27 -2.00 0.82 4.00 1.07 0.77
MiR-30a -0.81 0.86 1.75 -0.66 0.88 1.58 1.11 0.65
Let-7a -0.67 0.79 1.59 -0.39 0.70 1.31 1.21 0.30
MiR-21 -3.16 1.16 8.92 -2.75 0.79 6.75 1.32 0.26
MiR-96 -4.56 1.32 23.59 -3.81 1.40 14.04 1.68 0.13
MiR-143 -0.73 1.35 1.66 -1.76 1.55 3.38 0.49 0.07
MiR-217 -2.91 3.09 7.53 -1.64 3.10 3.12 2.41 0.30
MiR-133a 0.91 1.69 0.53 0.33 1.79 0.79 0.67 0.36
MiR-133b 0.98 1.74 0.51 0.39 2.23 0.76 0.67 0.41
MiR-19b -2.95 1.71 7.73 -2.45 1.37 5.45 1.42 0.37
Abbreviations: SE = standard error ; RQ = relative quotient 
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mucosa. MiR-205 expression was undetectable in both tumor and normal mucosa, therefore 
17 miRNAs were included in our final analysis. By using Normfinder40 and GeNorm41, the use 
of RNu6B as a reference gene was justified.
The expression level of 14 miRNAs showed a trend towards a higher expression in patients 
with a good response compared to patients with a poor response, however this trend was 
not statistically significant. MiR-143, miR-133a and miR-133b expression was decreased in 
patients with a good response, of which miR-143 showed a relative expression in good versus 
poor responders of 0.49 (p = 0.07) (table 2).
Figure 2. Box plots of the expression levels of miR-181a, miR-200b and miR-143 in mCRC patients 
according to clinical outcome and KRAS mutation status. Abbreviations: G = good responders;  
P = poor responders; Mt = mutant; Wt = wild-type
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MiRNA expression in good and poor responders according to  
KRAS mutation status
In patients with a wild-type KRAS tumor, the expression level of miR-181a showed a 1.87-fold 
increase in good responders compared to poor responders (p = 0.04), which was not observed 
in patients with mutated KRAS tumors (0.91-fold increase, p = 0.69). A higher expression of 
miRNAs in wild-type KRAS good responders compared with wild-type KRAS poor responders 
was also observed for MiR-200b (2.48-fold increase, p = 0.01) and miR-21 (1.66-fold increase, 
p = 0.06).
A difference between the expression of miR-143 in good versus poor responders was more 
obvious in mutated KRAS tumors. The relative expression level of miR-143 showed a 0.30 fold 
increase in mutated KRAS good responders versus mutated KRAS poor responders (p = 0.11) 
(figure 2).
Multivariate model of PFS in relation to miRNA expression and  
KRAS mutation status
Each miRNA was analyzed individually together with differentiation grade as a covariate for 
PfS in wild-type KRAS and mutated KRAS patients treated with first-line cetuximab-containing 
therapy (table 3). Differentiation grade was used as a covariate in the Cox regression model 
because this pathological feature is a well known prognostic factor and differentially distributed 
between good and poor responders.
Elevated expression of miR-200b was associated with a better PfS in patients with a mutated 
KRAS tumor (HR 0.56 (0.28-1.15); p = 0.10). this trend was not present in patients with a 
wild-type KRAS tumor. Surprisingly, increased expression of miR-143 resulted in a shorter PfS 
in patients with a mutated KRAS tumor (HR 1.59 (1.01-2.50); p = 0.04). the hazard ratio for 
PfS was not influenced by miR-143 expression in wild-type KRAS tumors.
DISCUSSION
We demonstrated that regulation of the KRAS oncogene at several levels might affect clinical 
outcome in a selected group of cetuximab-treated mCRC patients treated in a phase III trial.34 
Copy number loss of the KRAS locus was restricted to good responders, whereas a copy 
number gain was associated with a poor PfS in patients with wild-type KRAS tumors. Increased 
expression of miR-200b that targets KRAS was associated with improved PfS in patients with 
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a mutated KRAS tumor. Surprisingly, decreased miR-143 expression was correlated with 
improved PfS in these patients.
The predictive strength of KRAS mutation status stresses the importance of RAS-GTPase activity 
for the response to cetuximab. Therefore, other regulatory mechanisms of RAS-GTPase activity 
are obvious novel candidate markers. CNA of the KRAS locus occur independently of the 
KRAS mutation status in a considerable percentage of colorectal tumors (21.2%) as assessed 
in a large and unselected mCRC population. Previously, it has been shown that KRAS copy 
number gains are correlated with increased RAS-GTPase activity in colorectal cell lines and 
with worse clinical outcome in lung adenocarcinomas.27 Our results suggest that KRAS copy 
number gains are associated with worse clinical outcome in wild-type KRAS mCRC patients 
who are treated with a cetuximab-containing first-line regimen. this influence of KRAS copy 
number gain on prognosis was absent in mCRC patients treated without cetuximab, suggesting 
a predictive effect on cetuximab response. The correlation between miRNAs targeting KRAS 
and PfS was absent in wild-type KRAS patients. Inhibition of KRAS translation by miRNAs is 
probably only relevant when the KRAS expression levels are high, which is not the case in 
absence of an activating KRAS mutation.
KRAS mutations occur in approximately 38% of mCRC patients7, and these patients are 
currently excluded from treatment with anti-EGfR antibodies. However, in our selected good 
responders, 6 patients (35 %) had a KRAS mutated tumor. A recent publication showed that 
patients with codon 13-mutated tumors might benefit from cetuximab treatment.8 In the current 
series none of the good responders had a tumor with a KRAS codon 13 mutation. Our data 
show that the presence of KRAS copy number loss in two of the mutated KRAS mCRC patients 
might justify treatment with cetuximab. Decreased expression of KRAS caused by loss of gene 
copies in correlation with response to cetuximab has not been described earlier. Despite the 
limitations in sample size and concomitant treatment our results indicate that patients with 
KRAS copy number loss might benefit from treatment with an anti-EGfR antibody although 
their tumor is KRAS mutated.
Next, we demonstrated that increased expression of miR-200b was associated with improved 
PfS in mutated KRAS patients. We hypothesize that reducing KRAS protein levels in the 
presence of a mutation might improve clinical outcome in patients treated with cetuximab. 
KRAS is not the only target of the miR-200 family, miR-200b is also capable of reducing ERRFI-1 
mRNA and subsequent activation of EGfR.42 Adam et al. showed that increased expression of 
miR-200b facilitates optimal EGfR functionality, resulting in an efficient response of bladder 
cancer cells to cetuximab. to our knowledge, our results are the first data in vivo suggesting 
that in the presence of a KRAS mutation, an increased miR-200b expression is associated with 
an improved PfS in cetuximab-treated mCRC patients. Surprisingly a decreased expression of 
miR-143 was associated with improved PfS in patients with mutated KRAS tumors. MiR-143 
is thought to inhibit KRAS translation and thereby to suppress tumor cell growth during tumor-
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Table 3. A multivariate model in which each miRNA was analyzed individually together with 
differentiation grade as a predictor for PfS in wild-type KRAS and mutated KRAS patients treated with 
chemotherapy, bevacizumab and cetuximab
Overall
n = 32
KRAS wild-type
n = 18
KRAS mutation
n = 14
P-value
MiR-27b HR (95% CI) 0.74 (0.38-1.42) 0.94 (0.36-2.42) 0.51 (0.20-1.32) 0.38
p-value 0.36 0.89 0.16
MiR-105 HR (95% CI) 1.04 (0.84-1.29) 0.95 (0.76-1.21) 1.22 (0.83-1.78) 0.26
p-value 0.72 0.69 0.32
MiR-155 HR (95% CI) 0.92 (0.62-1.35) 0.77 (0.38-1.53) 0.96 (0.60-1.51) 0.60
p-value 0.66 0.45 0.85
MiR-346 HR (95% CI) 0.83 (0.63-1.10) 0.85 (0.61-1.19) 0.72 (0.40-1.32) 0.63
p-value 0.20 0.34 0.29
MiR-181a HR (95% CI) 0.75 (0.46-1.22) 0.70 (0.37-1.33) 0.94 (0.44-2.02) 0.57
p-value 0.24 0.27 0.87
MiR-19a HR (95% CI) 0.96 (0.78-1.19) 1.03 (0.80-1.33) 0.74 (0.45-1.20) 0.23
p-value 0.73 0.82 0.22
MiR-200b HR (95% CI) 1.03 (0.72-1.47) 0.90 (0.51-1.57) 1.78 (0.87-3.62) 0.18
p-value 0.86 0.70 0.10
MiR-27a HR (95% CI) 0.74 (0.43-1.27) 0.69 (0.31-1.54) 0.71 (0.35-1.43) 0.96
p-value 0.27 0.37 0.34
MiR-30a HR (95% CI) 0.70 (0.44-1.10) 0.77 (0.40-1.55) 0.70 (0.37-1.34) 0.86
p-value 0.12 0.46 0.28
Let-7a HR (95% CI) 0.94 (0.59-1.50) 0.89 (0.50-1.59) 1.28 (0.46-3.58) 0.55
p-value 0.80 0.68 0.63
MiR-21 HR (95% CI) 0.89 (0.57-1.39) 1.15 (0.52-2.55) 0.81 (0.49-1.33) 0.47
p-value 0.61 0.74 0.40
MiR-96 HR (95% CI) 0.84 (0.59-1.20) 0.74 (0.45-1.22) 0.93 (0.55-1.58) 0.54
p-value 0.33 0.24 0.79
MiR-143 HR (95% CI) 0.73 (0.51-1.05) 0.92 (0.56-1.51) 0.63 (0.40-0.99) 0.26
p-value 0.09 0.74 0.04
MiR-217 HR (95% CI) 1.01 (0.87-1.16) 0.85 (0.61-1.19) 0.78 (0.56-1.08) 0.72
p-value 0.95 0.34 0.13
MiR-133a HR (95% CI) 0.81 (0.63-1.05) 0.98 (0.68-1.43) 0.66 (0.41-1.06) 0.21
p-value 0.12 0.92 0.09
MiR-133b HR (95% CI) 0.89 (0.70-1.13) 1.04 (0.73-1.49) 0.80 (0.55-1.17) 0.32
p-value 0.32 0.83 0.25
MiR-19b HR (95% CI) 0.95 (0.75-1.20) 1.02 (0.77-1.34) 0.66 (0.36-1.23) 0.21
p-value 0.65 0.91 0.19
Abbreviation: HR = hazard ratio
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igenesis.32 In an established tumor, modulation of KRAS by miR-143 may be differentially 
regulated which could possibly explain our findings. However, since miRNAs are capable of 
repressing over a hundred different mRNAs28, miR-143 could also target mRNAs which may 
be relevant in response to capecitabine, oxaliplatin and bevacizumab. Previous studies on 
biomarkers have shown divergent results which stresses the importance of the results of our 
current hypothesis-generating study being confirmed in a larger, independent series of mCRC 
patients preferably treated with cetuximab monotherapy.
The patients used in this study were derived from a clinical trial, and the observed outcome is 
also influenced by the effect of the other agents used. the relative contribution of cetuximab 
to this outcome is therefore unclear. the phase III CAIRO2 trial showed that cetuximab plus 
chemotherapy and bevacizumab resulted in a significantly decreased median PfS compared 
to treatment with chemotherapy and bevacizumab alone. the explanation of this detrimental 
outcome is unclear43, and complicates the interpretation of the current analysis. Excessive 
toxicity in the cetuximab group does not appear to be cause of these results. Negative inter-
action between the antibodies or between antibodies and chemotherapy might have influenced 
the outcome although preclinical observations supporting this hypothesis are not yet available. 
The interpretation of the current analysis is complicated by the detrimental outcome of the 
trial. Whether this outcome also affects the PfS in the good responders remains unclear.
In conclusion, the analysis of KRAS CNA and miRNAs targeting KRAS may optimize the 
selection of mCRC patients eligible for anti-EGfR therapy. Elevated expression of miR-200b, 
decreased miR-143 level and copy number losses may identify patients with mutated KRAS 
tumors who benefit from anti-EGfR therapy, whereas copy number gains in wild-type KRAS 
patients could predict resistance to cetuximab. Our results are relevant for the development of 
predictive biomarkers for anti-EGfR therapy, and suggest that the clinical effects of KRAS are 
the result of a complex interaction of several regulatory mechanisms beyond the KRAS point 
mutation status.
CONCLUSIONS
KRAS activity, an important regulator of response to anti-EGfR therapy, can be influenced by 
genetic and epigenetic regulation. CNA and specific miRNAs may provide important additional 
information to KRAS mutation status and their use could further improve the selection of 
mCRC patients for anti-EGfR therapy. the hypothesis-generating nature of our study urges for 
our results to be confirmed in larger series.
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ABSTRACT
Metastatic disease is the major cause of death in colorectal cancer (CRC) patients. the 
metastatic process is highly inefficient and comprises multiple sequential steps. While many 
genetic factors relevant in this process already have been identified, the epigenetic factors 
underlying each step still remain obscure. MicroRNAs (miRNAs) are key regulators in tumori-
genesis, but their role in the development of cancer metastasis is poorly investigated. The 
majority of miRNAs involved in the metastatic process have been identified in breast cancer 
cell lines, and in CRC less data are available. We review the role of miRNAs in the metastatic 
pathway of CRC, including escape of apoptosis, epithelial-mesenchymal transition, angio-
genesis, and invasion. Better understanding of the complex role of miRNAs in the development 
of CRC metastases may provide new insights which could be of therapeutic consequence.
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INTRODUCTION
Colorectal cancer (CRC) is the second most common cause of cancer death worldwide.  Approx-
imately 50% of the patients diagnosed with CRC will die because of the complications of 
distant metastases. The formation of metastases is a multistep process, in which malignant cells 
disseminate from the primary tumor to colonize distant organs. this is a highly inefficient and 
complex process, which involves early steps of tumor cell invasion of the microenvironment, 
entering the bloodstream, survival during migration, and extravasation into distant organs. 
Subsequent steps including proliferation, induction of angiogenesis and evading apoptotic 
death, are crucial for colonization of the secondary site.1 tumor cells need to be proficient in 
all these processes in order to produce metastatic outgrowth. Therefore, each step in metastasis 
requires specific genetic and epigenetic changes.2 Although research has identified multiple 
genes responsible for carcinogenesis, the (epi)genetic alterations that provide cancer cells the 
ability to metastasize are largely unknown. 
MicroRNAs (miRNAs) are a family of small, highly conserved non-coding RNAs that post-
transcriptionally regulate gene expression. Typically, pri-miRNAs are transcribed by RNA 
polymerase II in the nucleus. these pri-miRNAs are processed by Drosha and its cofactor 
DGCR8, yielding 60-70 nt precursor miRNAs (pre-miRNAs). Pre-miRNAs are transported into 
the cytoplasm, where they undergo processing by the RNAse III enzyme Dicer, resulting in 
mature miRNAs which are incorporated into the RNA-induced silencing complex (RISC).3 
MiRNAs act as endogenous suppressors of gene expression through imperfect binding of RISC 
to the 3’-untranslated region (3’-utR) of target mRNAs, inducing either translational repression 
or mRNA degradation, yet mechanistic details of the function of each miRNA in translation 
inhibition and/or mRNA destabilization remain controversial. to date, more than 1000 human 
miRNAs have been identified (miRBase Sequence Database – Release 16) and each individual 
miRNA may control hundreds of target genes. More than 5300 human genes were predicted as 
miRNA targets, representing 30% of the human gene set.4 MiRNAs have important regulatory 
functions in basic biological processes that form the hallmarks of cancer, such as cellular 
differentiation, proliferation, migration, and apoptosis. Approximately 50% of the human 
miRNAs are located at chromosomal breakpoints and are therefore susceptible to dysregu-
lation in human cancer.5 MiRNAs are involved in the pathogenesis of CRC, partly by regulating 
the expression of oncogenes and tumor suppressors and partly by functioning as oncogenes or 
tumor suppressors themselves.6, 7 for example, the miR-135 family affects the Wnt signalling 
pathway by downregulating the tumor suppressor gene Adenomatous Polyposis Coli (APC), 
regardless of mutation status or promoter hypermethylation.8 MiR-137 and miR-342 both act 
as tumor suppressors and are frequently silenced by promoter hypermethylation in early stages 
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of CRC.9, 10 Another potential tumor suppressive miRNA in CRC development is miR-143, who 
might regulate DNA methylation by targeting DNA methyltransferase 3A (DNMT3A).11
An association between the dysregulation of miRNA expression and specific steps in the 
metastatic pathway is highly likely. The role of miRNAs in the development of metastases has 
been demonstrated in several different cancers, including hepatocellular carcinomas, head 
and neck cancer, and brain tumors.12 However, the majority of miRNAs involved in metastasis 
have been identified in breast cancer. Because the expression of miRNAs are highly tumor 
and tissue-specific, there is a need for more information on the association of miRNAs and 
metastases in other common types of cancer, such as colorectal carcinomas. Most studies in 
CRC analyzed the association between miRNAs and the metastatic pathway using in vitro and 
mouse models. There are also tissue-based experiments in CRC patients, but the amount of 
data is still limited. In other human cancers, progress has already been made in therapeutic 
approaches based on miRNAs. therefore, it is necessary to summarize the role of miRNAs in 
the development of metastasis, specifically in CRC.  
We present a review on the relationship between miRNAs and the CRC metastatic pathway, 
including escape of apoptosis, epithelial-mesenchymal transition (EMt), angiogenesis, 
invasion, migration, and proliferation. 
MIRNAS AND THE EVASION OF APOPTOSIS
Cells that have a permanent inactivation of tumor suppressive factors that induce cell-cycle 
arrest, senescence and apoptosis have a selective advantage and are more likely to metas-
tasize. the multifunctional tumor suppressor gene TP53 responds to DNA damage through the 
induction of cell cycle checkpoints, cellular senescence, and apoptosis.13 MiR-34a, a member 
of the miR-34 family, was identified as a direct downstream transcriptional target of TP53 
which is up-regulated after TP53 induction by DNA-damaging agents.14 MiR-34a-responsive 
genes are highly enriched for those that regulate cell-cycle progression, cellular proliferation 
(E2F), apoptosis (BCL2), DNA repair and angiogenesis.14 Transfection of CRC cells with 
miR-34a induces senescence and apoptotic cell death.14, 15 In human CRC, a significant subset 
(36%) of primary tumors show decreased miR-34a expression15, partially due to the presence 
of TP53 mutations.16 Another mechanism of miR-34a downregulation is loss of chromosome 
1p36 (the location of miR-34a), which is observed in 50% of the primary CRCs, 33% of the 
local recurrences, and 64% of the metastases.17 Primary CRC cells with metastatic ability 
may already contain a 1p36 deletion, or acquire such changes during the development of 
a metastatic lesion. Alternatively, epigenetic inactivation of the miR-34 family (consisting of 
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miR-34a, miR-34b, and miR-34c) by promoter hypermethylation is observed in the majority 
of cancer cell lines18, 19 and primary CRCs.19-21 The redundancy of methods by which tumor 
cells can cause down-regulation of miR-34a suggests an important role of this miRNA in CRC 
metastasis. 
MiR-192, miR-194-2, and miR-215 are additional downstream targets of TP53, and all 
capable of inducing p21 expression and cell cycle arrest in a p53-dependent manner. They are 
capable of inducing partial cell cycle arrest, which indicates cell death. In addition, miR-192 
and miR-215 are capable of inducing senescence to some extent but not as efficiently as 
miR-34a.22 Down-regulation of these miRNAs in CRC can partly be explained by loss or inacti-
vation of TP53.23 Additionally, for miR-194-2 a single nucleotide polymorphism (SNP) located 
within the miRNA precursor was identified that might be capable of modulating the expression 
and processing of this miRNA (SNP: rs11231899, rs11231898, rs15800646, rs15800644, 
Figure 1. Regulation of apoptosis in CRC by miR-34a, miR-192, miR-194, miR-215, miR-195,  
and miR-491. Abbreviation: SNP = single nucleotide polymorphism
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rs15800642, rs15800640, rs15800638).24 SNPs have also been identified for miR-192 and 
miR-215 but these have not yet been associated with miRNA biogenesis. Copy number alter-
ations of the genomic region of miR-192 (11q13.1), miR-194-2 (11q13.1), and miR-215 (1q41) 
have not been identified in CRC so far. 
In vitro assays suggest the involvement of miR-195 and miR-491 in the evasion of apoptosis 
in CRC. Indeed, restoration of miR-195 expression in CRC cell lines reduced cell viability, 
promoted cell apoptosis in vitro, and suppressed tumorigenicity in vivo.25 The pro-apoptotic 
function of miR-195 and miR-491 is mediated through inhibition of the translation of BCL2 
and BCLXL respectively, which are important anti-apoptotic molecules of the Bcl-2 family.25 
transfection of miR-491 in CRC cell lines decreased Bcl-Xl protein expression and induced a 
40% reduction in BCLXL mRNA levels. MiR-491 also induced a dose dependent decrease of 
cell viability and activates caspase 3/7 which are important apoptotic signalling molecules. 
Using a gain-of-function screen, miR-491 has also shown to be capable of suppressing prolif-
eration.26 Tumors derived from mice injected with miR-491-transfected CRC cells were around 
half the size of those derived from the negative control-transfected cells. Despite the fact that 
miR-491 inhibited cell proliferation of CRC cells in vitro and in vivo, there is no correlation 
between endogenous miR-491 expression and clinical outcome in human CRC.26 MiR-491 is 
located at chromosome 9p21.3, and the 9p chromosome arm is a region that showed copy 
number loss in 16% of the CRC patients.27 MiR-195 is down-regulated in CRC cell lines as well 
as in human CRC tissues25 and is located at chromosome 17p13.1. Chromosomal losses are 
detected at chromosome 17p, a region that also contains the TP53 tumor suppressor gene.27 
The functional relations of the different miRNAs in the escape of apoptotic cell death are 
summarized in figure 1.
MIRNAS AND EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
EMt is a cellular program converting polarized immotile epithelial cells into motile mesen-
chymal cells. This process enables cancer cells to promote their malignant phenotype and stem 
cell characteristics. Activation of EMT at the invasive front allows tumor cells to detach, migrate, 
and disseminate through blood or lymphatic vessels. transforming growth factor beta (TGFB1), 
an EMt activator, is produced by tumor cells and triggers the expression of zinc-finger-enhancer 
binding protein 1/2 (ZEB 1/2). ZEB1 represses E-cadherin transcription, promotes vimentin 
transcripton28, and also directly suppresses transcription of the highly conserved miR-200 
family (miR-141, miR-200b, and miR-200c), whose down-regulation is believed to be the 
essential feature of EMT. Surprisingly, one of the putative gene targets of the miR-200 family is 
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ZEB1 itself. Increased expression of miR-141 and miR-200c after knockdown of ZEB1 in CRC 
cells, induced an epithelial phenotype with an increased E-cadherin expression and cell-cell 
adhesion, as well as reduced cell migration and invasion. Overexpression of miR-200c leads 
to translational inhibition of ZEB1, which induces mesenchymal-epithelial transition (MEt) in 
cells that had previously undergone EMT.29 This EMT-enhancing feed-forward loop of ZEB1 
and the miR-200 family is important in invading cancer cells and might explain the strong 
phenotypic heterogeneity often seen within individual tumors and metastases.30 Depending 
on the initial signal, this loop could stabilize either mesenchymal or epithelial differentiation. 
The miR-200 family members are located in two clusters; miR-141 and miR-200c are located 
at chromosome 12p13.31 and miR-200b is located at chromosome 1p36.33. Expression of 
the miR-200c/141 cluster is regulated by DNA hypermethylation, demonstrating epigenetic 
regulation as a mechanism involved in the regulation of this miRNA locus.31 As mentioned 
before, loss of 1p36 is a recurrent aberration in CRC, indicating that there are two distinct 
mechanisms that regulate the expression of the miR-200 family.
Up-regulation of the EMT activator TGFB1 also increases the expression of miR-21 and miR-31. 
Overexpression of these miRNAs in vitro facilitates and accelerates TGFB1-induced EMT, 
resulting in a higher percentage of cells adopting a ‘spreading’ morphology.32 Remarkably, 
the genomic location of miR-31, chromosome 9p21.3, show copy number losses in 16% of 
45 CRC samples.27 Other regulatory pathways for miR-31 are unknown. MiR-21 is located at 
17q23.2, a genomic region that showed copy number gain in CRC. These copy number gains 
are more frequently observed in metastatic tumors, suggesting an important role for miR-21 in 
the metastatic pathway of CRC.27 Regulation of EMt by miRNAs is depicted in figure 2.
MIRNAS AND ANGIOGENESIS
Angiogenesis is essential for tumor growth and an important component in the metastatic 
pathway.33 tumor neovascularization is partly driven by hypoxia, which stimulates tumor cell 
production of angiogenic factors such as vascular endothelial growth factor-A (VEGFA). An 
important regulator involved in the cellular response upon hypoxia is TP53. As mentioned 
before, mutations in TP53 are common in CRC16 and associated with increased tumor angio-
genesis.34 MiR-107 was identified as a downstream target of TP53 and proved capable of 
inhibiting the translation of hypoxia inducible factor-1 beta (HIF1B).35 Upon hypoxic signalling 
in a CRC cell line, overexpression of miR-107 resulted in decreased VEGf expression. In 
a mouse model, miR-107 overexpression resulted in decreased vascularity, lower VEGf 
expression, and smaller tumors. A loss of copy number of chromosome 10q, the genomic 
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location of miR-107, was observed in 11% of CRC patients.27 In pancreatic cells, miR-107 was 
found to be epigenetically inactivated by promoter methylation but these findings have not 
been confirmed in CRC.36
the oncogene c-Myc (MYC) is an important regulator of tumor angiogenesis. MYC is often 
co-activated with RAS, of which HRAS and KRAS are known to up-regulate VEGF.37 In a CRC 
model the combination of mutations in KRAS and TP53 yielded indolent, poorly vascularized 
tumors.38 A robust tumor vasculature and progressive neoplastic growth only developed after 
overexpression of the MYC oncogene.38 MYC-induced up-regulation of the miR-17-92 cluster 
is directly responsible for activating angiogenesis by down-regulation of the anti-angiogenic 
thrombospondin-1 (THBS1).38 MiR-17-92 transduced cells formed larger, better-perfused 
tumors in mice models. The miR-17-92 cluster is located at 13q3139, a genomic locus that is 
frequently amplified in CRC samples.27, 40 In figure 3, the relationships of miRNAs with angio-
genesis are depicted schematically.
MIRNAS AND INVASION, MIGRATION, AND PROLIFERATION
In tumors with invasive properties, intercellular adhesion is reduced due to loss of E-cadherin 
and proteolytic degradation of extracellular matrix (ECM) components. In this process, 
embedded growth factors and chemokines are liberated, thereby activating latent proteins 
on the cell surface. Binding of the epidermal growth factor (EGf) to the cell surface receptor 
(EGfR) induced stimulation of intracellular signalling pathways such as the RAS-RAf-MAPK 
and the PI3K-AKT pathways, resulting in increased invasion, motility, and proliferation. 
MiRNAs responsible for a more invasive phenotype can be divided into miRNAs acting in an 
EGfR-dependent manner and in an EGfR-independent manner.  
RAS-RAF-MEK-MAPK pathway
Activation of the RAS-RAf-MAPK pathway component PDCD4 directly suppresses invasion by 
the inhibition of the urokinase receptor (u-PAR) and the subsequent plasmin-mediated degra-
dation of ECM components such as fibrin and collagen IV.41-43 Overexpression of PDCD4 in 
human CRC cells inhibited AP1-dependent transcription and subsequent invasion of CRC cells 
into Matrigel. furthermore, down-regulation of PDCD4 is associated with poor prognosis in 
resected CRC.44 MiR-21 has a full match target sequence for PDCD4 45 and in both CRC cell 
lines and human CRC tissues, PDCD4 is negatively regulated by miR-21 at the post-transcrip-
tional level.46 Overexpression of miR-21 induced invasion, intravasation, and metastasis in 
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Figure 3. Regulation of angiogenesis in CRC by miR-107 and the miR-17-92 cluster.  
Abbreviations: HIf1 = hypoxia inducible factor-1; VEGf = vascular endothelial growth factor;  
tHBS1 = thrombospoding-1
Figure 2. Regulation of epithelial-mesenchymal transition in CRC by miR-21, miR-31 and the miR-200 
family. Abbreviations: tGfB1 = transforming growth factor beta; ZEB1/2 = zinc-finger-enhancer binding 
protein 1/2; EMt = epithelial-mesenchymal transition; MEt = mesenchymal-epithelial
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
112
Chapter 7   MicroRNAs in colorectal cancer metastasis
CRC cells.46 this was confirmed in vivo, where miR-21 levels were positively correlated with 
the development of metastasis in human CRC.47 MiR-21 is the most commonly and highly 
up-regulated miRNA in CRC, and besides PDCD4, multiple other gene targets of miR-21 
have been recently identified. Sprouty (SPRY2), an inhibitor of fibroblast growth factor (fGf) 
signalling, branching morphogenesis, and neurite outgrowth, is one of the direct targets of 
miR-21. High levels of miR-21 in CRC cells lead to down-regulation of SPRY2 and subsequent 
up-regulation of microvillus-like protrusions, resulting in a higher cell migration count.48 
Another target of miR-21 is tumor suppressor tropomyosin1, encoded by TPM1, an actin-
binding protein stabilizing microfilaments which stimulate anchorage-independent growth in 
case of low expression.49 Also, maspin50, PTEN51, RECK, and TIMP352  are regulated by miR-21 
and involved in migration and the invasive potential of cancer cells. The genomic location of 
miR-21 (17q23.2) showed copy number gain in 16% of CRC patients.
In addition to miR-21, miR-31 positively regulates migration and invasion properties in CRC 
cells. t lymphoma invasion and metastasis 1 (TIAM1), a possible target for both miR-21 and 
miR-31, encodes a guanine nucleotide exchange factor of RAC regulating cell migration, 
invasion, and tumor progression. Repression of TIAM1 is a critical component in miR-21/
miR-31, stimulating the migratory and invasive properties of CRC in vitro.53 However, the 
effect of these miRNAs in vivo is still unknown. Copy number losses of miR-31 (9p21.3) were 
infrequently observed in CRC patients.27
The let-7 miRNA family and miR-143 are both capable of inhibiting KRAS translation, thereby 
blocking subsequent phosphorylation of MAPK and inhibiting growth. Both miRNAs act as 
a suppressor of colorectal tumorigenesis, but have not been directly linked to metastasis.54 
MiR-143 is located at chromosome 5q32, and CRC samples showed frequent deletions of 
5q14-32.27 Recently, a SNP (rs61764370) was observed in the let-7 miRNA complementary 
site of the 3‘ utR of KRAS in non-small cell lung cancer (NSCLS). this SNP disrupted the let-7 
regulation of the KRAS oncogene, resulting in an increased expression of KRAS in vitro.55 Also, 
in metastatic CRC, this SNP was observed and related to tumor response in KRAS wild-type 
patients treated with cetuximab monotherapy.56
In a human CRC cell line expressing a high level of endogenous miR-373, tumor cells depend 
upon this miRNA for their capacity to migrate in a trans-well cell migration assay.57 In germ-cell 
tumors, miR-373 has the ability to suppress the oncogene-induced p53 pathway and cooperates 
with oncogenic RAS to promote cellular transformation through direct inhibition of the tumor 
suppressor LATS2.58 Another target gene of miR-373 is CD44, which is a cell surface adhesion 
molecule, previously identified as a metastasis suppressor in CRC and capable of reducing the 
growth of experimental liver metastases.59 MiR-373 expressing cells showed a reduction of 
the CD44 gene product. In the human genome, miR-373 is located at chromosome 19q13.42. 
Copy number gains of chromosome 19q were observed in CRC patients.27
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The PI3K-AKT pathway
Receptor tyrosine kinase activation, mediated by the PI3K-AKT pathway, activates a cascade 
of anti-apoptotic and pro-survival signals.60 P85B, a fundamental component of the PI3K 
signalling network, was identified as a candidate target gene of miR-126. targeted degradation 
of p85β by miR-126 impaired the downstream signalling cascade through which PIP3, PDK1, 
and AKT eventually induce cell proliferation, survival, and increased motility. MiR-126 is often 
down-regulated in CRC cell lines. Restoring miR-126 expression showed a dose-dependent 
reduction in cell and colony numbers.61 In breast cancer cell lines, restoration of miR-126 
expression specifically decreased the lung colonizing activity and bone metastasis formation62, 
bus this has not been confirmed in CRC. MiR-126 is located at chromosome 9q34.3, a region 
that is not observed to be deleted or amplified in metastatic CRC.
High level expression of miR-196a was observed in 75% of pancreatic adenocarcinomas, 
which was  a negative predictive factor for survival.63 MiR-196a-transfected CRC cells showed 
a significant increase in the growth of pulmonary metastases.64 Increased phosphorylation 
of AKT was observed in miR-196a-transfected CRC cells, so induction of the pro-migratory 
phenotype is most likely linked to activation of the PI3K-AKt-mtOR pathway.64 Moreover, 
miR-196a was significantly up-regulated in metastatic cancer cell lines, in contrast to cells 
isolated from the primary CRC. Two isoforms of miR-196a are known: miR-196a-1 is located at 
17q21.32 and miR-196a-2 at 12q13.13. Copy number gains of chromosome 17q are observed 
in CRC, but there is no data available about the regulation of miR-196a-2 in human CRC.  
EGFR-independent pathway
As mentioned before, decreased cell-cell adhesion and the recruitment of proteases to 
degrade the ECM provide tumor cells invasive properties independent of the EGfR pathway. 
Macrophage migration inhibitory factor (MIF) is a potential target of miR-451. this recently 
discovered oncogene is overexpressed in several human cancers and correlated with tumor 
aggressiveness and metastatic potential.65 MiR-451 is often down-regulated in CRC, and these 
patients showed a significantly worse prognosis compared with those with overexpression.65 
transfecting CRC cell lines with miR-451 significantly reduced the number of metabolically 
active cells as well as decreased proliferation. This miRNA is essential for the translocation 
of β1 integrin to the basolateral membrane, which contributes to the formation of basolateral 
polarity in epithelial cells.66 MiR-451 is located at chromosome 17q, a genomic region showing 
copy number gains in CRC patients. As mentioned before, metastasizing tumors tend to have 
more gains of 17q compared with non-metastasizing tumors. 
Previous studies have linked up-regulation of metastatic tumor antigen 1 (MTA1) to the 
maintenance and progression of invasive phenotypes in CRC. MTA1 is a component of the 
chromatin remodelling complex, modulating transcription of its target chromatin by recruiting 
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histone deacetylases (HDACs) or RNA Polymerase II67, and is regulated by miR-661.68 Member 
of c/EBPα, a family of transcription factors, interact directly with the miR-661 promoter and 
positively regulate miR-661 expression. Expression of miR-661 and its activator c/EBPα are 
progressively reduced during cancer progression in breast cancer cell lines. Loss of miR-661 
allowed MTA1 levels to be sustained68, and introduction of miR-661 inhibited the motility, 
invasiveness, and anchorage-independent growth of invasive breast cancer cells. Although 
up-regulation of MTA1 was observed in CRC, a correlation between miR-661 and MTA1 was 
only experimentally observed in breast and prostate cancer cells. In the human genome, 
miR-661 is located at chromosome 8q24.3. High-level copy number gains were observed at 
chromosome 8q, a region that also maps the MYC oncogene.27
In CRC, the chromosomal regions containing miR-451 (17q) and miR-661 (8q) are often 
amplified, which is conflicting with the described anti-oncogenic function of these miRNAs 
in vitro. These contradictorily results might be explained by other mechanisms for miRNA 
dysregulation. the effect of chromosomal amplification of a miRNA gene could be perished 
by DNA promoter hypermethylation or decreased expression of components of the miRNA 
machinery. We cannot exclude combinatorial dysregulation of miR-451 and miR-661, but 
currently evidence is lacking. figure 4 gives a schematic overview of the different miRNAs 
related to regulation of invasion, migration, and proliferation.
Figure 4. Regulation of invasion, proliferation, and migration in CRC by miR-21, miR-31, miR-143, 
Let7, miR-196, miR-126, miR-661, miR-520c, miR-373, miR-338-3p, and miR-451.  
Abbreviations: MtA1 = metastatic tumor antigen 1; LAtS2 = large tumor suppressor homolog 2;  
MIf = migration inhibitory factor; fGf = fibroblast growth factor
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FUTURE PERSPECTIVES AND CLINICAL APPLICATION
Evidence is accumulating that miRNAs play an important role in cancer progression and 
metastasis. In breast62 and hepatocellular cancer69, there are already miRNA signatures 
identified that could distinguish primary tumors with metastases from metastasis-free tumors. 
We have summarized many miRNAs and their known target genes associated with the 
metastatic process that are dysregulated in CRC (table 1), but only limited data are available 
that link miRNA expression to the metastatic phenotype in CRC patients. To gain better insight 
into dysregulated miRNAs involved in CRC metastasis, one approach is to compare miRNA 
expression profiles in primary tumors and metastatic tissue. So far, only two studies compared 
these miRNA expression profiles, of which Kulda et al. used an unmatched-pair approach.70 
This type of unmatched comparison is unreliable, due to the differences in endogenous miRNA 
levels between primary colorectal carcinomas. In order to overcome this problem, comparison 
of matched metastatic and primary tumor tissue is essential. Baffa et al. compared miRNA 
microarray analyses of ten primary colon tumors with one of their related metastatic lymph 
nodes.71 this analysis identified 21 miRNAs that were differentially expressed between primary 
colon tumors and their related metastatic samples, of which four miRNAs were validated with 
qRt-PCR. Several significantly deregulated miRNAs observed in their analyses have already 
been reported as being related to processes of tumor invasion and metastasis. The use of 
microarray analysis in paired tissue is a useful approach for identifying candidate miRNAs 
involved in metastasis. Therefore, this approach should be applied to a large cohort of patients 
with CRC metastasis. A second approach is to compare miRNA expression in primary tumors 
of patients with and without metastatic disease, to identify changes in miRNA expression of 
primary tumors that are more likely to metastasize. MiRNA expression patterns of primary 
breast tumors were analyzed in patients with different clinical outcomes by comparing 
metastatic tumors with non-metastatic tumors. An aberrant miRNA expression signature was 
identified that distinguishes between metastatic and non-metastatic breast cancer.62 MiRNA 
analysis of the primary tumor might therefore be an important tool for predicting individual 
prognosis. In both approaches, the location of miRNA expression (stroma, tumor cells) should 
be investigated. This may be important as stromal cells can be a source of miRNA expression 
and influence tumor progression, survival, and patient outcome.
MiRNA expression is probably not only associated with the development of metastases and 
prognosis, but might be correlated with therapeutic outcome as well. High expression of miR-21 
in colon tumors of patients receiving adjuvant fluorouracil-based chemotherapy has been 
correlated with poor therapeutic outcome in two cohorts.72 Validation of these findings should 
be performed using larger cohorts and stratified for different types of adjuvant chemotherapy. 
Despite the fact, nowadays, that targeted therapies (bevacizumab, cetuximab, panitumumab) 
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Table 1. All MiRNAs regulating target genes involved in CRC metastasis
MiRNA Chromosomal 
location
Target gene Putative function Expression in 
CRC
Copy 
number 
alteration
Other 
regulatory 
mechanisms
Let-7 family Multiple 
members 
(3,9,11,19,21, 
22)
KRAS Invasion Down-regulated SNP in KRAS
MiR-17-92 13q31 THBS1 Angiogenesis Up-regulated Gain
MiR-21 17q23.2 PDCD4, SPRY2, 
TPM1, maspin,
PTEN, RECK,
TIMP3, TIAM1
EMT, invasion, 
migration
Up-regulated Gain
MiR-31 9p21.3 TIAM1 EMT, invasion, 
migration
Up-regulated Loss
MiR-34a 1p36.22 BCL2, E2F Cell-cycle 
progression, proli-
feration, apoptosis, 
DNA repair, angio-
genesis
Down-regulated Loss Promotor 
hyperme-
thylation
TP53  
inactivation
MiR-107 10q23.31 HIF1B Angiogenesis Loss Promotor 
hyperme-
thylation
MiR-126 9q34.3 P85B Invasion Down-regulated
MiR-141 12p13.31 TGFB1 EMT Down-regulated Promotor 
hyperme-
thylation
MiR-143 5q32 KRAS Invasion Down-regulated Loss
MiR-192 11q13.1 P21 Apoptosis Down-regulated TP53  
inactivation
MiR-194-2 11q13.1 P21 Apoptosis Down-regulated SNP in 
pre-miR-
194-2
TP53  
inactivation
MiR-195 17p13.1 BCL2 Apoptosis Down-regulated Loss
MiR-196a 17q21.32/
12q13.13
AKT Invasion, migration Up-regulated Gain 17q 
MiR-200b 1p36.33 ZEB1 EMT Down-regulated Loss
MiR-200c 12p13.31 ZEB1 EMT Down-regulated Promotor 
hyperme-
thylation
MiR-215 1q41 P21 Apoptosis Down-regulated TP53  
inactivation
MiR-373 19q13.42 LATS2, CD44 Invasion, migration Up-regulated Gain
MiR-451 17q11.2 MIF Invasion Down-regulated Gain
MiR-491 9p21.3 BCLXL Apoptosis, prolife-
ration
Down-regulated Loss
MiR-661 8q24.3 MTA1 Invasion Unknown Gain
Abbreviations: MiRNA = microRNA; CRC = colorectal cancer;  
EMT = epithelial to mesenchymal transition
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are part of the treatment strategy in metastatic CRC patients, there are no studies available 
evaluating the predictive value of miRNAs in treatment response to these therapies.
When specific miRNAs involved in the process of metastasis are identified, therapeutic 
strategies can be developed that aim at the silencing of oncogenes or up-regulating tumor 
suppressor genes. In order to silence an oncogene, reintroducing or over-expressing the miRNA 
that targets the oncogene is needed. Overexpression can be realized by introducing synthetic 
miRNA mimics or chemically modified oligonucleotides. this new approach is called ‘miRNA 
replacement therapy’. Vidic et al investigated the induced expression of KRAS targeting miRNA 
molecules on KRAS expression and growth of a CRC cell line.73 Inhibition of the KRAS oncogene 
resulted in growth inhibition in vitro and in vivo. This suggests that KRAS silencing could be 
used therapeutically in the treatment of different cancers.73 Wiggins et al. demonstrated the 
effects of miRNA overexpression by using chemically synthesized miR-34a and a lipid-based 
delivery vehicle that blocks tumor growth. Intra-tumoral injections of miR-34a prevented the 
outgrowth of viable tumors in tumor-bearing mice, as well as reduced expression of ki67 and 
increased expression of caspase-3 in the few viable tumor cells. This indicated that miR-34a 
actively inhibits proliferation and stimulates the apoptotic cascade. In addition, protein levels 
of direct miR-34a targets were repressed in tumors that received the miR-34a mimic. 
A second option for cancer treatment could be the down-regulation of miRNAs that suppress 
the function of tumor suppressor genes. This may be achieved by the introduction of antisense 
oligonucleotides or antagomirs, which are synthetic analogues of miRNAs that bind irreversibly 
to and inhibit the function of the miRNA of interest. An example is the stable expression of 
the adenovirus type E1A gene in cancer cells that can reduce their tumorigenic potential and 
promote apoptosis through down-regulation of miR-520h. In addition to the tumor-suppressive 
activity, expression of the E1A gene was able to convert human cancer cell lines from the 
mesenchymal phenotype into an epithelial-like phenotype, thereby inhibiting metastasis.74 
These promising results can provide a new opportunity to inhibit cancer metastasis.
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CONCLUSION
MiRNAs are important regulators of gene expression, and current data suggest an important 
role for miRNAs in the process of cancer metastasis. The genetic and epigenetic alterations 
that provide cancer cells the ability to metastasize are complex, and only a limited number 
of experimental models are available that allow examination of this in detail.  In comparison 
with other tumor types such as breast cancer, experimental data on the role of miRNAs in 
CRC metastases are still limited. However, several candidate miRNAs have been identified 
that are promising targets for therapeutic interventions. Most of the studies identifying these 
candidate miRNAs are based on a small number of patients. It is inevitable that there are more 
unidentified miRNAs involved in the metastatic pathway of CRC. therefore, we recommend 
identification of candidate miRNAs in a large cohort of metastatic CRC patients by comparing 
miRNA expression in metastatic and primary tumor tissue. Another approach to select miRNAs 
involved in metastasis is to compare miRNA expression in primary tumors of patients with and 
without metastatic disease. The next step is to gain insight into the biological consequences 
of these miRNAs on genes responsible for metastasis, using in vivo human CRC models. This 
useful approach should designate candidate miRNAs for further use as therapeutic targets in 
CRC treatment.
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ABSTRACT 
The metastatic process is complex and remains a major obstacle in the management of 
colorectal cancer (CRC). to gain a better insight into the pathology of metastasis, we inves-
tigated genomic aberrations in a large cohort of matched CRC primaries and distant metastases 
from various sites. In total, 62 primary colorectal cancers, and 68 matched metastases (22 
liver, 11 lung, 12 ovary, 12 omentum, and 11 distant lymph nodes) were analyzed by high 
resolution array comparative genomic hybridization for DNA copy number aberrations. 
findings were validated using a publicly available dataset consisting of 21 primary tumors and 
matched liver metastases. fluorescence in situ hybridization (fISH) was used to confirm some 
of the DNA copy number aberrations observed. Cluster analysis showed that metastases were 
highly correlated to their matched primary tumors in the majority of the patients. Recurring 
differences in chromosomal copy number aberrations between metastases and primaries 
were not observed in more than 2 of the 62 patients. Our data indicate that chromosomal 
copy number aberrations in colorectal metastases resemble their primary counterparts, and 
differences are typically non-recurrent. 
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE Chapter 8   Chromosomal copy number aberrations in colorectal metastases
125
INTRODUCTION
Metastatic disease is the principal event leading to death in patients with colorectal cancer 
(CRC), yet our understanding of the molecular events leading to metastasis is still incomplete. 
Tumor progression towards metastasis, meaning that malignant cells spread from the primary 
tumor to colonize distant organs, involves multiple steps, including invasion, intravasation, 
survival in the circulation, extravasation and colonization of the distant parenchyma.1,2
A variety of genetic and epigenetic events that lead to loss of function of tumor suppressor 
genes, such as APC, TP53 and SMAD4 and gain of function of oncogenes like KRAS and MYC, 
drive tumor cell behavior in a Darwinian selection process. two hypotheses aim to explain 
how tumor cells acquire the (epi)genetic alterations that make them proficient to metastasize. 
The “traditional model” suggests that the metastatic process is accompanied by a sequential 
accumulation of (epi)genetic alterations.3 Tumor cells pass through successive rounds of clonal 
progression and the most malignant cancer cells acquire the capacity to seed new colonies at 
distant sites.4 An alternative ”predestination” hypothesis, implies that the capacity to metas-
tasize is largely determined by the mutant alleles that are acquired relatively early during 
tumorigenesis.5 Subsets of genetic aberrations responsible for oncogenic transformation are 
also involved in the metastatic progression. This model does not question clonal selection 
or the accumulation of genetic alterations, but does not place metastatic dissemination near 
the end of tumor progression.6 According to this model, primary tumors that can and cannot 
metastasize will differ more in their biologic features than primary tumors and their associated 
metastases. 
A better understanding of the biology behind the metastatic process can have a major clinical 
impact in personalized cancer treatment for several reasons. first, if the metastatic potential is 
already encoded in the bulk of primary tumors, it could be of prognostic value for predicting 
metastatic recurrence of CRC patients. Second, genetic profiling of relevant pathways could 
predict the response to treatment. Especially in the era of targeted therapy it is important to 
understand the differences and commonalities in the genetic make-up of primaries and their 
matched metastases in order to determine which tumor tissue best reflects the presence of 
targets for therapy. third, if specific molecular alterations responsible for metastasis do exist, 
characterization of these could eventually lead to the development of new anti-metastatic 
therapies. 
So far, most studies aimed to unravel metastasis-associated genomic alterations by comparing 
the genetic profile of metastases with unmatched primary tumors.7,8 This approach is of limited 
value due to the heterogeneity between individuals in the genetic profile of their tumors. there 
are well designed tissue based studies using ‘matched’ primaries and metastasis.9,10 These 
studies revealed that gene expression and copy number patterns of metastatic tumor cells 
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were strikingly similar to that of the primary tumor. Recurrences reported were not indepen-
dently confirmed in larger datasets using independent techniques. Since the publication by 
Stange et al.9 the array comparative genomic hybridization (array CGH) technique has dramat-
ically improved. the oligo array CGH technique used here allows for a 20-fold higher spatial 
detection resolution, with also the capability of detecting focal aberrations.11-15 
In order to improve our understanding of the biology behind the metastatic process, we 
conducted such high resolution array CGH analysis on a large set of primary CRC and matched 
metastases of various distant sites. 
MATERIALS AND METHODS
Patients and tumor samples
formalin-fixed paraffin-embedded (ffPE) tissue of surgically resected primary tumor, matched 
distant metastasis and matched normal colon, was obtained from 62 patients. for 6 patients, 
tissue samples of two different metastatic sites were collected. The 68 metastatic tissue 
specimens consisted of 22 liver metastases, 11 lung metastases, 12 ovarian metastases, 12 
omental metastases, and 11 distant lymph node metastases. Eighteen patients included in this 
analysis participated in the CAIRO study16 (CKtO 2002-07, Clinical trials.gov; NCt00312000) 
and 36 patients were treated in the CAIRO2 study17 (CKtO 2005-02, Clintrials.gov; 
NCt00208546) of the Dutch Colorectal Cancer Group (DCCG). Written informed consent 
required for all patients before study entry also included translational research on tumor tissue. 
ffPE tissue of another 8 patients was collected from the tissue archive of the Department of 
Pathology at the Radboud University Nijmegen Medical Centre. 
Clinical and histopathological parameters
The following clinical features were collected for each patient: age, gender, site of the primary 
tumor, metachronous (> 6 months after initial diagnosis) or synchronous (> 6 months of initial 
diagnosis) onset of metastases. the tNM classification (5th ed.)18 was used to describe the 
extent of cancer spread in terms of invasion depth and lymph node stage. Tumors were histo-
logically classified using the World Health Organization guidelines.19 A tumor was considered 
to be of the mucinous type when at least 50% of the tumor volume consisted of mucin. 
Primary tumors were graded into well, moderately and poorly differentiated adenocarcinomas 
based on the part of poorest differentiation in the tumor. the mismatch repair system (MMR) 
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status was determined by immunohistochemistry and microsatellite instability (MSI) analysis.20 
Clinical and pathological parameters are summarized in table 1.
Table 1. Baseline characteristics of the 62 patients included in the analysis
Patients n, (%) 
(n=62)
Gender Male 33 (53%)
female 29 (47%)
Age Median (range) 60 (34-77)
Site of primary tumor Colon 29 (47%)
Rectosigmoid 15 (24%)
Rectum 16 (26%)
Unknown 2 (3%)
Onset metastases Metachronous 30 (48%)
Synchronous 32 (52%)
Diameter Median (range) 40 (15-135)
Invasion depth T1-2 5 (8%)
T3 47 (76%)
T4 10 (16%)
Lymph node status N0 12 (19%)
N1 22 (35%)
N2 26 (42%)
Unknown 2 (3%)
Classification Adenocarcinoma 54 (87%)
Mucinous carcinoma 8 (13%)
Differentiation grade Well 3 (5%)
Moderate 35 (56%)
Poor 24 (39%)
MSI status dMMR 2 (3%)
pMMR 60 (97%)
Site of metastases Liver 22 (32%)
Lung 11 (16%)
Omental 12 (18%)
Ovarian 12 (18%)
Distant lymph node 11 (16%)
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Chromosomal copy number detection by array CGH
the procedures for DNA isolation, labelling and hybridization have been described previously.21 
Briefly, DNA was isolated from an area containing at least 70% tumor cells. DNA was labelled 
and hybridized to dual channel Agilent 4x180K array CGH (Gene Expression Omnibus (GEO) 
platform GPL8687 Agilent technologies, Palo Alto, uSA). these arrays contain 180.880 in-situ 
synthesized 60-mer oligonucleotides, representing 169.793 unique chromosomal locations 
distributed across the genome at 17 kb intervals and are enriched with 4548 additional unique 
oligonucleotides, located at 238 of the Cancer Census genes. 
Array CGH preprocessing
Array image analysis was performed and local background was subtracted from the signal 
median intensities of both tumor and normal DNA. the log2 tumor to normal ratio was 
calculated in the statistical programming language R using the package CGHcall22 and was 
normalized against the median value of the log2 ratios of all the oligonucleotides mapped to 
the March 2006 human reference sequence (NCBI36/hg18) on chromosome 1-22 and X. 
Figure 1. flowchart of data preprocessing and analysis procedures. In grey analysis performed in R, 
in white analysis performed in Nexus.
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the cellularity parameter in the CGHcall data analysis software was set according to the 
estimates made by the pathologist (I.D.N.). further data interpretation and CNA calling was 
done with Nexus Copy Number 6.0 software (Biodiscovery, El Segundo, uSA) using default 
settings, except for the Segmentation Algorithm, which was set to “Rank”. The CNA calling 
cut-off value for gene copy number gain or loss was set to 0.2 and -0.2, and for amplifications 
or homozygous deletions this cut-off value was set to 0.6 and -1.0, respectively (figure 1).
Array CGH data analysis
Our dataset consisted of 62 primary tumor DNA copy number profiles and 68 metastatic 
profiles resulting in 130 profiles to analyze. unsupervised hierarchical clustering analysis was 
performed in R with the segmented data according to the same procedures as Stange et al.9 The 
distance was calculated based on a Spearman correlation (figure 1). for patients that did not 
cluster together, a likelihood of clonality was performed using the R package “clonality Bioin-
formatics”.23 To compare frequencies of aberrant regions between metastases and primary 
tumors a chi-square test was performed within Nexus 6.0. This was done for all metastases as 
together and per metastatic site separately. Concordance of paired DNA copy number profiles 
was defined by the percentage of the genome with the same copy number in the metastasis 
and the corresponding primary tumor. to compare the samples in pairs (primary tumors and 
matched metastasis) DNA copy number ratios of the primary tumor were subtracted from 
the corresponding metastases, resulting in a dataset of 68 combined samples. The GISTIC 
algorithm24 within Nexus 6.0 was used to identify genomic regions that are significantly 
amplified or deleted across this combined sample set. A gain or amplification means that 
higher DNA copy number ratios were detected in the metastasis compared to the primary 
tumor (figure 1). for the regions that showed a deletion, lower DNA copy number ratios were 
detected in the metastases compared to the primary tumor. The output included those regions 
with a high corresponding G score, indicating either a high frequency of occurrence or a high 
amplitude for several samples or a combination of the two. The method accounts for multiple-
hypothesis testing using the false-discovery rate (fDR), and a fDR below 0.05 was used as 
a level of significance. for validation purposes, the normalized array CGH data of Stange et 
al.9 including 21 primary tumors and matched liver metastases were re-analyzed in the same 
manner as described above.
Detection of chromosome 6q21 and 8q24.21 (MYC) co-amplification in 
large independent cohorts of primary colorectal tumors
the presence of the co-amplification of chromosome 6q21 and 8q24.21 (MYC) was assessed 
in array CGH data of 542 primary colorectal tumors. these array CGH profiles were 
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derived from 349 primary colorectal tumors who participated in either the CAIRO16 or the 
CAIRO217 study (JC Haan et al., in preparation), and from 193 primary colorectal tumors 
present in the Cancer Genome Atlas (tCGA). Chromosomal amplifications were identified 
by CGHcall22 for the CAIRO and CAIRO2 samples, and by cBio Cancer Genomics Portal 
(http://www.cbioportal.org)25 for the samples of the TCGA dataset, and were only acknowledged 
if the log2 ratio of the segmented values was higher than 2.
Figure 2. frequency plots of DNA copy number aberrations in 62 primary tumors and 68  
matched metastases. (A) frequencies of aberrations based on called data for primary tumors and  
(B) metastases. The x-axis displays clones spotted on the array sorted by chromosomal position.  
the y-axis displays the frequency of tumors with gains (above zero) or losses (below zero). 
Boundaries of chromosomes are indicated by dotted lines.
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Fluorescence in situ hybridization (FISH)
Copy number status of both chromosome 6q21 and 8q24.21 (MYC), as well as of the centromeres 
of chromosome 6 and 8 were assessed by fISH analysis. the MYC locus probe, 6q21 locus 
probe, and the centromere probes of chromosome 6 and 8 (Vysis, Abbott Molecular, Abbott 
Park, Illinois, uSA) were used following a standard protocol. Briefly, paraffin-embedded 
tissue section (4 µm) were deparaffinized, air-dried, and pretreated using a solution of MW 
Sodium Citrate pH 6.0 of HDP EDtA pH 9.0 (Klinipath, Duiven, the Netherlands). the slides 
were digested with Pepsin (200 u/ml; Sigma-Aldrich, St. Louis, uSA) for 15 to 30 minutes 
at 37°C and subsequently fixed for 5 minutes in 1% formaldehyde/PBS (Merck Millipore, 
Massachusetts, uSA). thereafter, the slides were dehydrated using increasing graded ethanol 
series, air-dried, and finally 10 µl of probe mix was applied to each tissue section. the slides, 
covered with a coverslip and sealed with rubber cement, were then incubated in a hybridizer 
(Dako, Heverlee, Belgium) for 10 minutes at 80°C and overnight at 37°C. the next day, the 
slides were washed for 5 minutes at 45°C, 3 minutes at 73°C, 5 minutes at room temperature 
using salted Sodium Citrate (Immunologic, Duiven, the Netherlands). After dehydration using 
increasing graded ethanol series and air-drying, the slides were counterstained by applying 
DAPI (Vector Laboratories inc. California, uSA). Hybridization signals were visualized using 
a Leica microscope (Leica Microsystems Inc., Rijswijk, the Netherlands). Signals for each 
probe were counted in at least 40 cells per tumor sample. Samples with a ratio greater than 
3 between MYC or 6q21 versus the centromere signals, in 10% of cells or more, were scored 
positive for amplification.
RESULTS
Striking similarity in DNA copy number status between primaries and 
matched metastases
We analyzed 62 primary tumors and 68 matched metastases for DNA copy number aberrations. 
Patterns of DNA copy number aberrations between primaries and metastases were highly 
similar for the majority of the patients (figure 2), confirming clonality. 
By comparing the group of primaries versus the group of metastases, only gain of chromosomes 
2p25.3 and 2q21.3 were more frequently observed in metastases compared to primaries 
(p<0.001; Supplemental table 1). However, after correction for multiple testing no significant 
regions were left (fDR>0.05).
Cluster analysis was used to assess similarities and differences in DNA copy numbers profiles 
between paired primary tumors and metastases relative to similarities and differences between 
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Supplemental Table 1. Comparison of copy number aberrations between primaries and metastases
Region Location Copy number 
status
Frequency in
metastasis 
(%)
Frequency in
primary 
tumor (%)
P-value FDR
chr2:2,609,073-
2,646,266
q21.3 Gain 36.8 8.1 < 0.001 0.42
chr2:2,646,266-
2,768,821
p25.3 Gain 38.2 8.1 < 0.001 0.42
chr2:2,786,596-
3,216,115
p25.3 Gain 39.7 9.7 < 0.001 0.42
chr2:2,768,821-
2,786,596
p25.3 Gain 38.2 9.7 < 0.001 0.45
chr2:3,216,115-
3,233,076
p25.3 Gain 35.3 9.7 < 0.001 0.45
chr2:3,233,076-
3,250,127
p25.3 Gain 35.3 8.1 < 0.001 0.45
chr2:3,250,127-
3,281,460
p25.3 Gain 33.8 8.1 < 0.001 0.45
chr2:3,281,460-
3,312,704
p25.3 Gain 32.4 6.5 < 0.001 0.45
Abbreviation: FDR = false discovery rate
Figure 3. Dendrogram of unsupervised hierarchical clustering of DNA copy number aberrations of 62 
primary CRC tumors (p) and 68 matched metastases (m). the numbers and pointers on the left show 
the patients of which the primary tumor and metastasis did not cluster together.
different tumors. Metastases were highly correlated to their matched primary tumors for 56 
patients (correlation higher than 0.55), which included the two MSI tumors present in our 
dataset. for 6 patients, metastases and the corresponding primary tumors were not joined pair 
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wise in the cluster dendrogram, with various distances (figure 3). Histological re-evaluation of 
these 6 matched pairs showed similar morphologies. Two of the 6 patients however clustered 
with only one tumor or tumor pair between them. the remaining 4 copy number profiles are 
shown in Supplemental figure 1. In these 4 patients we calculated the likelihood of clonality. 
The likelihood ratios of 3 of these samples were smaller than 1, statistically suggesting a low 
odds that the two tumors are clonal. for the other patient the likelihood ratio was 1.6 with a 
p-value of 0.042, statistically indicating that the tumor pair would be clonal.  
Rare non-recurrent differences between metastases and primaries of 
individual patients 
Even though a striking overlap of the aberration patterns was found between primary tumors 
and their matched metastases in the majority of the patients, also differences were observed. 
Overall, a median of 27% of aberrant genome was detected in primary tumors versus a median 
of 33% in the metastases. this difference is not a consequence of tumor cell percentage which 
was corrected for, nor a consequence of heterogeneity (data not shown). Pair wise comparison 
of the metastases and the primary tumor per patient revealed 4 patients with concordant 
segments for either gain, loss or normal DNA copy number of more than 95% (median 96.8% 
(95.6-100%)). In addition, 38 patients showed concordant segments between 70 and 95% 
(median 82.0% (72.0-94.7%)), and the remaining 20 patients had a concordance level in DNA 
copy number status of less than 70% (median 60.3% (41.6-69.7%)). there was no specific 
metastatic site overrepresented in one of these groups. Three of the four patients who did not 
join pair wise in the cluster analysis are in this last group with a concordance level of less than 
70% (53.4, 67.8 and 69.7%). the remaining one who did not cluster had a concordance level 
of 82%. Representative examples of copy number profiles in each concordance level group 
are shown in figure 4.
To establish which genomic regions show overall differences in copy number aberrations 
between the group of primary and metastatic tumors we generated a combined dataset. The 
log2 values of the primary tumors were subtracted from the log2 values of the metastases for 
each position (probe on the array) and analyzed these using the GIStIC algorithm in Nexus. 
GISTIC essentially combines ratios that are either highly recurrent or more sporadic, but with 
a high deflection. We observed 15 statistically significant events with, 13 regions of low DNA 
copy number ratios and 2 regions of high DNA copy number ratios (Supplemental table 2). 
the significant peaks identified were each determined primarily by deflection rather than by 
frequency across the patient cohort, and most non-recurrent except for one co-amplification 
(see below). 
We used the same approach of the combined data to assess the differences in copy number 
status between primary and metastatic tissue for each organ separately. The dataset of 22 
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Supplemental Figure 1. DNA copy number profiles of patients of which the correlation of the primary 
tumor (p) and their metastasis (m) was substantially low with more than one tumor pair between 
them. The patients showed concordant segments of (A-B) 67.8%, (C-D) 82.0%, (E-F) 69.7% and 
(G-H) 53.4%. the x-axis displays clones spotted on the array sorted by chromosomal position. the 
y-axis displays the log2 ratios of the clones. The segments are depicted by grey lines. Boundaries of 
chromosomes are indicated by dotted lines.
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Figure 4. Representative examples of DNA copy number profiles of primary tumors (p) and their 
matched metastasis (m). (A-B) Example of a tumor metastasis pair from the group with less than 
70% concordant segments (total 20 patients of which 3 patients were not joined pair wise in 
the dendrogram of figure 3), (C-D) example of a tumor metastasis pair from the group with 70 
and 95% concordant segments (38 patients of which 1 patient was not joined pair wise in the 
dendrogram of figure 3), and (E-F) example of a tumor metastasis pair from the group with more 
than 95% concordant segments (4 patients). the x-axis displays clones spotted on the array sorted by 
chromosomal position. The y-axis displays the log2 ratios of the clones. The segments are depicted by 
grey lines. Boundaries of chromosomes are indicated by dotted lines.
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patients with liver metastases revealed 7 regions with higher DNA copy number ratio and 8 
regions with lower DNA copy number ratio in the liver metastases compared to the primary 
tumor. In the study used for validation (Stange et al.9) of patients with liver metastases, a 
difference between primaries and matched liver metastases was reported for chromosome 
11p15.5 in 6 out of 21 patients. By re-analyzing the array CGH data of Stange et al.9 with the 
procedures we implemented, we confirmed the 11p15.5 gain in 6 liver metastases which was 
Supplemental Table 2. GISTIC approach in combined samples 
Extended Region Type FDR G-Score Genes
chr1:1,438,247-
12,034,621
Loss 0.002 8.1 >50 genes 
chr3:60,181,256-
60,563,627
Loss 0.005 7.8 FHIT
chr4:4,626,306-
31,693,271
Loss 0.05 6.8 >50 genes
chr4:85,226,936-
92,648,432
Loss 0.006 7.7 >50 genes
chr6:105,350,190-
107,821,131
Gain < 0.001 12.6 HACE1, LIN28B, BVES, C6orf112, POP3, 
POPDC3, PREP, PRDM1, ATG5, AIM1, RTN4IP1, 
QRSL1, AK124400, AK025967, LOC100422737, 
LOC553137, C6orf203, BEND3, PDSS2
chr6:162,581,750-
163,143,342
Loss 0.006 7.7 Parkin, PARK2, PACRG
chr8:39,380,297-
39,805,805
Loss < 0.001 13.4 ADAM5P, tMDC,  ADAM3A, tMDC III, ADAM18, 
ADAM2
chr8:127,000,942-
129,605,179
Gain < 0.001 18.8 LOC100130231, BX648371, FAM84B, AK125310, 
BC106081, DQ515898, DQ515899, DQ515897, 
POU5F1B, POU5F1, LOC727677, BC042052, 
MYC, MIR1204, TMEM75, PVT1, MIR1205, 
MIR1206, MIR1207, MIR1208, BC009730
chr16:6,458,969-
6,559,580
Loss 0.001 8.4 A2BP1, RBFOX1
chr18:3,458,748-
13,680,560
Loss < 0.001 8.8 >50 genes
chr18:48,738,234-
57,604,348
Loss < 0.001 10.8 >50 genes
chr20:14,932,222-
15,035,264
Loss < 0.001 9.9 MACROD2
chr21:35,205,722-
35,651,123
Loss 0.003 8.0 C21orf96, RUNX1
chrX:7,022,874-
7,471,041
Loss < 0.001 11.2 HDHD1A, HDHD1, MIR4767, STS
chrX:88,378,677-
88,554,287
Loss 0.002 8.2 No genes
Abbreviation: FDR = false discovery rate
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Figure 5. DNA copy number profiles of two patients containing a co-amplification of at 8q24.21 
(MYC) and chromosome 6q21 in the metastasis (B, D, E), which was not present in the primary 
tumor (A ,C). The x-axis displays clones spotted on the array sorted by chromosomal position. The 
y-axis displays the log2 ratios of the clones. The segments are depicted by grey lines. Boundaries of 
chromosomes are indicated by dotted lines.
absent in the corresponding primary tumors. this gain is based on BAC clones on their CGH 
arrays. In our set of 22 patients with liver metastases and the remaining 40 patients with other 
metastatic sites, gain of this region was not detected, despite the 38 oligonucleotides present 
on our arrays in the same chromosomal region. 
In the 12 patients with omental metastases 6 regions showed significant peaks, of which 1 
region showed a higher copy number ratio and 5 regions with a lower copy number ratio in 
the metastases compared to the primary tumor. In the other metastatic organs (ovary, lung, and 
distant lymph nodes) differences in DNA copy number ratios between metastases and primary 
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
138
Chapter 8   Chromosomal copy number aberrations in colorectal metastases
Figure 6. fISH analysis confirming high level co-amplification of MYC (8q24.21) and chromosome 
6q21 in metastatic tissue (lymph node) which were absent in the matched primary tumor.  
(A) Primary tumor without the MYC amplification (red probe: MYC (8q24.21), green probe: 
centromere chromosome 8). (B) Distant lymph node metastasis with the MYC (8q24.21)  
amplification (red probe: MYC (8q24.21), green probe: centromere chromosome 8, gain). (C) Primary 
tumor without the chromosome 6q21 amplification (green probe: 6q21, red probe: centromere 
chromosome 6). (D) Distant lymph node metastasis with the 6q21 amplification (green probe: 6q21). 
(E) Co-amplification of MYC (8q24.21)  and chromosome 6q21 in a distant lymph node (red probe: 
MYC, green probe: 6q21). Abbreviations: CEP6 = centromere chromosome 6; CEP8 = centromere 
chromosome 8.
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tumors were not observed with any statistical significance. Analysis of the patients according 
to the different metastatic sites revealed no aberrant regions to be overrepresented in one of 
the metastatic subgroups.
Recurrent additional DNA copy number aberrations in metastasis
In only two patients we observed recurrent high level co-amplifications in the metastases, 
which were not detected by array CGH in the primary tumor. the amplifications were located 
at 6q21 and 8q24.21, the latter encompassing the MYC oncogene. One of these patients had 
two metastatic sites involved, both harboring this MYC amplification (figure 5). All three MYC 
amplifications in the metastases had also chromosome 6q21 amplified. these high level ampli-
fications of 6q21 also were not observed in the primary tumor. the array CGH results were 
confirmed by fISH analysis showing high level amplifications of MYC and chromosome 6q21 
(figure 6). the co-amplification did not result from translocation, since no co-localization of 
the amplified chromosomal regions was observed in the fISH analysis. We also performed 
fISH analysis to analyze heterogeneity within the primary tumor cell population. However, 
we did not observe subclones with high level amplification of MYC and/or chromosome 6q21.
to confirm that the co-amplification is metastasis-specific we analyzed 349 primary colorectal 
tumors of the CAIRO studies and 193 primary colorectal tumors of the tCGA dataset. We 
detected high level amplification of MYC alone, once in a primary colorectal tumor of the 
CAIRO datasets and three times in the primaries of the tCGA dataset. the 6q21 amplification 
was only detected once in the CAIRO datasets, but not observed in the tCGA dataset. In none 
of these 542 primary tumors a co-amplification of MYC and chromosomal locus 6q21 was 
observed.
DISCUSSION
In a large set of clinical samples we observed highly similar DNA copy number aberrations in 
metastases compared to primary CRC in the majority of the patients. Copy number differences 
are present but rather than recurrent they were sporadic for individual patients. 
Given the significant overlap in chromosomal aberrations between primary tumors and corre-
sponding metastases in our dataset of 68 pairs, we validate the early findings by Stange et 
al.9 using 21 pairs. Therefore, we reason that many chromosomal aberrations arise in the 
primary tumor before metastatic spread. In the past years, genetic data have become available 
supporting the idea that the metastatic behavior seems to be predetermined relatively early in 
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tumorigenesis. first, micrometastases are observed in many individuals with small, low-stage 
tumors.26 Second, RNA expression profiling of the bulk of primary tumors predict the metastatic 
recurrence of cancer patients.27,28 Third, microarray analysis revealed that RNA expression and 
DNA copy number patterns of metastatic tumor cells were strikingly similar to that of the 
primary tumor.9,10,29 Sequence analysis of coding regions in primary and metastatic tumor 
genomes also suggest that only a few mutations are required to transform cells from an invasive 
colorectal tumor into cells that have the capability to metastasize.30 Genome wide sequencing 
of matched primary and metastatic tissues has only been performed in small patient cohorts. 
In the study of Kloosterman et al.31, significant overlap in somatic structural changes between 
4 primary tumors and their corresponding metastases was observed. Moreover, whole-genome 
sequencing of matched primary pancreatic tumors and metastases32, and genomic analyses 
of primary prostate cancer and metastases33 revealed highly similar genomic profiles in other 
solid malignancies as well. All these data suggest that essential mutations and chromosomal 
aberrations needed for cancer progression occur predominantly in the primary tumor before 
initiation of the metastatic spread, and are consistent with the genetic observations presented 
here.
Nevertheless, differences are observed in DNA copy numbers between primaries and 
metastases. There are several potential scenarios for the observed differences. Changes in 
chromosomal aberrations can occur because the primary and metastasis are different branches 
from a common yet heterogeneous ancestor34, or after the dissemination of metastatic cells 
from the primary tumor. We hypothesize that the most likely scenario is a combination of both 
heterogeneity within the primary tumor and post-dissemination effects. It is thereby important 
to take into account that by array CGH chromosomal aberrations can go undetected if present 
in less than 30% of the tumor cells.35 Since a primary colorectal tumor can be quite large 
and only a small cross section was taken for copy number analysis, heterogeneity would be 
reflected in the copy number measurements and explain some of the differences between 
matched primaries and metastases. Another explanation for the observed differences could be 
that some of the patients included in our cohort presented with metachronous metastases and 
consequently received (neo)adjuvant systemic treatment. the effect of systemic treatment on 
chromosomal instability however is largely unknown, but probably limited since in a small 
dataset no significantly increased number of gene variants (associated with pathways relevant 
in cancer) were observed as a result of chemotherapy.36 Our data strengthen this observation 
because the patients who did receive (neo)adjuvant systemic treatment clustered pairwise. 
None of the 6 patients who did not cluster together received chemotherapy and targeted 
agents. 
Stange et al.9 published a dataset of 21 paired samples where a characteristic gain was found 
in 1 out of 3.5 patients on chromosome band 11p15.5 in liver metastases. they report confir-
mation of this observation in an independent dataset of liver metastases (n=50). this obser-
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vation could not be confirmed in our set of patients with liver metastases (n=22), nor in other 
metastatic sites and could not be detected in the Kloosterman dataset of matched primary 
metastasis pairs.31 In the cohort of patients studied here we observed only one recurrent event; 
two patients with co-amplifications on the same chromosomal locations in the metastases, 
which were not present in the primary tumor. this co-amplification was not detected previously 
in larger series of primary tumors, and smaller studies of metastases, including the TCGA CRC 
samples. these series of metastases did not use high resolution array CGH (not able to detect 
focal amplifications), so the association of this specific co-amplification with metastasis needs 
further confirmation in larger series using the current available high resolution array CGH. the 
relationship between 6q21 and 8q24.21 described in the literature is in hematologic malig-
nancies were PRDM1, localized at chromosome 6q21, is able to decrease the expression of 
MYC.37,38 We hypothesize that these two amplifications would be obtained through selection 
and adaptation within developing metastases after dissemination. 
In a previous array CGH analysis of our group, we observed more gains at chromosome 20p11 
in primary tumors that metastasize to the liver compared to primary tumors that disseminate to 
extrahepatic organs.39 We also observed more gains at chromosome 20p11 in liver metastases 
compared to the metastases of other distant sites (data not shown). However, comparison of 
the metastasis and primary tumor in each group separately (liver, lung, lymph node, omentum, 
and ovary), did not reveal any recurrent additional copy number aberrations within one group 
compared to the others. this also fits our hypothesis that the genetic program responsible for 
metastatic tropism is already acquired relatively early during tumorigenesis.
In the era of personalized anti-cancer treatment it is essential to know the diverging features 
between primaries and metastases. It is therefore important to determine which tumor tissue 
will best predict treatment outcome. Current clinical practice is to use archived material of 
the primary tumor to determine the constitution of the molecular target to select patients 
for treatment of the metastasis. If true additional genomic aberrations would be required for 
metastatic progression, these regions would be relevant to design adjuvant treatment strategies 
for stage II-III CRC. Our data showed that genomic profiles are highly similar, which makes is 
unlikely that precursor cells of overt metastases in CRC disseminate early to sites where they 
proceed to undergo their own divergent genetic evolution. Instead of focusing on additional 
genetic features responsible for metastatic formation, identification and understanding of the 
chromosomal aberrations in precursor cells of the primary tumor is probably more important 
and should be the route to the discovery of new drug targets. 
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ABSTRACT
OBJECTIVE: Metastatic colorectal cancer (CRC) cells have a selective preference for certain 
target organs that cannot be explained by circulatory patterns alone. This study aimed to identify 
clinicopathological features and chromosomal aberrations of primary tumors associated with 
organ-specific CRC metastasis. 
DESIGN: Clinicopathological features were investigated in CRC patients with exclusively 
hepatic (n=182) versus exclusively extrahepatic (n=139) metastases. 139 primary tumors of 
patients with hepatic (n=85) and extrahepatic metastases (n=54) were screened for chromosomal 
aberrations by microarray-based comparative genomic hybridization, and the findings were 
validated in an independent set of 80 primary tumors. A publicly available database was used 
to correlate chromosomal aberrations with gene expression. Protein expression was evaluated 
by immunohistochemistry on tissue microarrays.
RESULTS: Patients with hepatic metastases were significantly more often male (71% vs 53% 
p=0.002), more often had abnormal lactate dehydrogenase activity (37% vs 14% p<0.0001), 
exhibited primary tumor localization in the colon (52% vs 40% p=0.03) and had synchronous 
onset of metastases (70% vs 19% p<0.0001). Primary tumors of patients with hepatic 
metastases were more commonly t3 tumors (79% vs 63% p=0.006) and less commonly of 
mucinous histology (5% vs 16% p=0.02). Gain of 20p11 was more often observed in patients 
with hepatic metastases (p<0.05), which was confirmed in an independent dataset (p<0.05; 
fDR<0.05). twelve genes mapping at 20p11 were significantly overexpressed as a conse-
quence of 20p11 copy number gain. C20orf3 showed the strongest correlation between RNA 
expression and DNA copy number. this was reflected in significantly higher protein expression 
in patients with hepatic metastases (59%; n=325) than in those with extrahepatic metastases 
(41%; n=256) (p=0.01). 
CONCLUSION: C20orf3 mapping at 20p11 is associated with hepatic-specific metastasis in 
patients with CRC. This gene is a candidate biomarker for liver metastases and may be of 
clinical value in early-stage CRC. 
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INTRODUCTION
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies, and the 
majority of these patients die as a result of metastatic disease. The phenomenon of cancer 
metastasis has been extensively studied and characterized as a complex, multistep process. to 
produce metastatic outgrowth, tumor cells need to be proficient in all steps of the metastatic 
process, including invasion, embolization, survival in the circulation, arrest in a distant capillary 
bed, and proliferation within the organ parenchyma. Tumor cells acquire these biological 
properties by accumulating (epi)genetic alterations.1 One hypothesis on the acquisition of a 
metastatic phenotype is that these modifications are already present in the primary tumor. this 
is supported by the finding that gene expression signatures of the primary tumor have been 
shown to predict the occurrence of metastasis in patients with breast cancer.2
Like other types of cancer, CRC shows organ preference for metastasis formation. The liver is 
the predominant site in approximately 80% of patients with CRC. In 40-50% of these patients, 
extrahepatic organs are also involved in metastatic colonization.3 Lung metastases develop in 
5-15% of the patients, and metastases in the central nervous system, adrenal glands, ovaries, 
skeleton, and skin together account for <10% of all colorectal metastases.4 Metastatic cells 
prefer to grow in certain organs in a way that cannot be explained by circulatory patterns 
alone. Organ specificity has mainly been investigated in animal models,5, 6 but gene expression 
profiling in human breast cancer tissue can predict bone and lung metastases.7, 8 The devel-
opment of DNA microarray technology, which allows for genome-wide profiling, has provided 
new insight into the genetic basis of metastasis. However, so far, neither chromosomal 
aberrations nor gene expression profiling in the primary tumor have been correlated with 
hepatic versus extrahepatic metastasis in CRC.
CRC in many aspects, including prognosis and survival, is a heterogeneous disease. In case of 
unresectable metastatic CRC, patients are treated with cytotoxic regimens (fluoropyrimidines, 
oxaliplatin, irinotecan) in combination with targeted therapy (vascular endothelial growth 
factor and epidermal growth factor receptor antibodies). there are conflicting data available 
on the prognostic value of organ-specific metastasis in patients treated with systemic therapy. 
Several studies have reported the presence of liver metastases as a negative predictor,9-14 while 
others observed survival benefit in patients with hepatic metastases compared with patients 
with lung metastases.15-17 So far, no studies have been performed to evaluate the differences in 
patients with hepatic versus extrahepatic metastases in terms of clinicopathological features 
and outcome.
The present study aimed to identify clinicopathological features, chromosomal aberrations and 
outcome associated with hepatic versus extrahepatic metastasis in patients with CRC.
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MATERIALS AND METHODS
Patients
the patients included in this analysis participated in the CAIRO study (CKtO 2002-07, 
http://Clinical trials.gov; NCt00312000) of the Dutch Colorectal Cancer Group (DCCG).18 In 
this multicentre phase III trial, 820 patients with metastatic CRC without previous systemic 
treatment for metastatic disease were randomized between sequential and combination 
treatment with capecitabine, irinotecan and oxaliplatin. The primary end point of the study 
was overall survival (OS). the written informed consent required for all patients before study 
entry also included translational research on tumor tissue. for the present analysis, we selected 
550 eligible patients who underwent a resection of the primary tumor, for which formalin-fixed 
paraffin-embedded (ffPE) material of the primary tumor was available. Patients were divided 
according to the site of the metastases in exclusively hepatic (n=182) and exclusively extra-
hepatic (n=139) disease. Patients with a combination of hepatic and extrahepatic metastases 
(n=221), locally advanced disease (n=7), and for whom the metastatic site was unknown (n=1) 
were excluded from this analysis. 
Clinical and histopathological parameters
The following clinical features were collected for each patient: age, gender, Eastern Cooperative 
Oncology Group (ECOG) performance status, serum lactate dehydrogenase (LDH), site of the 
primary tumor, previous adjuvant therapy, number of metastatic sites involved, metachronous 
(>6 months after initial diagnosis) or synchronous (≤6 months of initial diagnosis) onset of 
metastases, and regimen used as first-line treatment.
the tNM (tumor, node, metastases) classification was used to describe the extent of cancer 
spread in terms of invasion depth and lymph node stage.19 Histopathological review was carried 
out by two independent observers (LJMM, IDN). If the scoring was not unambiguous, the 
opinion of the pathologist (IDN) was final. tumors were classified using the WHO guidelines.20 
A tumor was considered to be of the mucinous type when at least 50% of the tumor volume 
consisted of mucin. Primary tumors were graded into well, moderately and poorly differen-
tiated adenocarcinomas based on the part of poorest differentiation in the tumor. The mismatch 
repair system status was determined by immunohistochemistry and microsatellite instability 
analysis.21
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Data analysis of clinicopathological features and outcome
Clinical and histopathological characteristics of patients with hepatic and extrahepatic 
metastases were compared using the Wilcoxon signed rank test or χ2 test where appropriate. 
OS was calculated as the interval from the date of randomization until death from any cause 
or until the date of last follow-up. Progression free survival (PfS) for first-line treatment was 
calculated from the date of randomization to the first observation of disease progression or 
death from any cause. OS and PfS curves were estimated using the Kaplan-Meier method 
and compared with the log-rank test. Patients were considered evaluable for response if they 
had completed at least three cycles of chemotherapy. Overall response was defined as partial 
response or complete response. Disease control was defined by stable disease with a duration 
of more than 4 months or partial response or complete response. Differences in response and 
disease control rates were analyzed by a χ2 model. Multivariate analysis of OS was performed 
by means of a Cox proportional hazards model, including the following covariates: gender, 
performance status, serum LDH, site of the primary tumor, number of metastatic sites involved, 
t stage, N stage, classification, and differentiation grade of the primary tumor. All statistical 
tests were two-sided, and p values of <0.05 were considered significant.
Sample selection for DNA copy number profiling
to asses DNA copy number profiles we used an array comparative genomic hybridization 
(CGH) dataset of 222 primary colorectal tumors from patients with metastatic CRC who 
were treated within the CAIRO study (Haan et al. unpublished data). We selected the 85 and 
54 CRC patients with exclusively hepatic and exclusively extrahepatic metastases, respec-
tively. the accuracy of the observed differences in DNA copy number profile was validated 
in an independent validation set of 45 and 35 primary tumors with hepatic and extra-
hepatic metastases, respectively. these tumors were derived from an array CGH dataset of 
134 metastatic CRC patients (Haan et al. unpublished data), who participated in the CAIRO2 
study (CKtO 2005-02, http://Clinicaltrials.gov; NCt00208546).22 In this multicentre phase 
III trial, patients were randomly assigned to first-line treatment with capecitabine, oxaliplatin 
and bevacizumab, or the same schedule with the addition of cetuximab. Since the CAIRO2 
study had a negative outcome, possibly because of a negative interaction between the study 
drugs, the array CGH profiles were determined only in patients receiving capecitabine, oxali-
platin and bevacizumab. the selection criteria for the patients used for both the training and 
validation set are described in detail elsewhere (Haan et al. unpublished data). Briefly, primary 
tumors were selected from patients who underwent a resection of the primary tumor and for 
whom ffPE material of the primary tumor was available. Since we used normal as well as 
tumor DNA from the same patient, ffPE material for both needed to be available. Stringent 
criteria were used to select patients based on tumor cell percentage (at least 70%), clinical 
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Supplemental Table 1. Clinicopathological features in the 85 patients with hepatic versus 54 patients 
with extrahepatic metastases used for DNA copy number profiling (CAIRO study; learning set) 
Hepatic
metastases
n = 85
Extrahepatic
metastases
n = 54
P-value
Age Median (range) 66.0 (37.0-78.0) 63.5 (40.0-79.0) 0.87
Gender Male 60 71% 31 57% 0.14
female 25 29% 23 43%
WHO performance 
status
0-1 80 94% 53 98% 0.33
2 5 6% 1 2%
LDH at 
randomization
Normal 59 69% 48 89% 0.008
> uLN 26 31% 3 11%
Site of primary tumor Colon 60 71% 56 60% 0.59
Rectosigmoid 19 22% 49 28%
Rectum 5 6% 34 10%
2 sites 1 1% 1 2%
Prior adjuvant 
therapy
No 78 92% 40 74% 0.007
Yes 7 8% 14 26%
Onset metastases Metachronous 22 26% 39 74% <0.0001
Synchronous 63 74% 14 26%
Metastatic sites 
involved
1 85 100% 28 54% <0.0001
2 0 18 35%
>2 0 6 11%
Treatment arm Sequential 45 53% 29 54% 0.93
Combination 40 47% 25 46%
Diameter Median (range) 45 (20-130) 50 (15-100) 0.82
Invasion depth T1-2 4 5% 5 9% 0.09
T3 76 80% 34 63%
T4 13 15% 15 28%
Unknown 1 0
Lymph node status N0 29 36% 23 43% 0.65
N1 29 36% 19 35%
N2 23 28% 12 22%
Unknown 4 0
Classification Adenocar-
cinoma
65 81% 36 69% 0.07
Mucinous 
carcinoma
5 6% 11 21%
Other 15 13% 7 10%
Differentiation grade Well 1 1% 5 4% 0.08
Moderate 51 65% 68 46%
Poor 27 34% 66 50%
Unknown 6 0
MMR status dMMR 3 4% 3 6% 0.57
pMMR 82 96% 51 94%
Abbreviations: WHO = World Health Organization; LDH = lactate dehydrogenase;  
ULN = upper limit of normal; MMR = mismatch repair; dMMR =  deficient mismatch repair system; 
pMMR = proficient mismatch repair system
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variables (matched to the stratification parameters in the original studies) and DNA quality 
(specific activity at least 16 pmol/µg). the clinicopathological features of patients in both the 
learning (Supplemental table 1) and validation (Supplemental table 2) array CGH datasets are 
representative of the larger dataset used for clinicopathological comparisons.
DNA isolation
DNA was isolated using an extensively validated protocol as previously described.23 for each 
tumor, an area was marked containing at least 70% tumor cells. Of the ffPE blocks two to 
six 10 µm sections were cut, deparaffinized and microdissected. DNA was extracted using a 
column-based method (QIAmp microkit, Qiagen, Hilden, Germany). Matched normal mucosa 
DNA was used from all of these samples as a reference and was obtained from the resection 
margins or at least 1 cm distance from the tumor. Normality was confirmed in silico for each 
reference by comparing the array signals of the normal reference of another patient by across 
array.24 All DNA concentrations were measured on a Nanodrop ND-1000 spectrophotometer 
(thermo Scientific, Wilmington, Delaware, uSA).
Array CGH
Labelling and hybridization was carried out as previously described.24 Briefly, 500 ng genomic 
DNA and matched normal DNA were labelled using a CGH labelling kit for oligo arrays 
(Enzo Life Sciences, farmingdale, New York, uSA) with cyanine 3-dutP and cyanine 5-dutP 
nucleotide mixture, respectively. Labelled DNA quality was tested by using the Nanodrop 
ND-1000 spectrophotometer (thermo Scientific) to measure specific activity. Samples with 
specific activity <16 pmol/µg were considered insufficient, and these cases were replaced by 
comparable samples. Hybridizations were performed on the Agilent 4x180K oligonucleotide 
arrays (AMADID number 022522, Agilent technologies, Palo Alto, California, uSA). these 
arrays contain 180880 in-situ synthesized 60-mer oligonucleotides, representing 169793 
unique chromosomal locations distributed across the genome at 17 kb intervals and is enriched 
with 4548 additional unique oligonucleotides, located at 238 of the Cancer Census genes. The 
exact array design can be found in the Gene Expression Omnibus (GEO) platform GPL8687 
http://www.ncbi.nlm.nih.gov/geo/. Images of the arrays were acquired using a microarray 
scanner G2505C (Agilent technologies) . 
Preprocessing array CGH data and data analysis
Array image analysis was performed using features Extraction software (V.10.5.1.1, Agilent 
technologies). Local background was subtracted from the signal median intensities of both 
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Supplemental Table 2. Clinicopathological features in the 45 patients with hepatic versus 35 patients 
with extrahepatic metastases used for DNA copy number profiling (CAIRO2 study; validation set)
Hepatic
metastases
n = 45
Extrahepatic
metastases
n = 35
P-value
Age Median (range) 66.3 (36.3-77.3) 64.8 (42.4-83.6) 0.94
Gender Male 23 51% 17 49% 0.82
female 22 49% 18 51%
WHO performance 
status
0 29 64% 19 54% 0.37
1 16 36% 16 46%
LDH at 
randomization
Normal 21 47% 28 80% 0.002
> uLN 24 53% 7 20%
Site of primary tumor Colon 11 24% 10 29% 0.89
Rectosigmoid 18 40% 14 40%
Rectum 16 36% 11 31%
Prior adjuvant 
therapy
No 42 93% 22 63% 0.0007
Yes 3 7% 13 37%
Onset metastases Metachronous 12 27% 27 77% <0.0001
Synchronous 33 73% 8 23%
Metastatic sites 
involved
1 45 100% 19 54% <0.0001
2 0 10 29%
>2 0 6 17%
Diameter Median (range) 40 (15-110) 40 (6-90) 0.86
Invasion depth T1-2 4 9% 4 11% 0.93
T3 34 77% 26 74%
T4 6 14% 5 14%
Unknown 1 0
Lymph node status N0 14 34% 10 31% 0.94
N1 15 37% 13 41%
N2 12 29% 9 28%
Unknown 4 3
Classification Adenocarcinoma 41 92% 23 66% 0.003
Mucinous 
carcinoma
2 4% 11 31%
Other 2 4% 1 3%
Differentiation grade Well 4 9% 6 18% 0.36
Moderate 33 75% 20 61%
Poor 7 16% 7 21%
Unknown 1 2
MMR status dMMR 3 7% 5 14% 0.26
pMMR 42 93% 30 86%
Abbreviations: WHO = World Health Organization; LDH = lactate dehydrogenase;  
ULN = upper limit of normal; MMR = mismatch repair; dMMR =  deficient mismatch repair system; 
pMMR = proficient mismatch repair system
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tumor and normal DNA. the log2 tumor to normal signal ratio was calculated and normalized 
against the median value of the log2 ratios of all the oligonucleotides mapped to the March 
2006 human reference sequence (NCBI36/hg18) on chromosome 1-22 and X. the median 
absolute deviation value was calculated as a quality measure of the final array CGH data. 
Samples from the learning and validation set with a median absolute deviation value above 
0.4 were excluded. 
Wave patterns occurring in the genomic profiles were smoothed with the R package NoWaves.25 
the R package CGHcall26 was used to preprocess and normalize the data. Cellularities were 
set to the cellularity determined by a pathologist, and median normalization was performed. 
the R package DNAcopy27 segmented the log2 ratios and they were renormalized by mode 
normalization. Chromosomal copy number losses and gains were identified by CGHcall, 
calling probabilities of 0.5 or more. the accuracy of the normalization, segmentation and 
calling was verified by visual inspection. to reduce the dimension of the array CGH data set 
without loss of information, regions were defined as previously described.28 
for supervised analysis, a two-sample Wilcoxon test using 10.000 permutations was performed 
to calculate the significance of DNA copy number differences between patients with hepatic 
versus extrahepatic metastases.29 Two separate tests were performed to compare frequencies 
of gains and losses between both groups. To account for multiple testing, a permutation-based 
false discovery rate (fDR) was applied to the p values.
Gene dosage effects
to identify genes on the relevant chromosomal regions that show a gene dosage effect (ie, 
mRNA expression levels are correlated with DNA copy number status) in CRC, a data set was 
used from the Cancer Genome Atlas (tCGA) Data Portal (http://tcga-data.nci.nih. gov/tcga/) 
with combined mRNA and DNA copy number data. DNA copy numbers were available as 
segmented data, of which primary tumors with log2 ratios lower than -0.5 were called as ‘loss’ 
and values higher than 0.5 were called as ‘gain’.  
A two-sample Wilcoxon test was used to compare log2 mRNA expression ratios between 
patients with and without DNA copy number gain. to account for multiple testing, a permu-
tation-based fDR was applied to the p values.
Immunohistochemistry on tissue microarrays (TMAs)
from the ffPE primary tumor tissues available from patients with CRC in the CAIRO and 
CAIRO2 study with hepatic and extrahepatic metastases, a 2 mm punch was taken to assemble 
tMAs. from each tMA, a 4 µm section was mounted on glass, deparaffinized and rehydrated. 
Endogenous peroxidase activity was blocked with 3% H2O2 for 30 min. After microwave antigen 
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Table 1. Clinicopathological features in patients with hepatic and extrahepatic metastases
Hepatic
metastases
n = 182
Extrahepatic
metastases
n = 139
P-value
Gender Male 129 71% 74 53% 0.002
female 53 29% 65 47%
LDH at 
randomization
Normal 115 63% 119 86% <0.0001
> uLN 67 37% 20 14%
Site of primary tumor Colon 95 52% 56 40% 0.03
Rectosigmoid 41 23% 49 35%
Rectum 46 25% 34 25%
Prior adjuvant 
therapy
No 168 92% 103 74% <0.0001
Yes 14 8% 36 26%
Onset metastases Metachronous 55 30% 112 81% <0.0001
Synchronous 127 70% 27 19%
Metastatic sites 
involved
1 182 100% 80 58% <0.0001
2 0 43 31%
>2 0 15 11%
Unknown 0 1
Invasion depth T1-2 9 5% 17 13% 0.006
T3 138 79% 86 63%
T4 28 16% 33 24%
Unknown 7 3
Lymph node status N0 51 30% 55 41% 0.09
N1 73 42% 44 33%
N2 48 28% 35 26%
Unknown 10 5
Classification Adenocarcinoma 151 83% 103 74% 0.02
Mucinous 
carcinoma
10 5% 22 16%
Other 21 12% 14 10%
Differentiation grade Well 7 4% 5 4% 0.32
Moderate 102 57% 68 49%
Poor 70 39% 66 47%
Unknown 3 0
Abbreviations: LDH = lactate dehydrogenase; ULN = upper limit of normal
retrieval using 10mM sodium citrate buffer (pH 6.0), slides were incubated with rabbit antibody 
to human polyclonal C20Orf3 (1:800, Sigma-Aldrich, St. Louis, Missouri, uSA) overnight at 
4°C. Subsequently, sections were incubated with Powervision Poly-HRP anti-Ms/Rb/Ra IgG 
(Immunologic, Duiven, the Netherlands) and developed using PowerDAB (Immunologic). the 
slides were counterstained with haematoxylin and evaluated by two independent observers 
(LJMM, MEVB). In case of discrepancy, a definite result was generated based on the expertise 
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of a third investigator (IDN). All three investigators were blinded for the clinical and array 
CGH data. Stromal tissue served as a positive internal control. C20orf3 protein expression 
was negative if none of the tumor cells showed cytoplasmic/nuclear membrane staining, 
and positive if at least one tumor cell showed staining. The staining intensity was graded as 
negative (no staining), weak (light brown), moderate (brown) and strong (dark brown) staining. 
A χ2 model was used to compare protein expression between patients with hepatic versus 
extrahepatic metastases. Subsequently, protein expression was also correlated with the ordinal 
array CGH data. All statistical tests were two-sided, and differences were considered significant 
when p values were below 0.05. 
RESULTS
Clinical and histopathological features associated with organ-specific 
metastasis
Compared with patients with extrahepatic metastases (n=139), patients with hepatic metastases 
(n=182) were significantly more often male (p=0.002), more often had a serum LDH activity 
above the upper limit of normal (p<0.0001), exhibited primary tumor localization in the 
colon (p=0.03), showed synchronous onset of metastases (p<0.0001), and had less commonly 
received previous adjuvant chemotherapy (p<0.0001). there were no significant differences 
between patients with hepatic versus extrahepatic metastases in age (median 65 vs 63 years, 
p=0.39, respectively), performance status at randomisation (both groups 97% WHO 0-1) and 
treatment arm (both groups 47% sequential arm) (table 1).
Primary tumors of patients with hepatic metastases more often had t3 stage (p=0.006), and 
mucinous histology (p=0.02) was less often observed in patients with hepatic compared with 
extrahepatic metastases. No significant differences between patients with hepatic versus extra-
hepatic metastases were observed in diameter (both median 45 mm), lymph node status, 
differentiation grade, and mismatch repair (MMR) status (deficient MMR in 3% vs 4%, p=0.44, 
respectively) (table 1).
The prognostic value of organ-specific metastases
No significant difference in median OS was observed for patients with hepatic versus extra-
hepatic metastases in univariate analysis (20.3 vs 19.9 months, respectively; p=0.55). the 
absence of a significant impact on prognosis was confirmed for hepatic versus extrahepatic 
metastases in multivariate analysis (HR 0.90; 95% CI 0.66-1.23; p=0.52). the median PfS in 
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Figure 1. Genomic aberrations in CRC patients with hepatic and extrahepatic metastases. frequency 
plots of DNA copy number alterations determined by aCGH in primary tumors of (A) 85 patients 
with hepatic versus (B) 54 patients with extrahepatic metastases (CAIRO study; learning set). 
Percentage gains and losses were validated in (C) 45 patients with hepatic versus (D) 35 patients 
with extrahepatic metastases (CAIRO2 study; validation set). the X-axis displays clones spotted on the 
array sorted by chromosome. the Y-axis displays the frequency of tumors with gains (above zero) or 
losses (below zero). Boundaries of chromosomes are indicated by dotted lines.
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first-line treatment was not significantly different between patients with hepatic versus extra-
hepatic metastases (8.2 vs 7.0 months, respectively; p=0.46). A total of 291 patients were 
assessable for response in first-line treatment: 158 in the hepatic group and 133 in the extra-
hepatic group. the overall response rate (complete plus partial tumor response) in first-line 
treatment was significantly better in patients with hepatic metastases than patients with extra-
hepatic metastases (43% vs 27%, respectively; p=0.007). the disease control rate (complete 
plus partial tumor response plus stable disease) in first-line treatment was not significantly 
different between patients with hepatic and extrahepatic metastases (85% vs 86%, respec-
tively; p=0.74).
Identification of a DNA copy number profile associated with organ-
specific metastasis
the frequency plots of DNA copy number aberrations throughout the genome in patients 
with hepatic (n=85) and extrahepatic (n=54) metastases were very similar (figure 1). Despite 
the high concordance level between the two groups, small differences in DNA copy number 
profile were observed. Patients with hepatic metastases had significantly more gains at 20p11 
than patients with extrahepatic metastases (p<0.05; fDR = 0.88)(Supplemental table 3). 
Supplemental Table 3. Percentage copy number gains of chromosomal regions of 85 patients with 
hepatic versus 54 patients with extrahepatic metastases (CAIRO study; learning set) 
Chromosome Bp start Bp end Hepatic
n=85
Extrahepatic
n=54
P-value FDR
7p15.2-p15.1 27225 28185 62.4% 42.6% 0.03 0.88
17q22-q23.2 53388 55856 4.7% 16.7% 0.04 0.88
19q13.13-q13.2 43029 45196 8.2% 22.2% 0.04 0.88
19q13.2 45309 46141 5.9% 20.4% 0.02 0.88
20q13.2-p11.22 20983 21652 54.1% 33.3% 0.02 0.88
20p11.21 22354 22994 57.6% 38.9% 0.04 0.88
20p11.21 23010 23234 58.8% 38.9% 0.03 0.88
20p11.21 23248 23821 60.0% 38.9% 0.02 0.88
20p11.21 23841 23925 60.0% 40.7% 0.03 0.88
20p11.21 23945 24324 61.2% 42.6% 0.04 0.88
20p11.21 24345 24637 64.7% 40.7% 0.006 0.88
20p11.21 24651 25235 64.7% 44.4% 0.02 0.88
Abbreviations: Bp = base pair; FDR =false discovery rate
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Supplemental Table 4. Percentage copy number losses of chromosomal regions of 85 patients with 
hepatic versus 54 patient extrahepatic metastases (CAIRO study; learning set) 
Chromosome Bp start Bp end Hepatic
n=85
Extrahepatic
n=54
P-value FDR
2p21-q35 45612 217250 0% 7.4% 0.04 0.55
2q35 217262 217702 1.2% 11.1% 0.03 0.51
2q35 217729 218518 1.2% 13.0% 0.01 0.51
2q37.1 232927 232995 3.5% 14.8% 0.04 0.54
5q11.2 50533 51478 7.1% 24.1% 0.01 0.51
5q11.2 51498 52584 8.2% 24.1% 0.02 0.51
5q11.2 52607 54776 8.2% 25.9% 0.01 0.51
5q11.2 54800 54868 9.4% 24.1% 0.04 0.54
5q11.2 54887 56243 9.4% 25.9% 0.02 0.51
5q35-q12.1 56254 58905 10.6% 29.6% 0.01 0.51
5q12.1 58921 59531 12.9% 31.5% 0.02 0.51
5q12.1 59548 59781 11.8% 31.5% 0.009 0.51
5q12.1 59799 59884 12.9% 31.5% 0.02 0.51
5q12.1 59911 61912 10.6% 29.6% 0.01 0.51
5q12.1 61936 62402 11.8% 27.8% 0.03 0.51
5q12.3 64013 65193 14.1% 31.5% 0.03 0.51
5q12.3 65218 66277 15.3% 33.3% 0.02 0.51
5q35-q13.1 66292 67610 16.5% 35.2% 0.02 0.51
5q13.1 67614 67789 16.5% 37.0% 0.01 0.51
5q37.1-q13.2 67811 69274 16.5% 35.2% 0.02 0.51
5q13.2 70623 70763 14.1% 29.6% 0.04 0.55
5q11.2-q14.1 70785 79782 16.5% 33.3% 0.04 0.54
5q31.1 131772 131866 20.0% 38.9% 0.03 0.51
5q31.1 131893 133685 16.5% 33.3% 0.04 0.54
5q31.2 138632 138781 12.9% 29.6% 0.03 0.51
5q31.3 139498 139660 11.8% 27.8% 0.03 0.51
5q31.3 139674 140933 11.8% 29.6% 0.02 0.51
5q31.3 140947 143033 11.8% 27.8% 0.03 0.51
5q11.2-q32 143045 146785 10.6% 25.9% 0.03 0.51
5q11.2-q33.1 146933 148722 9.4% 25.9% 0.02 0.51
5q33.1 148726 148735 9.4% 29.6% 0.007 0.51
5q33.1 148749 149538 10.6% 27.8% 0.02 0.51
5q11.2-q33.2 149551 153853 9.4% 25.9% 0.02 0.51
5q11.2-q35.1 154550 172078 8.2% 22.2% 0.04 0.54
5q11.2-q35.3 172103 180154 7.1% 22.2% 0.02 0.51
5q35.3 180168 180356 9.4% 24.1% 0.04 0.54
5q35.3 180365 180533 5.9% 22.2% 0.01 0.51
5q35.3 180548 180645 7.1% 24.1% 0.01 0.51
6q12.1-q22.1 112779 114303 9.4% 24.1% 0.03 0.51
9q12.1-q12 38471 69214 9.4% 0% 0.03 0.51
10q11.21 42937 44189 5.9% 18.5% 0.04 0.54
10q12.1-q11.22 44197 46568 7.1% 20.4% 0.04 0.54
16p13.3 5675 6013 10.6% 0% 0.02 0.51
17q21.2 35826 36110 9.4% 24.1% 0.04 0.54
Abbreviations: Bp = base pair; FDR = false discovery rate
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Loss at 5q12 was significantly less commonly observed in patients with hepatic versus extra-
hepatic metastases  (p<0.05; fDR = 0.54)(Supplemental table 4). 
to validate these differences in DNA copy number profiles, an additional independent validation 
set of 45 patients with hepatic metastases and 35 patients with extrahepatic metastases was 
selected. Significantly more gains at 20p11 in patients with hepatic versus extrahepatic 
metastases were confirmed (fDR<0.05) (figure 1; Supplemental table 5). Differences in copy 
number aberrations at 5q12 could not be validated.
Identification of differentially expressed genes at 20p11
to determine the most relevant genes at 20p11 with a potential role in hepatic-specific CRC 
metastasis, we used a publicly available dataset of 141 CRC patients. for these patients, both 
DNA copy number and gene expression profiling of the primary tumor were available. Putative 
genes with a dosage effect were identified by comparing tumors with 20p11 gain to tumors 
without 20p11 gain. This approach revealed 12 out of 28 genes with expression levels that 
were significantly influenced by the occurrence of 20p11 gain, namely XRN2, NXT1, GZF1, 
NAPB, CSTL1, CST3, CST5, C20orf3, ACSS1, ENTPD6, PYGB, ABHD12 (Supplemental table 
6). Of these 12 differentially expressed genes, C20orf3 showed the strongest correlation 
between copy number status and RNA expression (fDR<0.0001) (figure 2). 
Figure 2. C20orf3 mRNA expression correlated with DNA copy number. Box plot of C20orf3 mRNA 
expression in 141 patients with and without gain of 20p11. A strong correlation was observed 
between copy number status and RNA expression (fDR<0.0001). 
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Supplemental Table 5. Percentage copy number gains of chromosomal regions of 45 patients with 
hepatic versus 35 patients with extrahepatic metastases (CAIRO2 study; validation set)  
Chromosome Bp start Bp end Hepatic
n=45
Extrahepatic
n=35
P-value FDR
20p11.23-p11.22 20983 21652 68.9% 34.3% 0.005 0.01
20p11.21 22354 22994 71.1% 34.3% 0.002 0.01
20p11.21 23010 23234 68.9% 40.0% 0.02 0.02
20p11.21 23248 23821 68.9% 40.0% 0.02 0.02
20p11.21 23841 23925 68.9% 40.0% 0.02 0.02
20p11.21 23945 24324 68.9% 40.0% 0.02 0.02
20p11.21 24345 24637 71.1% 40.0% 0.01 0.02
20p11.21 24651 25235 71.1% 42.9% 0.02 0.02
Abbreviations: Bp = base pair; FDR = false discovery rate
Supplemental Table 6. Differences in mRNA expression of genes located at 20p11 in patients with 
and without gain of 20p11
Chromosome Bp Start Bp End Gene P-value FDR
20p11.23-p11.22 20983 21652 XRN2 <0.0001 <0.0001
20p11.21 22354 22994 NXt1 <0.0001 <0.0001
20p11.21 23010 23234 GZf1 <0.0001 <0.0001
20p11.21 23248 23821 NAPB <0.0001 <0.0001
20p11.21 23841 23925 CSTL1 <0.0001 <0.0001
20p11.21 23945 24324 CST3 <0.0001 <0.0001
20p11.21 24345 24637 CST5 <0.0001 <0.0001
20p11.21 24651 25235 C20orf3 <0.0001 <0.0001
20p11.23-p11.22 20983 21652 ACSS1 <0.0001 <0.0001
20p11.21 22354 22994 ENtPD6 <0.0001 <0.0001
20p11.21 23010 23234 PYGB 0.0007 0.002
20p11.21 23248 23821 ABHD12 <0.0001 <0.0001
Abbreviations: Bp = base pair; FDR = false discovery rate
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Confirmation of differential expression by immunohistochemistry
using the tMAs of both CAIRO and CAIRO2 patients, C20orf3 expression could be determined 
in 581 patients, of which 325 had hepatic metastases and 283 extrahepatic metastases. 
Examples of C20orf3 expression in TMA cores of primary adenocarcinomas were shown 
in figure 3. In situ confirmation of C20orf3 protein expression yielded a higher percentage 
of primary tumors with presence of C20orf3 staining in patients with hepatic versus extra-
hepatic metastases (59% versus 41%, respectively; p=0.01)(table 2). In 199 out of the 219 
patients with copy number data, copy number status was correlated with C20orf3 expression. 
A significant positive correlation of C20orf3 protein expression with the ordinal array CGH 
ratios was showed as well (p<0.0001)(table 3). Validation of other genes was hampered by the 
unavailability of adequate antibodies for immunohistochemistry on ffPE tissues.
Table 2. C20orf3 protein expression in correlation with organ-specific metastasis
C20orf3 protein expression
Absence Presence Total P-value
Hepatic 
metastases
50 (45%) 275 (59%) 325
0.01
Extrahepatic 
metastases
61 (55%) 195 (41%) 256
Total 111 470 581
C20orf3 protein expression in primary colorectal tumors in patients with hepatic and extrahepatic 
metastases by immunohistochemistry on TMAs 
Table 3. C20orf3 protein expression in correlation with genomic aberrations at 20p11
C20orf3 protein expression
Absence Presence Total P-value
Loss 21 (50%) 2 (1%) 23
<0.0001
No CNA 18 (43%) 45 (29%) 53
Gain 2 (5%) 102 (65%) 104
Amplification 1 (2%) 8 (5%) 9
Total 42 157 199
C20orf3 protein expression in primary colorectal tumors correlated with the genomic aberrations 
at chromosome 20p11. In 20 patients with a known copy number status, C20orf3 expression was 
not accessible due to an insufficient amount of tumor cells on the TMA. Abbreviation: CNA = copy 
number aberration
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DISCUSSION
In this study we characterized specific clinicopathological features and genomic aberrations of 
the primary tumor in patients with CRC with hepatic versus extrahepatic metastases. 
Figure 3. C20orf3 protein expression. Examples of C20orf3 protein expression in TMA cores of 
primary colorectal adenocarcinomas showing no expression (A), weak expression (B), moderate 
expression (C), strong expression (D) and heterogeneity of expression (E).
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In patients with hepatic metastases, the primary tumor was more often in the colon. The 
venous drainage of the colon is via the portal system, therefore the liver has always been 
regarded as the first site of hematogenous spread. the increased incidence of extrahepatic 
metastases in rectosigmoid and rectal carcinoma can be attributed to the direct hematogenous 
spread into the systemic circulation via the inferior and middle rectal veins. However, over 
one-third of patients with colon carcinomas develop extrahepatic metastases. This supports a 
substantial role for features that are inherent to the cancer cell and the micro-environment. 
In the present study, liver-specific metastasis was more often observed in male than female 
patients. This observation was also reported in a smaller cohort of patients30, but a clear 
explanation is lacking. The onset of metastases is another clinical feature associated with 
site-specific metastasis. the majority of patients with stage IV disease present with hepatic 
metastases at diagnosis, and only one-sixth of the patients had extrahepatic metastases. These 
differences may partly be related to the diagnostic procedures, since extrahepatic metastases 
may be more difficult to detect. Indeed, progress has been made in diagnostic techniques, 
which may explain the rising incidence of synchronous pulmonary metastases from CRC.31 The 
third clinical feature associated with site-specific metastasis is serum LDH. Our results confirm 
that this variable is not only a surrogate estimate for tumor burden, but also a serological factor 
for hepatic metastases.32
Pathological examination of CRC resection specimens identified t stage and tumor type, which 
are correlated with organ-specific metastases. t1 and t2 tumors do not often metastasize, 
but, if distant spread occurs, they are more likely to arrest outside the liver. These tumors are 
located in the mucosa or submucosa, which have the greatest density of lymphatic vessels.33 
We hypothesize that t1 and t2 tumors metastasize via these lymphatic vessels, thereby 
escaping entrapment in the liver and producing outgrowth in extrahepatic organs. Mucinous 
adenocarcinomas are a less common histological subset of CRC, also appearing to metastasize 
more often in extrahepatic organs. these tumors probably possess specific traits that stimulate 
invasion in extrahepatic organs, but the underlying mechanism is unknown.
Several prognostic factors have been investigated in metastatic CRC, but the influence of 
the metastatic site as an additional predictor of outcome is highly controversial. Despite 
differences in clinicopathological features between patients with hepatic and extrahepatic 
metastases, the median OS and PfS were not significantly different between the groups. Even 
after correction for multiple prognostic factors, established in the same study population in a 
previous study34, metastatic site is not an independent prognostic factor for survival in CRC. 
However, we observed a higher overall response rate to first-line chemotherapy in patients 
with hepatic metastases than in those with extrahepatic metastases. first, there may be a 
bias in response assessments, since liver metastasis may be easier to assess than extrahepatic 
metastases. Second, significantly more patients with extrahepatic metastases were treated with 
previous adjuvant chemotherapy, while patients with hepatic metastases were not. This could 
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in theory have resulted in a (partial) resistance to chemotherapy in the former group. However, 
the differences in overall response rates between patients with hepatic and extrahepatic 
metastases did not translate into differences in survival. This is in line with a previous study by 
our group34 in which we established that the application of previous adjuvant chemotherapy 
was not of prognostic value in the same patient cohort.
Genomic aberrations responsible for CRC metastasis to the liver remain speculative and poorly 
understood. Most of the existing data were obtained using experimentally derived mouse tumor 
models. In the present study, we aimed to investigate genomic aberrations that drive CRC cells 
to the liver directly from human samples. The comparison of primary tumors derived from 
patients with hepatic and extrahepatic metastases identified more gains at 20p11 in patients 
with hepatic metastases. In contrast to 20q, the correlation of 20p11 with liver metastasis 
has not previously been described. Gain of 20q is a common genomic aberration in CRC 
and an indicator of poor prognosis35 and metastatic potential.36 Chromosome 20q gains are 
more often observed in primary tumors that metastasize to the liver compared to tumors that 
metastasize to the peritoneum and tumors without distant metastases.30 The design of our study 
and our patient selection are different, as we exclusively used tumors that possess metastatic 
potential. Therefore, differences in gain of 20p11 are more likely to be attributable to organ-
specific metastasis. Next, our array contained 180880 nucleotides, and an adequate number 
of samples was analyzed, therefore we expect an increased power in our analysis. However, 
our results only suggest a correlation between 20p11 gain in the primary tumor and liver 
metastases. We should keep in mind that primary tumors are highly heterogeneous in terms of 
both their cell populations and their ability to metastasize. therefore, it may be that the genes 
responsible for organ tropism might not be detected in the bulk of the primary tumor. A next 
step could be to search directly for genes involved in organ-specific metastases by profiling 
metastatic samples from different secondary sites in relation to their primary tumor. 
The number of genes at 20p11 is too high to really disclose those that play a role in organ-
specific metastases. Not all genes mapping at gained regions are recurrently overexpressed; 
therefore we compared gene expression between tumors with and without 20p11 gain. Of the 
12 out of 28 genes at 20p11 with a dosage effect on expression, C20orf3 showed the strongest 
correlation, and protein expression was associated with hepatic-specific metastases. C20orf3 
is a member of the lactonohydrolase super family, and the potential involvement of this protein 
in enzymatic processes is suggested.37 Protein expression has mainly been demonstrated in 
the liver, but no relation to hepatic-specific metastases has yet been reported. In vitro assays 
should provide evidence for a causal role of this gene in metastasis formation. In addition, 
confirmation of their relevance to liver-specific metastasis can be made by showing functional 
evidence of the pro-liver-metastatic effect in a xenograft model. It is interesting that C20orf3 
maps on the opposite allele at a distance of a few kilobases from the human CMAP gene, 
which is correlated with liver metastases.38 However, in the publicly available dataset we used, 
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CMAP was not overexpressed in 20p11 gained primary tumors. Expression of XRN2, NXT1, 
GZF1, NAPB, CSTL1, CST3, CST5, ACSS1, ENTPD6, PYG and ABHD12 was also increased 
in primary tumors with 20p11 gain, but we could not analyze the correlation of their protein 
expression with organ-specific metastases. However, if 20p11 gain influences organ-specific 
metastases, this could well be caused by altered expression of multiple genes rather than a 
single gene.
Organ-specific metastasis is a highly complex process, and the capacity to disseminate 
also depends on additional features other than chromosomal aberrations at chromosome 
20p11. first, smaller alterations including somatic mutations are probably important, and 
novel technologies such as next-generation sequencing will play a pivotal role. Germline 
variants detectable by genome-wide association studies might also contribute to organ-
specific metastasis, but have not yet been identified. Second, the barriers to infiltrating an 
organ depend on the architecture and specific features of the microenvironment. Endothelial 
adhesive interactions and certain aspects of the vasculature have been proposed to contribute 
to dissemination in specific organs.39 Some studies suggest that the secretion of cytokines 
results in a pro-metastatic microenvironment,40,41 but these data need further characterization 
in cancer models. 
In conclusion, an array CGH profile including the protein-encoding gene C20orf3 was over-
represented in primary CRCs that preferentially metastasize to the liver. Although selected 
from a large clinical trial, it should be realized that our results are derived from a retrospective 
analysis. Therefore selection bias cannot be excluded, and prospective studies on this topic are 
warranted. furthermore, the possible role of this liver metastasis-associated gene in specific 
steps of the hepatic metastatic process needs to be functionally validated. This could result in 
the development of (1) new prognostic markers that could help in identifying patients who are 
most likely to develop liver metastases and (2) liver-specific anti-metastatic therapies for the 
future.
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GENERAL DISCUSSION
Only a limited number of patients with metastatic CRC are candidates for curative resection, 
the majority of patients present with unresectable disease. Survival benefit in these patients 
can be achieved with systemic treatment including cytotoxic and targeted agents. These 
targeted agents, which in the treatment of CRC concern anti-VEGf and anti-EGfR antibodies, 
have further increased the life expectancy of metastatic CRC patients. However, despite this 
increase in median survival, the heterogeneity in survival rates between patients is striking. In 
this thesis we attribute this heterogeneity in survival to a number of prognostic and predictive 
factors, which should tailor patient care and improve survival in individual patients. In addition, 
to encourage the development of new targeted therapies and subsequent improvement of 
survival, we aimed to further define the (epi)genetic alterations which are involved in the 
metastatic cascade. 
Clinical applicable nomogram for predicting prognosis
Metastatic CRC represents a heterogeneous group of tumors. Until now an extraordinary 
amount of research has focused on differentiating the good, the bad and the ugly tumors. 
Most of these studies concerned retrospective analyses in small patient cohorts that were not 
externally validated. Currently, clinicians have a hard time in finding their way among all 
the prognostic markers that have been presented in CRC patients. However, it is critical that 
healthcare professionals are familiar with the impact of clinicopathological features on the 
outcome of their individual patients. Obviously, no single factor can account for the wide 
variability in outcomes, as is observed among individual patients. A variety of clinical and 
pathological features have been identified as prognostic markers in retrospective analysis 
of clinical trials. In our clinical studies (CAIRO and CAIRO2) we have confirmed most of 
these well-known prognostic factors, like serum LDH, number of lymph nodes retrieved, and 
number of metastatic sites involved. However, we also investigated several other clinical and 
pathological features of which the prognostic value is less well established. We demonstrated 
that the onset of metastasis (synchronous versus metachronous) does not influence clinical 
outcome, but that the histology of the primary tumor is of substantial importance in predicting 
the prognosis of metastatic CRC patients.
The research on prognostic markers in this thesis should initiate additional studies that aim 
to determine the most strongest prognostic factors and incorporate them in a model that can 
be used in clinical practice. Nomograms (prognostic models) that combine patient survival 
factors are useful clinical tools when determining prognosis and subsequent tailoring of the 
most appropriate treatment options. These algorithms could also be used by investigators to 
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guide the inclusion of patients in clinical trials, and prevent heterogeneity in outcome. In other 
tumor types, like renal cell carcinoma, nomograms have been identified as user-friendly and 
provide the clinician and the patient a tool to predict a specific outcome over time. 
A nomogram predicting the prognosis for CRC patients with irresectable metastases should 
be generated by combining the outcome data of multiple randomized clinical trials. these 
clinical trials should be carefully selected because prognosis can be influenced by differences 
in best supportive care among various countries as well as over time, and also by differences in 
reimbursement systems. Before generating a nomogram it is essential to establish how extensive 
this algorithm should be. It should be realized that a nomogram must be user-friendly and that 
markers need to be easily determined in general practice. After establishing these conditions, 
the relevant prognostic markers should be prospectively evaluated in a large test cohort with 
proper validation in an independent dataset. 
Predictive value and targeting of mutant KRAS in more detail
Nowadays, anti-EGfR therapy is restricted to patients with a KRAS wild-type tumor. The KRAS 
mutation as a negative predictive marker for response to anti-EGfR therapy is one of the most 
important discoveries in CRC in recent years. An activating point mutation in KRAS results in a 
12-fold increase of the RAS-GTPase activity, independent of binding of the epidermal growth 
factor to the EGfR. Obviously, a point mutation is not the only mechanism that can alter 
KRAS protein expression. Epigenetic factors, genomic aberrations, single nucleotide polymor-
phisms, and dysregulation of transcription factors may also regulate KRAS activity. In this 
thesis we correlate KRAS copy number aberrations and miRNAs that target KRAS with clinical 
outcome to cetuximab in metastatic CRC patients. These results suggest that the clinical effects 
of KRAS are the result of a complex interaction of several regulatory mechanisms beyond the 
KRAS point mutation status. However, our study is only hypothesis-generating and additional 
analyses should be performed. firstly, our data require an independent validation, which 
should also include patients who do not receive anti-EGfR therapy. Secondly, to get insight 
in the effects of miRNAs and copy number aberrations at the KRAS protein level, functional 
studies should be performed measuring RAS-GTPase activity and KRAS protein expression. 
The correlation between miRNAs that inhibit the translation of KRAS and the response to 
cetuximab is of special interest because it can result in the development of new treatment 
strategies. Targeting KRAS is probably only relevant in patients harboring an activating point 
mutation in KRAS because of the elevated levels of RAS-GTPase activity. Mutations in KRAS 
have been found in 30-50% of metastatic CRC patients. therefore, silencing of mutant KRAS 
by miRNAs has become an attractive therapeutic strategy in metastatic CRC patients. Recently, 
an in vitro study showed that miRNAs targeting KRAS efficiently reduced KRAS expression. 
Subsequent silencing of KRAS by miRNAs in vivo showed pronounced antitumor effect without 
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substantial side effects.1 These promising animal studies should stimulate researchers to inves-
tigate which miRNA is the most potential silencer of KRAS in human samples, which should 
be further analyzed as a new treatment modality in KRAS mutated metastatic CRC patients.
KRAS oncogene as a model to study metastasis 
Because of the increased use of anti-EGfR therapy in metastatic CRC patients, a test for KRAS 
mutation status is frequently determined in tumor tissue. KRAS mutation analysis is usually 
performed on primary tumor tissue since metastatic tissue is often not available. Previous 
studies were inconclusive whether the result of the primary tumor corresponds with that of 
metastatic tissue, and some investigators suggested to routinely perform a mutation analysis 
in both primary tumor and metastatic tissue. In this thesis we present the largest study on this 
topic to date, involving 305 CRC patients, and we demonstrate that the KRAS mutation status 
is highly concordant between primary tumors and liver metastases. The implication of these 
results for general practice is that tissue of both the primary tumor and liver metastases may be 
used for KRAS mutation testing.
Since KRAS mutation is an early event during  colorectal carcinogenesis, an identical KRAS 
mutation status between primary tumors and distant metastases is to be expected as in our 
study on primary tumors and matched liver metastasis. Surprisingly, others have shown 
(although in small series) a substantial discordance in KRAS mutation status between the 
primary tumor and regional metastatic lymph nodes, which questions the role of lymphatic 
spread in relation to hematogenous dissemination. Traditionally, regional lymph nodes are 
considered to have an important role in the metastatic process, and both staging and the appli-
cation of adjuvant chemotherapy depends on lymph node involvement. It is yet unexplained 
how lymph node metastases can lose or acquire a mutation in KRAS. One hypothesis is that 
alternative pathways of metastases, such as vascular invasion and perineural growth, might be 
more important in CRC liver metastases. Therefore, additional analyses should be performed 
using the human KRAS oncogene as a model to study metastases. firstly, KRAS mutation status 
should be determined and compared in areas of perineural growth and vascular invasion 
within the primary tumor. Secondly, these areas of vascular invasion, perineural growth, and 
regional lymph nodes of the primary tumor should also be investigated in patients with other 
metastatic organs involved, like the lungs and the peritoneal cavity. Identification of CRC 
dissemination pathways is clinically important for an adequate tailoring of adjuvant systemic 
treatment in stage II and III CRC patients. 
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From dissemination to colonization: the role of (epi)genetics
The transition from colorectal hyperplasia to adenoma and subsequent invasive carcinoma is 
characterized by the acquisition of specific genetic alterations (APC, KRAS, TP53, TGFB). this 
model of stochastic mutational events has found widespread acceptance. Once the colorectal 
tumor becomes invasive, metastatic progression can proceed rapidly without latency resulting 
in synchronous metastases. The relatively short latency of most of the metastatic relapses in 
CRC implies that the metastatic competence is already acquired during the early stage of 
malignant transformation. Indeed, our data showed that overt metastases and primary tumors 
share similar genomic aberration patterns, implying that most of the metastatic traits are 
already present in the primary tumor. Genetic evolution within the primary tumor is probably 
necessary to generate cell populations with increased fitness, because even cancer cells that 
are fully neoplastic have extremely low chances of proliferating at sites of dissemination. 
This makes it very unlikely that precursor cells of overt metastases disseminate early to sites 
where they proceed to undergo their own divergent genetic evolution (parallel progression 
model). However, oncogenic transformation is probably not completely sufficient for 
metastatic competence, and tumor cells must acquire some additional abilities to surmount 
the natural barriers against metastases. Indeed, our metastases showed few non-recurrent 
additional genetic aberrations which were absent in the corresponding primary tumor. Due 
to the non-recurrence of the observed additional genomic aberrations, this (last) part of the 
metastatic outgrowth cannot be generalized to all CRC patients.
In some CRC patients metachronous metastases occur after a prolonged latency period. The 
presence of disseminated tumor cells (DtCs) in patients whose primary tumors have been 
removed correlated with metastatic relapse. Malignant cells that disseminate can reside as 
single cells or micrometastatic clusters, mainly in the blood, lymph nodes or bone marrow. The 
latent DtCs either lack the ability to colonize or are prevented to colonize by the microenvi-
ronment. (Epi)genetic dysregulation of a latent DtC population probably combined with local 
changes in the microenvironment endow surviving DtCs towards full metastatic competence 
at secondary sites. However, it remains unclear when these DtCs abandon the primary tumor 
and if they need additional traits for outgrowing at secondary sites. Progress in understanding 
the origin and fate of DtCs, by characterizing the (epi)genetic aberration in DtCs in respect 
to the primary tumor and the metastases, will offer new insight into the process of metastases.
Within clinical oncology new targeted treatments are being developed for metastatic disease, 
and for several reasons it is important that we established that genetic aberrations between 
primary CRC and metastases were highly similar. firstly, comparing genetic profiles contribute 
to the determination which tumor tissue will best predict treatment outcome. Current clinical 
practice can proceed using archived material of the primary tumor to determine the consti-
tution of the molecular target to select patients for treatment of the metastasis. Secondly, instead 
of focusing on additional genetic features responsible for metastatic formation, identification 
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and understanding of the metastases-associated genes in the primary tumor is probably more 
important and should be the route to the discovery of new drug targets.
Intrinsic tumor cell properties and organ-specific metastases
Colorectal tumors predominantly spread to the liver in 80% of patients with recurrent disease. 
The mesenteric circulation from the bowel and the permissiveness of the liver capillary sinusoids 
are thought to favor liver metastases. following circulatory patterns from the liver or directly 
from primary tumors in the descending colon and rectum, the second most common site of 
metastases is the lungs. However, in addition to the influence of hematogenous dynamics, 
colon carcinoma cells preferentially adhere to the liver and lung endothelia, suggesting the 
existence of specific molecular interactions that favor the retention of tumor cells in these 
organs. this ‘homing’ process is probably the result of both intrinsic tumor cell properties and 
organ microenvironment, and might be provided by (epi)genetic dysregulation that provide 
a selective growth advantage. The dysregulation of genes in tumor cells could already be 
prominently expressed in a primary tumors, although there unique role becomes obvious at a 
specific distant site.
the role of chromosome 20p11 in liver-specific metastases is suggested in this thesis which 
emphasizes the ‘seed and soil’ theory of Paget. the function of the most prominently overex-
pressed gene (C20orf3) in patients with 20p11 gain is not clear. functional in vitro assays 
should provide evidence for a causal role of this gene in metastasis formation. In addition, 
confirmation of their relevance to liver-specific metastases can be made by showing functional 
evidence of the pro-liver-metastatic effect in a mouse model. translation of these findings to 
the clinic should stimulate the development of targeted therapeutics to prevent such organ-
specific metastases. 
Next to the clinical implications of chromosome 20p11 in organ-specific metastases, this 
aberrant region could also be used to gain insight in the dissemination pathways of CRC. 
In situ hybridization of chromosome 20p11 in the primary tumor with regions of vascular 
invasion, perineural growth, and lymph node involvement visualizes the pathway of tumor 
cells with and without 20p11 aberrations. We could also demonstrate tumor cell hetero-
geneity, by comparing in situ hybridization analysis of chromosome 20p11 in the metastasis 
and the primary tumor. It is well-known that tumors are heterogeneous and contain numerous 
subpopulation of cells that have a different metastatic potential. However, heterogeneity in 
‘homing’ associated chromosomal aberrations has not yet been investigated. 
In the past decennia, management of metastatic CRC has mainly focused on patient and histo-
logical characteristics, which were completed with data from the laboratory and radiological 
imaging. These traditional parameters are still relevant, but recent advances in human genetics 
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and proteomics enabled us to a more detailed understanding of metastatic CRC. The trans-
lational studies performed in this thesis offer new insights into the intriguing process of CRC 
metastases, and are a step forward into the era of personalized medicine.
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SUMMARY
Most colorectal tumors develop as benign lesions and progress to more invasive phenotypes 
when the appropriate (epi)genetic alteration in oncogenes and tumor suppressor genes occur. 
This process also involves the selection of traits that are advantageous to disseminating cancer 
cells allowing them to colonize a secondary site, resulting in metastases. Yet, it is still a matter 
of debate how tumor cell populations evolve to acquire molecular alterations in metastases-
associated genes. Unraveling the question how, when, and where the precursors of overt 
metastases arise, will give insight in the clinical opportunities to target and prevent metastatic 
disease. However, currently there are no curative options in case of permanently irresectable 
metastatic disease, but a significant and clinically relevant benefit in survival can be achieved 
with systemic treatment. Heterogeneity in response rates and overall survival are mainly 
due to differences in the presence of prognostic and predictive markers. More clarity about 
prognostic and predictive markers could individualize follow-up and treatment of metastatic 
CRC patients.
In chapter 2 we describe the prognostic value of the number of examined lymph nodes in 
1227 rectal cancer patients who were selected from a multicenter prospective randomized 
trial investigating the value of short-term neoadjuvant radiotherapy. In these patients we also 
determined which factors relate to the number of lymph nodes found and the presence of 
lymph node metastases. The median number of examined lymph nodes in all patients was 
7. the number of retrieved lymph nodes was significantly higher in patients with node-
positive compared to node-negative patients. After short-term neoadjuvant radiotherapy fewer 
lymph nodes were retrieved compared to the surgery only group. Substantial variance was 
found between the 49 participating laboratories, with median yields varying between 1.5 
and 13.5 lymph nodes. These variations in lymph node yield between pathology laboratories 
and individual pathologists were striking. The following patient and tumor characteristics 
were associated with a significant lower lymph node retrieval: age over 60 years, obesity, 
small tumor size, low invasion depth, poor differentiation grade, and absence of a lymphoid 
reaction surrounding the tumor. Node-negative patients in whom 7 or less lymph nodes were 
examined had a smaller recurrence free interval compared with patients in whom at least 8 
lymph nodes were examined. We concluded that the number of retrieved lymph nodes after 
total mesorectal excision surgery is partially dependent on biological features, and is also 
influenced by the choice of treatment and pathological assessment of the specimen. Our data 
indicate that a median number of 8 or more examined lymph nodes is reliable for adequate 
staging in patients with rectal cancer.
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Mucinous adenocarcinomas are a rare histological subtype of CRC (5-15%), in which the tumor 
cells secrete abundant extracellular mucin involving more than 50% of the tumor volume. the 
comparison of clinicopathological features and outcome in 1010 metastatic CRC patients with 
mucinous adenocarcinomas and the more common adenocarcinomas are presented in chapter 
3. Patients with mucinous adenocarcinomas (n=99) were older, more often had a normal 
serum LDH, extrahepatic localization of metastases, a larger primary tumor diameter, and a 
higher t stage compared to patients with adenocarcinomas (n=911). A deficient mismatch 
repair system and BRAF mutations were more frequently observed in patients with mucinous 
adenocarcinomas versus adenocarcinomas. OS, PfS, and overall response rates were signifi-
cantly worse for patients with mucinous adenocarcinomas compared to adenocarcinomas. In 
multivariate analysis, mucinous histology was a negative prognostic factor for OS resulting in 
a combined hazard ratio of 1.78 (95%CI 1.35-2.35). this strong negative prognostic value of 
mucinous adenocarcinomas supports the use of this histopathological feature as a stratification 
factor for randomized clinical trials in metastatic CRC.  
In chapter 4 we report the differences in clinicopathological features and outcome in 550 CRC 
patients with metachronous (beyond 6 months of the primary diagnosis) versus synchronous 
(within 6 months of the primary diagnosis) metastases. the clinical and pathological character-
istics associated with poor prognosis that we observed more often in patients with synchronous 
metastases (n=280) versus metachronous metastases (n=270) concerned an abnormal serum 
LDH concentration, a worse WHO performance status, primary tumor localization in the 
colon, and a higher t stage. unexpectedly, we observed no significant difference in median OS 
and PfS between patients with synchronous and metachronous metastases. A possible expla-
nation includes a (partial) chemo resistance in patients with metachronous disease because of 
previous adjuvant systemic treatment. Possible differences in screening procedures resulting 
in a lead time bias to diagnosis or in prognostic molecular markers between patients with 
synchronous versus metachronous metastases as a cause for this finding remains speculative. 
Comparing our results with the literature, most studies observed a worse OS for patients 
with synchronous versus metachronous metastases. However, our analysis differs from the 
published literature in one important aspect, in that only patients with a prior resection of the 
primary tumor were included in the synchronous group. If patients with both resected and 
non-resected primary tumors were included in the synchronous group, a significant worse 
median OS was observed for patients with synchronous versus metachronous metastases. 
therefore, the conflicting results on the prognostic role of synchronous disease may be caused 
by differences among the status of the resection of the primary tumor. The prognostic value 
of resection of the primary tumor in patients with synchronous metastases is the research 
question in a new randomized clinical trial of the DCCG.   
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Due to the negative predictive value of KRAS mutations, the use of anti- EGfR antibodies in 
metastatic CRC is restricted to patients with KRAS wild-type tumors. KRAS mutation analysis is 
usually performed on primary tumor tissue because metastatic tissue is often not available. A 
possible discordance of test results between primary tumor and metastases has been suggested 
as an explanation for the failure rate of anti-EGfR therapy in patients with KRAS wild-type 
tumors. In chapter 5 we describe the concordance of the KRAS mutation status in 305 primary 
colorectal tumors and their corresponding liver metastases. KRAS mutations were detected in 
35.4% of the primary tumors. In 11 cases (3.6%) we observed a discordance between primary 
tumors and metastases: 5 primary tumors had a KRAS mutation with wild-type metastases, 
1 primary tumor was wild-type with a KRAS mutation in the metastasis, and in 5 cases the 
primary tumor and the metastases had a different type of KRAS mutation. In this largest and 
most homogenous study to date, we observed a high concordance of KRAS mutation status of 
96.4% (95% CI 93.6-98.2%) between primary colorectal tumors and their corresponding liver 
metastases. In only 6 patients (2.0%; 95% CI 0.7-4.2%) the discordance in KRAS mutation 
status was clinically relevant. We concluded that both primary tumors and liver metastases can 
be used for KRAS mutation analysis. 
In chapter 6 we present the results of a sub-analysis were we correlated KRAS modification 
by gene copy number aberrations and miRNAs to clinical outcome in metastatic CRC patients 
treated with cetuximab containing first-line treatment. In this pilot study, 34 metastatic CRC 
patients were selected based upon their good (n=17) and poor (n=17) PfS upon treatment with 
cetuximab in combination with capecitabine, oxaliplatin, and bevacizumab. Good response 
was associated with 12p12.1 copy number loss, even in patients with a KRAS mutation, while 
copy number gain in wild-type KRAS patients was correlated with a poor response. In KRAS 
mutated tumors increased miR-200b and decreased miR-143 expression were associated with 
a good response. In wild-type KRAS patients, miRNA expression did not predict response in a 
multivariate model. Thus, assessment of KRAS copy number aberrations and miRNAs targeting 
KRAS might further optimize the selection of patients eligible for anti-EGfR therapy. However, 
given the small number of patients included in our study, confirmation in larger series is 
warranted.
Metastatic disease is the major cause of death in CRC patients. The metastatic process 
comprises multiple sequential steps, including tumor cell invasion of the microenvironment, 
entering and survival in the bloodstream, extravasation, proliferation, induction of angio-
genesis, and evading apoptotic death at the secondary site. The role of epigenetic regulation in 
the metastatic pathway remains obscure, therefore we reviewed in chapter 7 the relationship 
between miRNAs and the CRC metastatic pathway. We have summarized several miRNAs 
and their known target genes that are associated with specific steps in the metastatic process, 
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mainly investigated using ‘in vitro’ and ‘in vivo’ models. Many of these miRNAs are known to 
be dysregulated in CRC, but only limited data are available that link miRNA expression to the 
metastatic human CRC phenotype. To gain better insight in the miRNAs involved in human 
CRC metastasis, we suggest to compare miRNA expression profiles in primary tumors and 
metastatic tissue. In addition, to identify miRNAs involved in metastases it is also relevant to 
compare miRNA expression in primary tumors of patients with and without metastatic disease. 
The next step is to assess the biological consequences of these miRNAs on genes responsible 
for metastases, using in vivo human CRC models. This approach appears useful and should 
designate candidate miRNAs for further use as therapeutical targets in CRC treatment.  
In addition to the epigenetic alterations reviewed in the previous chapter, also chromosomal 
aberrations are involved in the metastatic process. It is still a matter of debate how, where, and 
when the tumor cells acquire the genetic alterations that drive the metastatic process. In chapter 
8 we present the differences of 62 primary colorectal cancers, 62 matched normal specimens, 
and 68 matched metastases (from liver, lung, ovary, omental, and distant lymph nodes) by high 
resolution array CGH for DNA copy number changes. Overall patterns of DNA copy number 
aberrations were highly similar between primary tumors and their metastases, confirming 
clonality. Additional copy number aberrations in metastases are rare and rather than recurrent 
they were sporadic for individual patients. The only recurrent differences between primary 
tumors and their metastases were observed in two chromosomal regions, 6q21 and 8q24.21 
encompassing the MYC oncogene, that coamplified in three metastases of two patients (3.2%). 
the co-amplification was confirmed by fluorescent in situ hybridization analysis and did not 
result from translocation, since no co-localization of the amplified chromosomal regions 
was observed. from this large array CGH study we showed highly similar patterns of DNA 
copy number aberrations between primary CRC and their metastases. These observations are 
consistent with the hypothesis that the metastatic potential is predestined early in the devel-
opment of the primary tumor. 
In chapter 9 we describe the clinicopathological features and genome-wide chromosomal 
aberrations associated with organ-specific metastases in CRC. Clinicopathological features 
were investigated in metastatic CRC patients with exclusively hepatic (n=182) versus extra-
hepatic (n=139) metastases, who participated in the phase III CAIRO study. A total of 139 
primary tumors of patients with hepatic (n=85) and extrahepatic metastases (n=54) were 
screened for chromosomal aberrations by array CGH, and the findings were validated in an 
independent set of 80 primary tumors. Moreover, a publicly available database was used 
to correlate chromosomal aberrations with gene expression, and protein expression was 
evaluated by immunohistochemistry. Patients with hepatic metastases were significantly more 
often male, had more frequently an abnormal LDH, primary tumor localization in the colon, 
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synchronous onset of metastases, T3 tumors, and were less frequently of mucinous histology. 
No significant difference in clinical outcome was observed between patients with hepatic and 
extrahepatic metastases. Gain of 20p11 was more frequently observed in patients with hepatic 
metastases, which was confirmed in an independent dataset. twelve genes mapping at 20p11 
were significantly overexpressed as a consequence of 20p11 copy number gain. C20orf3 
showed the strongest correlation between RNA expression and DNA copy number. this was 
reflected in a significantly higher protein expression present in patients with hepatic metastases 
(59%; n=325) versus extrahepatic metastases (41%; n=256) (p=0.01). the possible role of this 
hepatic metastasis-associated gene in specific steps of the hepatic metastatic process needs 
to be functionally validated. This could result in the development of new prognostic markers 
that could help identifying patients who are most likely to develop liver metastases and the 
development of liver-specific anti-metastatic therapies in the future.
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GENERAL CONCLUSION
This thesis focuses on translational aspects of CRC metastases. CRC is a heterogeneous disease 
in many ways, as is reflected by the large number of already known prognostic factors. We 
investigated several other factors with potential prognostic value in metastatic CRC, and 
observed that mucinous histology of the primary tumor is an important negative prognostic 
marker for clinical outcome. Synchronous presentation of metastases at diagnosis is considered 
to be of worse prognostic value compared with metachronous metastases. We have challenged 
previous data by performing a more homogeneous study and concluded that the onset of 
metastases is not of prognostic value in metastatic CRC. We also established the relationship 
between lymph node retrieval and outcome in rectal cancer patients. The use of these and other 
established prognostic markers in clinical practice may individualize patient care. In addition, 
optimalization of predictive markers is necessary to initiate an individualized treatment. the 
identification of a KRAS mutation as a predictive marker for response to anti-EGfR agents 
has been one of the most important achievements in CRC research in recent years. The high 
concordance rate in KRAS mutation status that we established between primary tumor and 
metastatic tissue justifies testing in the primary tumor before initiating anti-EGfR therapy. We 
excluded a discordance in test results as explanation for the failure rate of anti-EGfR therapy in 
patients with KRAS wild-type tumors. Other regulatory mechanisms of KRAS, such as miRNAs 
and copy number aberration, are probably important in predicting response to anti-EGfR 
agents and could further improve the selection of patients for anti-EGfR therapy. However, our 
results are only hypothesis-generating and should be further tested in larger patient cohorts. 
to develop new targeted therapies in CRC it is essential to identify (epi)genetic alterations 
responsible for metastatic progression. therefore we reviewed miRNA profiles and performed 
array CGH profiling, resulting in a better comprehension of the metastatic behavior. In the near 
future, these basic research findings should be translated to the development of new targeted 
treatments which can be used in the oncology clinic. In addition, the role of organ-speci-
ficity in the pathway of CRC metastases is even more complex and still largely unknown. We 
identified an array CGH profile including the protein encoding gene C20orf3 that is overrep-
resented in primary CRC with a preferential metastatic pattern to the liver. this finding may 
contribute to the development of new prognostic markers that identify patients who are most 
likely to develop liver metastases and to the development of liver-directed cancer therapies in 
the future. 
  
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
Chapter 10 
Nederlandse samenvatting
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE
184
Chapter 10    Nederlandse samenvatting
SAMENVATTING
Dikke- en endeldarmkanker (colorectaal carcinoom) is één van de meest voorkomende vormen 
van kanker in de westerse wereld en de incidentie ervan neemt toe. De meeste colorectaal 
carcinomen ontstaan als goedaardige afwijkingen die door een opeenvolging van genetische 
defecten kwaadaardig worden. Deze kwaadaardige tumorcellen kunnen van de oorspron-
kelijke darmtumor losraken en via de bloedvaten of de lymfevaten terecht komen in andere 
organen. Dit proces wordt uitzaaiing of metastasering genoemd. De moleculaire mechanismen 
die verantwoordelijk zijn voor metastasering zijn nog grotendeels onbekend. Meer kennis 
over de biologie van metastasering zal ons in staat kunnen stellen om meer effectieve behan-
delingen te ontwikkelen. Ongeveer 50% van alle patiënten met een colorectaal carcinoom 
ontwikkelt metastasen, met name in de lever en longen. Een beperkt deel van patiënten met 
levermetastasen komt in aanmerking voor chirurgische resectie van deze metastasen, waarbij 
genezing in minder dan de helft van deze patiënten mogelijk is. Bij het grootste deel van 
patiënten met metastasen is genezing dus niet mogelijk, maar kan er wel een aanzienlijke 
overlevingswinst behaald worden met medicamenteuze therapie. Deze behandeling bestaat 
uit een combinatie van chemotherapie (fluoropyrimidines, oxaliplatin en irinotecan) en 
zogenaamde targeted therapie (VEGf en EGfR antilichamen). Laatstgenoemde middelen 
remmen specifieke groeisignalen in de kankercel waardoor processen zoals proliferatie 
(vermenigvuldiging), angiogenese (bloedvat nieuwvorming), en het uitblijven van apoptose 
(geprogrammeerde celdood) geremd kunnen worden. De medicamenteuze behandeling van 
het gemetastaseerde colorectaal carcinoom kent een enorme variatie in effectiviteit op de 
ingestelde therapie. Deze variatie wordt bepaald doordat er tussen patiënten verschillen zijn 
in prognostische en predictieve factoren. Prognostische factoren geven informatie over het 
ziektebeloop onafhankelijk van de behandeling, en predictieve factoren voorspellen hoe een 
tumor op een bepaalde behandeling reageert. Het vergroten van de kennis op het gebied van 
deze factoren kan de behandeling van een kankerpatiënt individualiseren en optimaliseren.
In hoofdstuk 2 beschrijven we de prognostische waarde van het aantal verkregen lymfeklieren 
in 1227 patiënten met endeldarmkanker (rectumcarcinoom) die behandeld zijn in een geran-
domiseerde fase III studie. In deze studie zijn patiënten met een rectumcarcinoom gerando-
miseerd voor tME chirurgie met of zonder een kortdurende preoperatieve bestraling. Volgens 
de huidige standaard dienen tenminste 10 regionale lymfeklieren verkregen te worden om een 
betrouwbare inschatting van de prognose te kunnen maken. Het mediane aantal onderzochte 
regionale lymfeklieren in alle patiënten die deelnamen aan deze studie is 7. Bij patiënten 
die behandeld zijn met preoperatieve bestraling worden minder lymfeklieren verkregen in 
vergelijking met de patiënten die niet bestraald zijn voor de operatie. Er hebben 49 pathologie 
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laboratoria deelgenomen aan deze studie en verrassend genoeg is het aantal verkregen lymfe-
klieren zeer verschillend tussen pathologen en tussen laboratoria. De volgende patiënt- en 
tumorgerelateerde factoren zijn geassocieerd met een te laag aantal verkregen lymfeklieren: 
leeftijd ouder dan 60 jaar, overgewicht, kleine tumor diameter, lager T stadium, slechte diffe-
rentiatie, afwezigheid van lymfekliermetastasen, en weinig tot geen ontstekingsreactie rondom 
de primaire tumor. Patiënten met lymfeklieren waarin zich geen uitzaaiingen bevinden hebben 
een langer ziektevrij interval als er minimaal 8 lymfeklieren verkregen waren, in tegenstelling 
tot patiënten waarbij 7 of minder lymfeklieren verkregen zijn. Geconcludeerd kan worden 
dat het aantal onderzochte lymfeklieren afhankelijk is van meerdere factoren die gerelateerd 
zijn aan de patiënt, tumor, en behandeling. Het streven naar een goede opbrengst (minimaal 
8 lymfeklieren) is noodzakelijk voor adequate stadiëring daar dit de prognose van een rectum-
carcinoom patiënt verbetert. 
Mucineuze adenocarcinomen zijn een histologisch subtype van het colorectaal carcinoom, 
waarvan de incidentie 5-15% bedraagt. De tumorcellen van een mucineus adenocarcinoom 
produceren extracellulair slijm, wat meer dan 50% van het tumor volume omvat. Het adenocar-
cinoom is een histologisch subtype dat nauwelijks slijm produceert en vormt de meerderheid 
binnen het colorectaal carcinoom (90%). In hoofdstuk 3 worden de verschillen besproken 
tussen patiënten met een gemetastaseerd mucineus adenocarcinoom en een gemetastaseerd 
adenocarcinoom. Hierbij is gekeken naar klinische karakteristieken, pathologische kenmerken 
van de primaire tumor, en uitkomst van behandeling. De patiënten zijn geselecteerd uit twee 
grote gerandomiseerde fase III studies, en betreft de grootste studie op dit gebied tot nu toe. 
Patiënten met een mucineus adenocarcinoom (n=99) zijn ouder, hebben vaker een normaal 
serum LDH, extrahepatische lokalisatie van metastasen, een grote diameter van de primaire 
tumor, en een hoger t stadium vergeleken met patiënten met een adenocarcinoom (n=911). 
BRAF mutaties en afwijkingen in het DNA herstel mechanisme worden vaker geobserveerd in 
patiënten met een mucineus adenocarcinoom. totale overleving, progressie vrije overleving 
en respons percentages zijn slechter in patiënten met een mucineus adenocarcinoom die 
behandeld worden met chemotherapie en targeted therapie in vergelijking met de adenocar-
cinoom groep. In de multivariate analyses voor de totale overleving is mucineuze histologie 
een sterke onafhankelijke negatief prognostische marker bij patiënten met een gemetastaseerd 
colorectaal carcinoom. Op grond van onze resultaten stellen wij voor om mucineuze histologie 
te gebruiken als een stratificatieparameter bij klinische studies met colorectaal carcinoompa-
tiënten. 
Op het moment van de initiële diagnose heeft 20% van de patiënten met een colorectaal 
carcinoom reeds synchrone metastasen. In totaal ontwikkelt circa 50% van de patiënten 
metachrone metastasen, welke meestal binnen drie jaar na het stellen van de diagnose 
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optreden. In de literatuur wordt het hebben van synchrone metastasen geassocieerd met een 
slechtere prognose in vergelijking met patiënten met metachrone metastasen. In hoofdstuk 4 
wordt een analyse beschreven waarbij de klinische parameters, pathologische kenmerken van 
de primaire tumor, en overleving vergeleken worden tussen patiënten met synchrone versus 
metachrone colorectale metastasen. Vergeleken met de groep met metachrone metastasen 
(n=270), hebben de patiënten met synchrone metastasen (n=280) vaker een jongere leeftijd, 
een verhoogd serum LDH, de lever als het meest betrokken orgaan van metastasering, de 
primaire tumor in het colon, een slechte performance status, een grote diameter van de primaire 
tumor, een hoger t en N stadium, weinig tot geen lymphoïde reactie, en een diffuus infiltra-
tiepatroon. Van de parameters die significant vaker voorkomen bij patiënten met synchrone 
metastasen zijn een verhoogd serum LDH, slechte WHO performance status, primaire tumor-
lokalisatie in het colon, en het T stadium geassocieerd met een slechte overleving in de 
totale studiepopulatie. Echter, ondanks het significant vaker voorkomen van factoren geasso-
cieerd met een slechte prognose in de groep met synchrone metastasen, is er geen verschil 
in overleving tussen patiënten met synchrone en metachrone metastasen waarbij de primaire 
tumor verwijderd is. Een mogelijke verklaring hiervoor is dat patiënten met metachrone 
metastasen frequenter adjuvante chemotherapie hebben gehad in vergelijking met die met 
synchrone metastasen, wat theoretisch zou kunnen leiden tot chemoresistentie. Echter, vele 
studies waaronder de CAIRO studie laten geen onafhankelijk prognostische waarde zien voor 
eerder gegeven adjuvante chemotherapie.
In eerdere studies is de uitkomst van patiënten met synchrone metastasen wel vaak slechter 
ten opzichte van de groep met metachrone metastasen. In vergelijking met deze studies laat 
onze analyse één belangrijk verschil zien, namelijk dat wij alleen patiënten met synchrone 
metastasen hebben geanalyseerd die eerder een resectie van de primaire tumor hebben 
ondergaan. Dezelfde analyse in de totale CAIRO studiepopulatie, dus ook de patiënten met 
synchrone metastasen die geen resectie van de primaire tumor hebben ondergaan, toont wel 
een overlevingswinst voor patiënten met metachrone metastasen. In een dergelijke analyse 
is er echter een potentiële bias van de resectie van de primaire tumor aanwezig, daar alle 
patiënten met metachrone metastasen deze resectie ondergingen, hetgeen niet het geval 
is bij de synchrone metastasen. Onze analyse is de eerste studie die bij patiënten met een 
verwijderde primaire tumor aantoont dat de overleving bij synchrone versus metachrone 
metastasen niet verschillend is als gestart wordt met een medicamenteuze behandeling. De 
prognostische waarde van een resectie van de primaire tumor bij patiënten met synchrone 
metastasen is thans onderwerp van prospectief onderzoek.
Het is gebleken dat patiënten met een KRAS mutatie in het tumorweefsel niet responderen 
op behandeling met EGfR remmers, zoals cetuximab en panitumumab. Het is daarom alleen 
zinvol om patiënten met een KRAS wild type tumor te behandelen met anti-EGfR therapie. 
StuDIES IN COLORECtAL CANCER MEtAStASES: IMPLICAtIONS fOR CLINICAL PRACtICE Chapter 10    Nederlandse samenvatting
187
KRAS mutatie analyse wordt meestal uitgevoerd op weefsel van de primaire tumor, omdat 
weefsel van de metastasen meestal niet beschikbaar is. Of het uitmaakt in welk type tumor-
weefsel de test wordt uitgevoerd is tot op heden niet duidelijk vanwege de heterogene studies 
in kleine patiënten populaties. In hoofdstuk 5 beschrijven we in 305 primaire colorectale 
tumoren en corresponderende levermetastasen de overeenkomst in KRAS mutatie status. 
Het KRAS oncogen is gemuteerd in 35.4% van de primaire tumoren. In 11 patiënten wordt 
een discordantie aangetoond tussen de primaire tumor en de metastase; 5 patiënten met een 
KRAS mutatie in de primaire tumor en een wild type in de metastase, 1 patiënt met een 
KRAS wild type in de primaire tumor en een mutatie in de metastase, en 5 patiënten met 
een verschillende KRAS mutatie tussen de primaire tumor en metastase. Concluderend is er 
sprake van een hoge concordantie (96.4%) in KRAS mutatie status tussen de primaire tumor 
en de levermetastase. Het klinische relevante percentage ligt nog hoger als de 5 patiënten met 
een verschillende KRAS mutatie niet meegeteld worden, namelijk 98%. uit deze tot nu toe 
grootste studie concluderen we dat zowel weefsel van de primaire tumor als van de metastase 
gebruikt mag worden voor de KRAS mutatie analyse. Daarnaast stellen we vast dat het niet 
responderen op behandeling met EGfR remmers bij patiënten met een KRAS wild type tumor 
niet kan worden verklaard door discordantie in de KRAS mutatie status van de primaire tumor 
en het doelwit van de anti-EGfR behandeling, de metastasen. 
Een andere verklaring voor de afwezige respons op anti-EGfR therapie in KRAS wild type 
patiënten ligt op het terrein van de regulatie van KRAS. Naast de puntmutatie kunnen ook 
andere regulatie mechanismen de expressie van KRAS beïnvloeden, waarbij veranderingen 
in het aantal KRAS kopieën en microRNAs (miRNAs) die aangrijpen op KRAS onze speciale 
interesse hebben. MiRNAs zijn kleine stukjes RNA die niet coderen voor een eiwit, maar wel 
de expressie van andere genen kunnen beïnvloeden. In hoofdstuk 6 correleren we afwijkingen 
in het aantal KRAS kopieën en miRNAs die aangrijpen op KRAS, met de klinische uitkomst 
van patiënten die behandeld zijn met cetuximab bevattende eerstelijns behandeling. In deze 
studie hebben we 34 patiënten met een gemetastaseerd colorectaal carcinoom geselecteerd 
op basis van een lange (n=17) en korte (n=17) progressie vrije overleving na behandeling met 
cetuximab, bevacizumab en chemotherapie. Bij deze patiënten hebben we gebruik gemaakt 
van array comparative genomic hybridization (array CGH) om het aantal KRAS kopieën vast te 
stellen en kwantitatieve RT-PCR om de miRNA expressie te bepalen. Een lange progressievrije 
overleving is geassocieerd met het verlies van kopieën van het KRAS gen, zelfs in patiënten met 
een KRAS mutatie. Daarnaast gaat een toename van het aantal KRAS kopieën gepaard met een 
korte progressievrije overleving in patiënten met een KRAS wild type. Verhoogde expressie van 
miRNA-200b en verlaagde expressie van miRNA-143 voorspellen een lange progressievrije 
overleving op cetuximab bevattende behandeling bij patiënten met een KRAS mutatie. In een 
multivariate analyse lijkt miRNA expressie geen effect te hebben op de cetuximab respons in 
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patiënten met een KRAS wild type tumor. Wij concluderen dat het vaststellen van chromo-
somale afwijkingen in KRAS en miRNAs die aangrijpen op KRAS de selectie van patiënten voor 
anti-EGfR therapie verder kan optimaliseren. Gezien de beperkte aantallen patiënten en het 
feit dat de patiënten naast cetuximab ook behandeld zijn met chemotherapie en bevacizumab 
dienen deze resultaten bevestigd te worden in toekomstige studies.
Het ontwikkelen van metastasen op afstand is de belangrijkste oorzaak van kanker-gerela-
teerde sterfte bij patiënten met een colorectaal carcinoom. Metastasering is een gefaseerd 
proces bestaande uit invasie, proliferatie, extravasatie, en angiogenese. MiRNAs zijn betrokken 
bij het ontstaan van kanker, maar de rol in het proces van metastasering bij het colorectaal 
carcinoom is grotendeels onbekend. In hoofdstuk 7 wordt een overzicht gegeven van de tot 
nu toe bekende gegevens over de relatie tussen miRNA expressie en alle facetten van de 
metastase cascade bij patiënten met een colorectaal carcinoom. De miRNAs zijn met name 
geselecteerd op onderzoek met ’in vitro’ studies en diermodellen. Vervolgens hebben we 
meer in detail gezocht naar gegevens over (epi)genetische afwijkingen op deze specifieke 
miRNA loci. We hebben voor deze benadering gekozen omdat er in de huidige literatuur maar 
weinig gegevens beschikbaar zijn die miRNA expressie direct correleren met het metastatisch 
fenotype. Om een beter inzicht te krijgen in de rol van miRNA expressie in het metastase-
ringsproces adviseren wij om het miRNA expressie profiel van primaire tumoren te vergelijken 
met de corresponderende metastasen op afstand. Daarnaast is het ook zinvol om het miRNA 
expressie profiel van primaire tumoren te vergelijken bij patiënten met en zonder metastasen 
op afstand. De aldus geselecteerde miRNAs moeten vervolgens in humane colorectaal 
carcinoom modellen functioneel getest worden om zodoende het biologische mechanisme te 
kunnen verklaren. Deze benadering zou er toe moeten leiden dat doelgerichte therapie tegen 
miRNAs een nieuwe therapiemodaliteit gaat vormen van het colorectaal carcinoom. 
Zoals duidelijk is uit het voorafgaande hoofdstuk is metastasering een ingewikkeld proces 
waarbij de relevante chromosomale gebieden en genen nog niet zijn geïdentificeerd. Om 
te onderzoeken of er in het proces van metastasering nieuwe chromosomale afwijkingen 
ontstaan hebben we in hoofdstuk 8 het aantal en de soort chromosomale afwijkingen in 
de metastase vergeleken met de bijbehorende primaire colorectale tumor van een patiënt. 
Hiervoor hebben we 62 patiënten geselecteerd waarbij we de 62 primaire tumoren en de 
68 gepaarde metastasen (lever, long, ovarium, omentum, lymfeklier op afstand) geanalyseerd 
hebben middels array CGH op het vóórkomen van chromosomale afwijkingen. We hebben 
onze bevindingen gevalideerd met behulp van een bestaande beschikbare array CGH dataset 
en fluorescentie in situ hybridisatie (fISH). Bij deze laatste techniek kleuren we de chromo-
soomdelen aan die we vervolgens kunnen bestuderen onder een fluorescentie microscoop. 
De resultaten van onze studie laten zien dat het array CGH profiel van de metastase en de 
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gepaarde primaire tumor sterk met elkaar overeenkomen. In de clusteranalyse, clustert de 
meerderheid (56 paren) naast elkaar wat betekent dat ze meer op elkaar lijken dan op een 
andere tumor. De tweede bevestiging voor clonaliteit krijgen we door het aantal kopieën van 
de  primaire tumoren af te trekken van het aantal kopieën van de metastase. Dit hebben we 
voor elk chromosomaal gebied gedaan. Bij de meerderheid van de chromosomale gebieden 
wijkt het aantal kopieën tussen de metastase en de primaire tumor niet van elkaar af. Echter, 
bij twee patiënten werd een bijzondere toename van het aantal kopieën (amplificatie) op 
twee gebieden in de metastase gezien, welke niet aanwezig waren in de primaire tumor. 
Deze sterke amplificatie omvat het gebied waar ook het MYC oncogen ligt die betrokken is 
bij de pathogenese van het colorectaal carcinoom. Deze bevinding is intrigerend, maar zien 
we slechts in twee van de 62 patiënten. uit deze grote array CGH studie concluderen we dat 
metastasen geen extra chromosomale afwijkingen hebben in vergelijking met de correspon-
derende primaire tumor. Deze bevinding is zeer relevant voor het begrip van het model van 
metastasering, waarbij we aannemen dat de genen die verantwoordelijk zijn voor metasta-
sering al vroeg in de primaire tumor aanwezig zijn.
In hoofdstuk 9 onderzoeken we een aantal klinische, histopathologische, en chromosomale 
afwijkingen die betrokken zijn bij orgaanspecifieke metastasering van het colorectaal carcinoom. 
De klinische en pathologische kenmerken worden vergeleken tussen colorectaal carcinoom 
patiënten met alleen levermetastasen (n=182) versus patiënten met alleen metastasen buiten 
de lever (extrahepatische metastasen)(n=139). In 139 primaire tumoren van patiënten met 
alleen levermetastasen (n=85) en patiënten met alleen extrahepatische metastasen (n=54) is 
het gehele genoom geanalyseerd op chromosomale afwijkingen. Deze bevindingen worden 
vervolgens gevalideerd in een tweede set van 80 primaire colorectale tumoren. We maken 
gebruik van eerder verrichte genexpressie studies om genen te selecteren op de belangrijke 
chromosomale gebieden, en immunohistochemie om het effect op eiwit niveau te evalueren. 
Patiënten met alleen levermetastasen zijn vaker van het mannelijk geslacht, hebben vaker 
een verhoogd serum LDH, primaire tumor lokalisatie in het colon, synchrone presentatie 
van metastasen, t3 tumoren, en zijn minder vaak van mucineuze origine in vergelijking 
met patiënten met alleen extrahepatische metastasen. Er is geen verschil in progressie vrije 
overleving en totale overleving tussen patiënten met alleen lever versus alleen extrahepa-
tische metastasen. Na evaluatie van het gehele genoom op chromosomale instabiliteit wordt 
een toename van het aantal kopieën (gain) van chromosoom 20p11 vaker geobserveerd in 
patiënten met levermetastasen versus patiënten met extrahepatische metastasen, hetgeen wij 
hebben bevestigd in een onafhankelijke dataset. Genexpressie profilering toont 12 genen op 
chromosoom 20p11 aan, die een significante overexpressie hebben in patiënten met 20p11 
gain versus patiënten zonder 20p11 gain. Van deze 12 genen, heeft C20orf3 de sterkste 
correlatie tussen RNA expressie en de mate van chromosomale instabiliteit. Bij patiënten met 
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levermetastasen (n=325) zien we ook daadwerkelijk vaker aanwezigheid van C20orf3 eiwitex-
pressie in vergelijking met patiënten met extrahepatische metastasen (n=256). Het biologische 
mechanisme achter 20p11 gain en C20orf3 expressie in orgaanspecifieke metastasering is nog 
onbekend. Deze marker zou van prognostische waarde kunnen zijn en is mogelijk een nieuw 
aangrijpingspunt bij de preventie of behandeling van levermetastasen bij patiënten met een 
colorectaal carcinoom. 
ALGEMENE CONCLUSIE
Dit proefschrift richt zich op de translationele aspecten van metastasering bij patiënten met 
een colorectaal carcinoom. Het gemetastaseerd colorectaal carcinoom manifesteert zich als 
een heterogene ziekte, met name als we kijken naar prognose. Wij hebben enkele factoren 
onderzocht die dit verschil in prognose zouden kunnen bepalen. Mucineuze histologie van 
de primaire tumor is een belangrijke negatieve voorspeller voor de overleving van een patiënt 
met een gemetastaseerd colorectaal carcinoom. Uit eerdere studies wordt het hebben van 
synchrone versus metachrone metastasen als prognostisch slecht ervaren. Wij hebben deze 
bevinding weerlegd door in een homogene groep van colorectaal carcinoom patiënten aan te 
tonen dat er geen verschil is in de overleving tussen patiënten met synchrone versus metachrone 
metastasen. Een andere prognostische factor is het aantal lymfeklieren dat verkregen wordt uit 
een resectie preparaat. Het verkrijgen van lymfeklieren is afhankelijk van meerdere patiënt-, 
tumor-, en behandelingsgerelateerde factoren. Echter, een goede opbrengst (minimaal 8 lymfe-
klieren) is noodzakelijk voor adequate stadiëring hetgeen van belang is om de prognose in 
te kunnen schatten van een rectumcarcinoom patiënt. Verder onderzoek moet leiden tot de 
identificatie van de meest relevante klinische en pathologische prognostische factoren. Deze 
factoren kunnen aangevuld worden met (epi)genetische prognostische markers waardoor een 
prognostisch model opgesteld kan worden. Met een dergelijk model lijkt het mogelijk om een 
betere inschatting te maken van de overleving per individuele patiënt, hetgeen belangrijke 
consequenties heeft voor de algemene praktijk. 
Het inschatten van de overleving met behulp van prognostische markers maakt individuali-
sering van de behandeling mogelijk, echter het ontdekken van predictieve markers maakt een 
individueel aangepaste behandeling werkelijkheid. Het aantonen van een mutatie in het KRAS 
oncogen als negatieve predictieve marker voor anti-EGfR therapie is een grote doorbraak van 
de afgelopen jaren. Het is tot op heden onduidelijk of de KRAS mutatie status in weefsel van 
zowel de primaire tumor als de (veel minder vaak beschikbare) metastase vastgesteld moet 
worden voorafgaand aan de start van anti-EGfR therapie. Gezien de hoge concordantie in 
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KRAS mutatie status tussen de primaire tumor en de metastase, is het valide om alleen de 
primaire tumor te testen. Daarnaast geven deze resultaten aan dat een verschil in de uitslag 
van de KRAS mutatietest tussen de primaire tumor en de metastase dus geen verklaring is voor 
het feit dat een aanzienlijk aantal KRAS wild type patiënten toch niet reageren op anti-EGfR 
therapie. Ook andere potentiële predictieve markers, zoals PtEN expressie, PIK3CA mutaties 
en kiembaan veranderingen, kunnen de afwezige respons in KRAS wild type patiënten niet 
volledig verklaren. Veel centra in de wereld zijn op dit moment bezig om nieuwe predictieve 
markers voor anti-EGfR therapie op te sporen. Echter, naast het zoeken naar nieuwe markers 
verdient de predictieve waarde van KRAS verdere optimalisatie. Een puntmutatie in het KRAS 
oncogen is niet de enige regulator van de KRAS activiteit, want uit in vitro studies blijken andere 
(epi)genetische afwijkingen ook de expressie te reguleren. uit onze hypothese genererende 
studie blijkt dat het bepalen van het aantal KRAS kopieën en de expressie van miRNAs die 
aangrijpen op KRAS, de selectie van patiënten voor anti-EGfR therapie kan verbeteren. Onze 
uitkomsten moeten in ander onderzoek gevalideerd worden om de werkelijke waarde van het 
aantal KRAS kopieën en miRNAs op KRAS te evalueren voordat dit toegepast kan worden in 
de klinische praktijk.
Het proces van metastasering is zeer complex, maar het is essentieel om meer inzicht te 
krijgen in specifieke chromosomale afwijkingen en genen die betrokken zijn bij de metasta-
sering van het colorectaal carcinoom. Dit inzicht wordt verkregen door in de primaire tumor 
en de gepaarde metastase te kijken naar chromosomale afwijkingen en veranderingen in 
de miRNA expressie. Op deze manier komen (epi)genetische afwijkingen aan het licht, die 
mogelijk de drijvende kracht zijn achter het ontstaan van metastasen op afstand. Nog een 
stap verder en complexer is het proces van orgaanspecifieke metastasering. Orgaanspecifieke 
metastasering berust onder meer op de mechanische theorie waarbij de veneuze bloedafvoer 
van de primaire tumor het orgaan van metastase bepaald. Ons onderzoek laat echter zien 
dat deze theorie niet een sluitende verklaring is maar dat orgaanspecifieke metastasering in 
ieder geval mede bepaald wordt door het chromosomaal profiel van de primaire tumor. We 
hebben een array CGH profiel geïdentificeerd welke geassocieerd lijkt te zijn met primaire 
tumoren die naar de lever metastaseren in vergelijking met primaire tumoren die niet naar 
de lever metastaseren. Deze gegevens zijn om meerdere redenen zeer belangrijk. ten eerste 
kan het bepalen van dit profiel in niet-gemetastaseerde colorectale tumoren de follow-up 
individualiseren. Daarnaast biedt het inzicht in en reden tot verder onderzoek om het biolo-
gische mechanisme van orgaanspecifieke metastasering te ontrafelen. Dit onderzoek zal 
moeten bestaan uit functionele studies, waarbij met behulp van in vitro en in vivo modellen 
nieuwe targets worden ontwikkeld als wapen in de strijd tegen het gemetastaseerd colorectaal 
carcinoom. 
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DANKWOORD
In dit laatste gedeelte van mijn proefschrift wil ik een aantal mensen bedanken. Allereerst 
gaat mijn dank uit naar alle patiënten die deelgenomen hebben aan de CAIRO studies en 
ten behoeve van translationeel onderzoek tumorweefsel hebben afgestaan. tevens dank aan 
de pathologie laboratoria in heel Nederland die het benodigde weefsel hebben verstrekt, in 
het bijzonder het Pathologie Laboratorium van het Rijnstate ziekenhuis en het Laboratorium 
Pathologie Oost Nederland te Enschede waar we hartelijk ontvangen zijn.
Prof. Punt, beste Kees, ik heb het als een voorrecht ervaren dat ik onderzoek mocht doen 
in jouw team. Naast je wetenschappelijke kennis heb ik ook van je klinische ervaring veel 
kunnen leren en hoop ik in de toekomst nog veel te leren. Nogmaals dank voor het in mij 
gestelde vertrouwen.  
Prof. Nagtegaal, beste Iris, sinds mijn vertrek uit het Radboud mis ik onze wekelijkse bespre-
kingen en brainstorm momenten. Ik wil je met name bedanken voor de verheldering die je 
bracht tijdens de discussies, je geduld, en voor je hulp in de vorming van mij als onderzoeker. 
Jouw passie voor je vak en je geloof in onze samenwerking werkt zeer enthousiasmerend. 
Dr. Koopman, beste Miriam, tijdens jouw promotietraject mocht ik samen met je onderzoek 
doen. Jouw verhalen over het onderzoek en het vak ‘oncologie’ hebben mij een bepaald pad 
doen inslaan. Dank voor je hulp, begeleiding, positieve insteek en ontzettend veel interesse.
Prof. J.H.W. de Wilt, Prof. N. Hoogenbrugge, en Prof. J.P. Medema wil ik bedanken voor hun 
bereidheid plaats te nemen in de leescommissie.
Dr. W.M. Smit en Dr. A.N.M. Wymenga. Beste Wim, allereerst wil ik jou bedanken als mijn 
opleider in het Medisch Spectrum twente. Ook na mijn terugkomst heb je me de ruimte 
gegeven om het onderzoek af te ronden. Daarnaast wil ik je bedanken voor je vertrouwen en 
klinische kennis waarvan ik veel kan leren. Machteld, jij hebt mij gestimuleerd mijn opleiding 
tot internist te onderbreken voor promotie onderzoek. Jouw oncologische kennis waardeer ik 
enorm en ik hoop nog veel van je te mogen leren. Daarnaast wil ik alle internisten en mijn 
collega assistenten in het Medisch Spectrum Twente bedanken voor hun interesse in mijn 
onderzoek en de goede sfeer op de werkvloer. Na twee jaar onderzoek werd ik weer warm 
ontvangen waardoor ik met veel plezier mijn werk doe. Daarnaast wil ik dr. Marie-Cecile 
Legdeur bedanken voor de kritische noot bij de ‘Nederlandse stukken tekst’ in dit proefschrift.
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Beste Jeroen, Elisa, Shannon en Marjolein, wat is het CAIRO team zonder de hardwerkende 
analisten op het lab. Jeroen en Elisa, mijn paranimfen, ik wil jullie beiden in het bijzonder 
bedanken voor jullie hulp, begeleiding, en gezelligheid op het lab. Beste Jeroen, naast het vele 
werk wat je verricht hebt voor ons onderzoek, is jouw expertise op het gebied van moleculair 
onderzoek van onschatbare waarde geweest. Lieve Elisa, als vriendin en collega ben ik je veel 
dank verschuldigd, allereerst voor de vele coupes die je gekleurd hebt. Daarnaast kon ik altijd 
mee blijven eten of een slaapplekje krijgen in jullie huis. Dit heb ik zeer gewaardeerd en ik 
hoop dat we nog veel gezellige ‘uitjes’ gaan hebben!
Mijn collega onderzoekers van het CAIRO team wil ik bedanken voor de gezellige tijd die we 
samen hebben gehad. Er was altijd tijd om te overleggen en om advies te vragen. Nikki Knijn, 
Jolien tol, Lieke Simkens, Sabine Venderbosch, en Steven Bosch, bedankt voor jullie collegi-
aliteit. Daarnaast dank ik dr. William Leenders voor de creatieve ideeën en discussies tijdens 
het CAIRO overleg.
Mijn woord van dank gaat uit naar Steven teerenstra. Wat heb je veel data mogen ontvangen 
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